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ABSTRACT 
Recent developments in genetic engineering and biotechnology have resulted in an 
increase in availability of therapeutic peptides and small anti-cytokines. Oral 
administration is inappropriate as these molecules are unstable in the gastrointestinal 
tract and are subject to hepatic first-pass effect.  Transdermal delivery is an attractive 
alternative as the skin exhibits less enzymatic activity and allows for a controlled, 
sustained local therapeutic drug concentration over a prolonged period of time.  
However, the skin’s lipophilic stratum corneum acts as a major barrier to the 
delivery of hydrophilic molecules, including peptides, resulting in lack of efficacy of 
these compounds if applied topically.  Considerable research effort has been 
focussed on the development of skin penetration enhancement techniques. However, 
many of these techniques have been limited by insufficient penetration enhancement 
and/or induced irritancy.  
We have investigated three approaches to enhance the delivery of peptides that have 
therapeutic or cosmetic effect in the skin. These approaches include the use of 
physical energy to enhance the delivery of Alanine-Tryptophan (Ala-Trp), lipoamino 
acid (LAA) conjugation to increase the permeability of a HNE inhibitor Ala-Ala-Pro-
Val (AAPV) and a cosmetic peptide, acetyl hexapeptide-3 and cyclisation to enhance 
the delivery of a core peptide (CP) which has anti-inflammatory activity.  
In vitro permeation studies across human epidermis were performed in Pyrex glass 
Franz-type diffusion cells. Ala-Trp was selected as a small molecular weight model 
dipeptide to study the penetration enhancement effects of Dermaportation, which is a 
newly developed pulsed electro magnetic field (PEMF) technology. The dipeptide 
was found to be unstable on exposure to skin at 37°C and Dermaportation (Pulsed 
electromagnetic field technology) significantly increased the in vitro permeability 
coefficient of Ala-Trp across human epidermis from 7.7 x 10-4 cm/h with passive 
diffusion to 1.94 x 10-2 cm/h with Dermaportation over an 8 h period. 
Dermaportation thus may provide an effective means of delivering molecules that are 
highly susceptible to degradation like dipeptides, in higher amounts and in a 
relatively short duration. 
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The effectiveness of coupling a short chain lipoamino acid to enhance trans-
epidermal delivery of a model human neutrophil elastase (HNE) inhibitor (Ala-Ala-
Pro-Val) was assessed. The optimal conjugate structure for skin penetration and 
biological activity of this therapeutic peptide with anti-inflammatory activity was 
determined. In order to enhance the trans-epidermal delivery of the peptide, 
lipophilic derivatives with LAAs of chain length C6, C8, and C10 were prepared by 
solid phase synthesis. Conjugation to a C6-LAA enhanced epidermal permeability of 
the tetrapeptide. Stereoselective permeation of the lipopeptide diastereomers across 
the human epidermis was observed. The amount of C6(D)-LAA-AAPV (467.94 
µg/cm2) was significantly higher than C6(L)–LAA-AAPV (123.04 µg/cm2). The 
same was observed with C8(D)-LAA-AAPV. The effect of donor concentration and 
skin hydration on skin permeability of C8(D,L)-LAA-AAPV and C10(D,L)-LAA-
AAPV was also assessed and it was observed that there was higher permeation of 
C10(D,L)-LAA-AAPV at a higher donor concentration. The lipoamino acid 
conjugates were more stable than the native tetrapeptide and biological activity was 
retained after coupling of the tetrapeptide to C6, C8 and C10 LAA.  
A cosmetic peptide, acetyl hexapeptide-3 was coupled to individual diastereomers of 
C12 (A)-LAA and C12 (B)-LAA. The preliminary study was designed to assess the 
effect of coupling of a LAA of higher molecular weight on the transepidermal 
permeation and accumulation of this hexapeptide. Accumulation of these peptides in 
the skin was also quantified. Detectable amounts of C12(A)-LAA-hexapeptide-3 and 
C12(B)-LAA-hexapeptide-3 were not found in the receptor solution but higher 
quantities of these conjugates were found to be retained in the skin. The amount of 
C12(B)-LAA-hexapeptide-3 (59.92 µg/cm2 ± 10.64) in the epidermis was highest 
followed by C12(A)-LAA-hexapeptide-3 (33.06 µg/cm2 ± 3.70) and acetyl 
hexapeptide-3 (12.64 µg/cm2 ± 1.48). 
Lastly, skin permeability and in skin stability of an anti-inflammatory peptide (core 
peptide: CP) and two analogues that have demonstrated improved biological efficacy 
and specificity: a cyclic peptide sequence (C1) and its linear sequence counterpart 
(C1-L) were assessed. The stability of C1 and C1-L was significantly higher as 
compared to CP when placed in contact with skin at 37ºC. The epidermal penetration 
of the core anti-inflammatory peptide improved after cyclisation.  The order of 
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permeation of the analogues was C1>C1-L>CP after 48h and 6 days. The amount of 
peptide retained in the skin was higher after 48h as compared to 8h due to greater 
partitioning of these peptides in the skin. 
This work demonstrates the enhancement effects of these three techniques to 
optimize the transdermal/topical permeation of therapeutic and cosmetic peptides.  
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Chapter 1.  
 Introduction 
 
 
 
 
 
 
 
 
 
 2
The advances in synthetic chemistry and molecular biology techniques over the past 
years have resulted in the application of peptides or peptide-like drugs becoming a 
growing field in therapeutics.1 A number of peptides and proteins have been 
approved by the regulatory authorities for medical use in cardiovascular disorders, 
incontinence, cancer, viral infections, calcium metabolism, immunity, inflammation, 
diabetes, homeostasis and obesity. Currently parenteral injection is the most frequent 
mode of administration for protein and peptide drugs as they are unstable if given 
orally. Most proteins and peptides have short plasma half-lives, thus requiring 
frequent injections therefore an alternative delivery mode that can offer controlled 
release is more attractive. Hence current research is focused on finding alternative 
routes of delivery, including inhaled, buccal, intranasal and transdermal routes as 
well as novel delivery systems.2 Transdermal delivery is an attractive option for the 
delivery of peptides for a number of reasons: it avoids first-pass degradation in the 
liver or GIT and the skin exhibits less enzymatic activity than the other routes of 
administration. In addition, whilst most proteins and peptides are intended for 
systemic action, many peptides have potential therapeutic or cosmetic value if they 
can be locally administered to target sites within the skin.3 Figure 1.1 describes the 
various sites of solute action after topical application to the skin. Therapeutic targets 
within the skin and underlying tissues vary according to disease localization and 
other factors. For instance, penetration of active ingredient to the depth of stratum 
corneum only is desired for sunscreens and insect repellants4. Treatment of acne 
requires drug targeting of pilosebaceous structures and in psoriasis therapeutic drug 
levels should be attained in deeper epidermal layers.5 Antimicrobial peptides (AMPs) 
are one class of peptides which may have potential in the management of atopic 
dermatitis, psoriasis and skin infections. A number of peptides are incorporated in 
cosmeceutical products, particularly those marketed for anti ageing. To be effective 
as either therapeutic or cosmetic skin care products or for systemic action, the 
applied peptide must reach its target site, either within the skin or systemically, in 
sufficient quantity to generate a therapeutic response and this requires overcoming 
the considerable barrier properties of the skin.6  
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 Figure 1.1 Sites of solute action below the skin after topical application7 
1.1 Skin barrier properties and function 
The skin is one of the most extensive and readily accessible organs of the human 
body with at least five different cell types contributing to its structure, and other cell 
types from circulatory and immune systems being transient residents of the skin.8 It 
receives about one-third of the blood circulation through the body.9 Its primary 
function is protection, including physical, chemical, immune, pathogen, UV radiation 
and free radical. For the purpose of transdermal drug delivery, human skin can be 
categorised into four main layers: the innermost hypodermis or subcutaneous fat 
layer, the overlying dermis, the viable epidermis and the outermost layer of the skin, 
the stratum corneum (Figure 1.2). 
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Figure 1.2  Structure of human skin 
The dermis (or corium) is typically 3–5 mm thick and is the major component of 
human skin. It is composed of a network of connective tissue, predominantly 
collagen fibrils providing support and elastic tissue providing flexibility, embedded 
in a mucopolysaccharide gel. In terms of transdermal drug delivery, this layer is 
often viewed as essentially gelled water, and thus provides a minimal barrier to the 
delivery of most polar drugs, although the dermis may be significant when delivering 
highly lipophilic molecules.10 
The epidermis, is approximately 100 to150 μm thick and contains four histologically 
distinct layers which, from the inside to the outside, are the stratum germinativum, 
stratum spinosum, stratum granulosum and the stratum corneum.10 The stratum 
corneum (or horny layer) is the final product of epidermal cell differentiation, and 
though it is an epidermal layer it is often viewed as a separate membrane in topical 
and transdermal drug delivery studies. Typically, the stratum corneum is around 10 
μm thick when dry, although it may swell to several times this thickness when 
hydrated.10 It is a nonviable, desiccated layer that acts as a first line of defense 
against invading microorganisms11 and contributes significant resistance to 
molecular transport both from and into the body.12 It is 10–15 cell layers thick over 
much of the body and, although histologic sections demonstrate wide separations 
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between corneocytes (the so-called "basket-weave" appearance), this is an artifact 
and the cells are actually tightly held to each other. The intercellular spaces between 
corneocytes are filled with stacked sheets of lipid bilayers whose organization and 
chemical composition confer a high degree of water impermeability. It is these lipid 
lamellae that constitute the epidermal permeability barrier, both to water and to other 
foreign materials.13 
1.2 Endogenous Peptides – Activity and therapeutic uses in human 
skin 
This physical skin barrier is susceptible to injuries or may be compromised by some 
diseases that allow the entry of opportunistic microbial agents into the skin.14 When 
these microorganisms gain access to the otherwise sterile internal environment, they 
activate a complex immune defence system.15 Human skin is also known to produce 
antimicrobial agents that form an innate epithelial chemical shield.16 These 
endogenous antimicrobial peptides (AMPs) are produced by the epithelial surface of 
the host.15 Two major classes of peptides have been identified in mammalian skin: 
defensins and cathelicidins. These peptides act as effector molecules and exhibit 
activity against a broad range of microorganisms such as bacteria, fungi and 
viruses.17-19 They are also involved in host repair and adaptive immune responses. 
Many AMPs have recently been isolated, including lysozyme, RNase 7, elafin, 
psoriasin, dermicidin1L, granulysin, antileukoprotease and human cationic 
antimicrobial protein (hCAP18).17, 20 The AMP activity in the skin is summarised in 
Table 1-1.  
1.2.1 Human skin diseases and relevant therapeutic peptides 
1.2.1.1 Atopic Dermatitis (AD)  
Atopic Dermatitis is a chronic inflammatory skin disease with abnormal expression 
or processing of AMPs.21 It is characterised by dry skin and involves non lesional 
skin and increased transepidermal water loss. Staphylococcus aureus can be isolated 
from skin lesions. The bacterium gains access to underlying viable skin layers due to 
skin barrier dysfunction, reduced skin lipid content, alkaline pH of the skin and 
increased deposition of fibrinonectin and fibrinogen. About 30% of patients with AD 
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have bacterial or viral infections of the skin, which is more than the 7% infection rate 
with psoriasis.22 LL-37 and HβD- 2 expression is greatly increased in patients with 
inflammatory skin conditions.19, 23 Furthermore, the AMPs that are normally induced 
in keratinocytes by inflammation show good antimicrobial activity against S. aureus, 
herpes simplex virus (HSV) and vaccinia virus.24 This suggests that lack of AMP 
expression in AD might contribute to bacterial and viral infections associated with 
the disease. Keratinocytes in lesional AD exhibit evidence of cytokine and 
lymphokine modulation.25 In addition, AD patients show reduced expression of DCD 
in their sweat. A marked reduction in viable bacterial cells on the skin surface of 
healthy individuals was observed after sweating, but not in patients with AD. Thus 
decreased DCD expression correlated with infection and therefore may contribute to 
the propensity of AD skin to recurrent bacterial and viral skin infections, and altered 
skin colonisation.26  
1.2.1.2 Psoriasis 
Psoriasis is a condition of unknown aetiology characterized by epidermal 
hyperplasia, vascular alterations and inflammation.27 Almost 2% of the population in 
western countries is affected by this disease and genetic factors are thought to be of 
fundamental importance in the expression of the disease. Many studies have been 
directed towards understanding the involvement of cytokines, growth factors and 
arachidonic acid derived mediators as potential candidates with a pathogenic role in 
cutaneous inflammation.27, 28 The protein psoriasin is highly upregulated in psoriatic 
epidermis and is most likely linked to the inflammatory stimuli.27 Identification of 
the receptor or cellular target for this protein will facilitate the development of new 
strategies to block the local epidermal inflammatory response that characterizes 
psoriasis.29 
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Figure 1.3 Development of psoriatic skin lesions30 
Expression of the peptide elafin is also elevated in the spinous layers of psoriatic 
skin.31 IL-1β and TNF- α are thought to be the major inflammatory cytokines 
released from PMN in the early stages of acute inflammation32 (Figure 1.3) and it is 
suggested that over-expression of elafin may be caused by IL-1β and TNF-α released 
by dermal neutrophils. In psoriatic skin this peptide functions as a protective agent 
against damage of the epidermis caused by neutrophil elastase.33 Antileukoprotease 
like elafin, a potent serine protease inhibitor, is also present in psoriatic scales with a 
role in protecting the psoriatic epidermis against proteolytic degradation.  
Peptide T analogue, D-[Ala]-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-amide (DAPTA) has 
been shown to clear psoriasis lesions in clinical trials.34 In this study it was seen that 
DAPTA significantly inhibited the monocyte and lymphocyte chemotactic properties 
of RANTES (a beta chemokine found in increased amount in psoriatic lesions).34  
ALP is present in psoriatic scales in concentrations sufficient for inhibition of 
neutrophil derived serine proteases human leukocyte elastase and cathepsin G.35 
Chronic inflammatory skin disorders could benefit from the development of serine 
protease inhibitors for use in therapy. The restitution of the HLE-HLE inhibitory 
balance in psoriasis may be of therapeutic value given that bathing in hypertonic 
solutions is known to remove HLE from the surface of psoriatic lesions.35 In 
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microbiocidal assays recombinant ALP exhibited antimicrobial activity against 
several human skin associated microorganisms like Pseudomonas aeruginosa, 
Staphylococcus aureus, Staphylococcus epidermidis and Candida albicans indicating 
that ALP may actively participate in mechanisms allowing homeostasis of bacterial 
and yeast colonization on human skin.36 
IL-1 is of particular interest in psoriasis because of its ability to stimulate production 
of chemotactic cytokines. IL-6 and IL-8 may directly contribute to the epidermal 
hyperplasia seen in psoriatic lesions. TGF-α, which is required for the normal growth 
of epithelial cells, is over-expressed in psoriasis.37 In addition EGF/TGF-α receptor 
expression is also increased in lesional epidermis.38 LTB4 levels are also seen to be 
increased in lesional psoriatic skin. Neutrophil activating peptide-1/IL-8, which is 
responsible for the release of LTB4 has been isolated from psoriatic skin. This 
peptide shares homology with a number of peptides which have pro-inflammatory or 
growth stimulating activities, such as β thromboglobulin, platelet factor 4, γ-
interferon and a peptide with melanoma growth stimulatory activity.39 
HD 2 and HD 3 have also been isolated from extracts of lesional scales of 
psoriatic skin18. In keratinocytes the expression of HD2 is induced by IL-1α, IL-1β 
or Pseudomonas aeruginosa.18 IL-1 and HD2 have a key role in epidermal defence 
during inflammation. It is known that secondary infection is rare in psoriasis. This 
has been attributed to the presence of a number of AMPs including granulysin which 
is known to be expressed in psoriatic plaques.40, 41 In addition, antimicrobial activity 
of lesional cytokines,42 defensin expression by keratinocytes and increased numbers 
of NK-T cells in lesions is likely to contribute to the bacterial resistance in psoriasis 
plaques. RNase 7 is another broad spectrum AMP present in normal skin and in 
elevated levels in psoriatic skin. Support for its antimicrobial defence action is 
strengthened by the observation that contact of keratinocytes with bacteria induced 
RNase 7 gene expression. In addition, peptide T analogue DAPTA, which inhibits 
the lymphocyte/monocyte chemotactic activities of RANTES, is expressed in high 
amounts in the keratinocytes of psoriatic tissue.34  
A better understanding of the role of these peptides may provide new strategies for 
the treatment of diseases like psoriasis and to prevent secondary infection in a 
number of skin conditions.43 For example, the development of peptides structurally 
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related to AMPs and/or with a similar mode of action as psoriasin (Table 1-1) could 
be utilised. Antimicrobial peptides can also be artificially induced to fight skin 
infections. Another strategy could be to apply substances known to induce AMP 
synthesis or activity such as L-isoleucine and some structurally related molecules.44 
1.2.1.3 Wound Healing 
The wound healing process involves four stages: inflammation, which involves the 
release of chemotactic agents; migration, where keratinocytes migrate from the 
wound edge towards the centre of the wound; deposition, which involves deposition 
of the matrix components in the dermis by fibroblasts and; maturation which 
involves contraction of the dermis and squamous differentiation of the keratinocytes 
on the wound surface. Cytokines act as mediators in all  four phases of wound 
healing.45 EGF, TGF and several other growth factors have been isolated from 
wounds and are known to promote keratinocyte growth and migration both in culture 
and in wounds.46 In a murine model, the EGF-receptor-mediated signalling systems 
played an active part in epidermal wound repair: an increase in the number of EGF 
receptors precedes the hypertrophic response, and a decrease precedes the attenuation 
of this response.47 Combinations of platelet derived growth factor (PDGF) with 
either IGF-1 or TGF-α have been shown to enhance connective tissue deposition, 
angiogenesis and collagen content and maturity.48 Potent activators of keratinocytes 
such as IL-1 have an important role to play in the wound healing process. IGF-1 and 
TGF-α also induce or enhance the expression of the antimicrobial 
peptides/polypeptides hCAP-18, hD-3, NGAL and SLPI in human keratinocytes 
thereby fighting potential secondary infection. TGF-α has also been shown to induce 
the expression of the same number of antimicrobial peptides/ polypeptides as the 
proinflammatory cytokine IL-1.49 PMN-specific α-chemokine IL-8 is a major 
biologically active PMN attractant in wound fluid but prolonged IL-8 levels may also 
contribute to additional healing activities in the later phases of wound healing. A 
strong correlation between TNF-α levels and IL-8 levels in wound fluid has been 
found.50 
During the proteolytic remodelling of the extra cellular matrix, small soluble RGD-
containing peptides are released into the matrix milieu.51 As these peptides are 
known to directly activate apoptosis they are likely to be especially helpful in 
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situations in which leukocyte accumulation and resistance to apoptosis contribute to 
disease pathology.52 They are useful in wound repair as they are internalized into a 
cell and are able to bind and activate caspase 3 inducing apoptosis.51 
Copper peptides have also been used as wound healing agents.53, 54 For example, 
glycyl-L-histidyl-L-lysine-Cu (GHK) accelerates wound healing and stimulates 
biological events important in tissue repair such as angiogenesis, nerve outgrowth 
and chemoattraction of cells critical to healing (e.g., macrophages, monocytes, mast 
cells, capillary endothelial cells). A stimulating effect of GHK-Cu on collagen 
synthesis by fibroblasts has been reported.54 Copper peptides have also been used in 
combination with retin A to reduce inflammation.55 These agents improve healing 
after cosmetic procedures such as chemical peels, laser and dermabrasion 
procedures, where they are reported to decrease skin inflammation by increasing skin 
nutrient density.55 
 
 
 11 
Table 1-1 Biological activity of various endogenous and synthetic peptides 
Peptide Abbreviation Source Biological Activity  Reference 
THERAPEUTIC PEPTIDES 
Adrenomedullin AM Keratinocytes of the epidermis and 
hair follicles, cells of the glands 
and secretary ducts of normal skin 
and in skin tumours of different 
histologies 
Antibacterial and antifungal activity. 
May be involved in the wound repair 
process and functions as a growth 
regulator. Role in skin homeostasis, 
carcinogenesis and acne vulgaris 
56 
Alpha defensins 
 
HNP-(1, 2, 3 
and 4) 
Neutrophil granules, macrophages, 
monocytes, T cells, paneth cell 
granules 
Antimicrobial effect, macrophage 
phagocytosis, complement activation 
57 
Antileukoprotease  ALP Human callus and detected in 
supernatants of cultured human 
primary keratinocytes 
Antimicrobial activity against several 
microorganisms and maintains 
homeostasis 
35, 36 
Antiflammin-1 and 
Antiflammin-2 
 Synthetic nonapeptides Potent anti-inflammatory action  58 
Cathelicidin  LL37 Keratinocytes, epithelial cells, 
neutrophils, monocytes, T cells, 
Mast cells 
Antimicrobial effect, cytokine and 
chemokine production by monocytes and 
keratinocytes 
59 
Copper peptides e.g. Gly-His-
Lys-Cu 
Synthetic Antioxidant, growth and regulation of 
hair follicles and increases collagen 
disposition 
53
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Dermicidin 1L DCD 1L Synthetic: recombinant dermcidin-
1L was expressed in Escherichia 
coli as a fusion protein and 
purified by affinity 
chromatography 
New class of potential broad-spectrum 
antimicrobial and anti-tumour drug 
60 
Elafin SKALP Isolated from psoriatic skin Specific inhibitor of human leukocyte 
elastase (HLE), porcine pancreatic 
elastase (PPE), proteinase3 
33, 61 
Granulysin  Psoriatic plaques Broad spectrum antimicrobial 62 
Growth hormone GH Expressed in whole human skin 
(normal and BCC) 
Assosciated with fibroblast activity, 
sebum production and induction of IGF-
1 production. 
63 
Human beta defensin   
 
HβD (1-4)  
 
Suprabasal keratinocytes of the 
skin and  sweat ducts within the 
dermis 
wound healing and 
skin diseases such as atopic eczema 
 
16, 64  
Human neutrophil 
elastase  
HNE  Detected in psoriatic lesions Physiological functions in host defence 
against bacterial infections and matrix 
remodelling following tissue injury 
65 
Interleukins  IL Released from an intracellular 
preformed pool in kaeratinocytes 
Involved in wound healing 50 
Peptide T  Synthetic Anti-chemotactic activity – therapeutic 
efficacy in psoriasis 
34 
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Proopiomelanocortin 
and melanocortin 
peptides  
POMC Found in the basal layer of the 
intermolecular epidermis. 
Stimulate eumelanin synthesis, 
antipyretic and antiinflammatory 
66, 67 
Psoriasin  Discovered in psoriatic skin 
lesions and constitutive expression 
in healthy skin keratinocytes 
Psoriasin preferentially kills E. coli, but 
has a weak antimicrobial activity against 
S. aureus, P. aeruginosa and Staph. 
epidermidis 
68 
RNase 7  Expressed in healthy skin (isolated 
from skin derived stratum 
corneum).  
Broad spectrum antimicrobial 43 
Skin peptide tyrosine-
tyrosine  
 
SPYY Isolated from the amphibian skin Antifungal and antiparasitic activity 69 70 
Soluble RGD peptides RGD Released during the proteolytic 
remodelling of the extracellular 
matrix 
Wound healing - internalized into a cell 
and able to bind and activate caspase 3 
inducing apoptosis 
51 
Transforming growth 
factor  
TGF-α, TGF-β Intercellular space of all the layers 
of the epidermis and the 
subepidermal area of the dermis. 
Regulator of both cell growth and 
differentiation 
71 
COSMETIC PEPTIDES 
Pal-KTTS  Pentapeptide fragment Stimulates collagen I and III and 
fibronectin production 
72 
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Acetyl hexapeptide- 3  Synthetic peptide Improvement in periorbital rhytides 73 
Palmitoyl 
pentapeptide-3 
 It is a fatty acid mixed with amino 
acids 
Superior anti-wrinkle effects (www.sederma.fr) 
Syn-Ake  Synthetic tri-peptide Anti-wrinkle/anti-aging effect (www.centerchem.co
m) 
Antioxidative collagen 
derived peptides 
e.g. Arg-Ser-
Arg-Lys 
Tetrapeptide Antioxidant and decreases cellular 
activity 
74 
Carnosine  Naturally occurring histidine 
containing dipeptide 
Wound healing and acts as an anti-
ageing peptide 
75,76 
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1.2.1.4 Viral disease 
Alterations in the skin barrier can lead to infection with bacteria and selected viruses, 
including herpes simplex virus, varicella-zoster virus and vaccinia virus. Evidence of 
the protective effect of AMPs in skin is demonstrated by the induction of epidermal 
cathelicidin LL37 during the development of verruca vulgaris and condyloma 
accuminatum, two human papilloma virus infections responsible for common 
cutaneous warts.77 The effects of cathelicidin, α-defensins, -defensins and control 
peptides on vaccinia virus replication in vitro have been investigated. Cathelicidins 
but not defensins demonstrated antibacterial activity which caused a reduction in 
vaccinia viral plaque formation.24 It was observed that mice deficient in the murine 
LL-37- equivalent showed less effective wound healing upon infection with group A 
Streptococci. Thus LL-37 is an attractive candidate as a novel therapeutic agent. A 
cathelicidin based indolicidin like peptide has been developed for acne treatment and 
is currently in phase 2 clinical trials (Migenix Inc., Vancouver, BC, Canada). LL-37-
versions for topical treatment of atopic dermatitis are in preclinical research stages 
(Ansata Therapeutics Inc., La Jolla, CA).44 
1.2.1.5 Human epithelial cancer 
Adrenomedullin (AM), a calcitonin gene related peptide is found to be present in 
normal and malignant skin. AM may be involved with the wound repair process, 
sustaining normal epidermal turnover and influencing tumour initiation and 
proliferation.78 It plays an important role in skin homeostasis and carcinogenesis.  
Some metastatic melanomas showed strong expression of AM at the periphery of the 
metastasis, whereas the majority of melanoma cells at the centre showed little or no 
expression. Keratoacanthoma showed a similar pattern of AM distribution. Thus, 
AM is a possible growth regulatory factor of the skin and malignant tissue, therefore 
targeted delivery to induce inhibition in malignant tissue could be a treatment option.  
1.2.1.6 Peptides as cosmeceuticals 
Cosmeceuticals are topical cosmetic- pharmaceutical hybrids lying on the spectrum 
between drugs and cosmetics.72, 79 There is an increasing trend towards the use of 
these agents in skin care regimens. There are numerous cosmeceutically active 
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products on the market which can be broadly classified into the following categories: 
antioxidants, amino-peptides, growth factors, anti-inflammatories, polysaccharides 
and pigment lightning agents.72 In most cases the overall purpose is antiageing but 
the method by which this is achieved varies. With the advances in biotechnology 
various peptides are now being used as cosmeceuticals. Examples include copper 
peptides, amino-peptides, acetyl hexapeptide-3 and dimethylaminoethanol.72 Copper 
peptides such as GHK-copper complex are included in products to improve skin 
firmness and texture, fine lines and hyperpigmentation.80 Pal-KTTS is a pentapeptide 
fragment that stimulates collagen I and III and fibronectin production in vitro and 
functions in wound healing. Another synthetic peptide, acetyl hexapeptide-3 when 
tested in an open label trial demonstrated improvement in periorbital rhytides 
(wrinkles on the face and near eyes).72,73 It is claimed to have muscle-relaxing effects 
similar to Botox injections (www.centerchem.com). Palmitoyl pentapeptide-3 
(Matrixyl) is a fatty acid mixed with amino acids (www.sederma.fr). Sederma 
conducted three different "half-face" studies with a total of about 45 participants 
showing the palmitoyl pentapeptide-3 product to have superior anti-wrinkle effects 
than a retinol or vitamin C product. Similar claims have been made for Syn-Ake, a 
synthetic tri-peptide based on Waglerin 1, a peptide derived from the venom of the 
Temple Viper (www.pentapharm.com). It reduces the contraction frequency of 
muscle cells in the face thereby decreasing expression lines to provide an anti-
wrinkle/anti-aging effect. 
Antioxidative collagen derived peptides are present in human placenta where they 
protect the embryo from oxidative stresses. The antioxidant activity of these collagen 
peptides accounted for approximately 15% of the total antioxidant activity of human 
placenta extract (PLx).81 A number of patents have been filed on the use of peptides 
for cosmetic products. These include the tripeptide Lysine-proline-valine for 
stimulating or inducing hair growth.82  Another patent describes topical compositions 
containing the tetrapeptide Arg-Ser-Arg-Lys for reducing wrinkles.74 This 
tetrapeptide is a fibroblast growth factor derived peptide which slows down or 
decreases cellular activity. Carnosine and related naturally occurring histidine 
containing dipeptides such as anserine, exhibit antioxidative properties by quenching 
free radicals.75,83,76 Carnosine also accelerates healing of wounds and ulcers and is 
reported to act as an anti-ageing peptide.75,76 Fibroblast collagen production has been 
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reported to be stimulated by a pentapeptide fragment (Lys-Thr-Thr-Lys-Ser) of the 
collagen molecule. It is a potent stimulator of collagen and fibronectin synthesis, 
which are both important components of the interstitial matrix84 and if enhanced can 
decrease signs of ageing in the skin. 
Growth factors act as regulatory proteins to mediate inter- and intra-cellular 
signalling pathways. They play an active role in wound healing and are involved in 
the induction of collagen, elastin and glycosaminoglycan formation. A study 
conducted by Fitzpatrick et al (2003) showed their efficacy in improving wrinkles 
through stimulation of epidermal thickening.85 
The use of chemically modified peptides for healing, hydrating and improving skin 
appearance has stimulated substantial patent activity. A combination of peptides with 
the general sequence X-Thr-Thr-Lys-Y was reported to have activity against the 
formation or deterioration of wrinkles.86 Cosmetic compositions have been 
formulated with at least one ceramide compound and one peptide attached to a fatty 
acid chain. Ceramides and their analogues have been known to protect and repair 
skin or hair fibres from damage caused by various agents and hair treatments. They 
provide a barrier effect which minimizes the leakage of proteins.87 Protein 
hydrolysates such as wool keratin hydrolysate were included in the formulation to 
improve ceramide binding to the skin or hair fibre. 
It is thus clear that many peptides play a wide variety of roles in normal skin and 
many are present or increased in skin disease. As we further develop our 
understanding of the role of these peptides in normal function and disease, the 
potential to exploit them for therapeutic or cosmetic purposes becomes clearer. This 
requires the synthesis of these peptides, or in some cases chemicals capable of 
inhibiting their action. In addition an efficient means of delivering them in an active 
form to their target sites within the skin is required. As many of these peptides are 
greater than 500 Da and hydrophilic in character they will not diffuse passively 
across intact skin, therefore their delivery will require an enhancement system. The 
potential for new treatment options, particularly for chronic skin diseases that are 
often poorly controlled by available therapeutics, is a priority in dermatological 
research. 
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1.3 Strategies to enhance delivery of peptides across the skin 
Recent developments in genetic engineering and biotechnology have resulted in an 
explosion in availability of therapeutic peptides and small anti-cytokines.  Oral 
administration is inappropriate as these molecules are unstable in the gastrointestinal 
tract and are subject to hepatic first-pass effect.88 Currently only a small number of 
transdermally delivered drugs are commercially available despite the potential 
advantages of this route of administration.  
 
 
Figure 1.4 Diagrammatic representation of the stratum corneum and the intercellular and 
transcellular routes of penetration89 
Ideal characteristics for successful transdermal delivery are a relatively low 
molecular weight (<500 Da) and melting point (<200°C), moderate lipophilicity (log 
P 1–3) and aqueous solubility (>1 mg/mL) and high pharmacological potency. A 
penetrant applied to the skin surface has three potential pathways across the 
epidermis: via the hair follicles and associated sebaceous glands; through sweat 
ducts; or across the continuous stratum corneum (Figure 1.4). The fractional surface 
area of the appendages is only about 0.1%90 therefore it is generally accepted that 
this route makes a negligible contribution to steady state drug flux into and across the 
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skin. It may, however, contribute in the early time period between drug application 
and establishment of steady state flux and could be a more important route for large 
polar molecules, polymers and colloidal particles that do not readily diffuse across 
the stratum corneum. This barrier layer is composed of primarily long chain 
ceramides, free fatty acids, triglycerides, cholesterol, cholesterol sulphate and 
sterol/wax esters.91, 92 It is generally accepted that the intercellular lipid matrix is the 
predominant route through the stratum corneum for the majority of penetrant 
molecules. Within the viable epidermis and dermis a number of proteases may exert 
enzymic degradation of peptides and proteins.93, 94 However the proteolytic enzyme 
activity in the skin is substantially less than GIT or hepatic enzymatic metabolism95 
and a transdermal delivery system tends to expose the peptide to a relatively small 
application area. The potential for metabolic activity in the skin must be considered 
in the design of the transdermal device and dose of active peptide required to be 
delivered to the target site. 
1.3.1 Skin penetration of peptides 
Peptides are hydrophilic and often charged molecules at physiological pH. They 
range in molecular weight from 300 Da to greater than 1000 kDa. Consequently their 
skin permeation is poor and despite generally having high potency, they are 
ineffective if administered transdermally. Several penetration enhancement 
techniques have been developed to overcome the skin barrier and facilitate the 
permeation of peptides and proteins through the skin. Strategies include chemical 
modification to form a conjugate with increased lipophilicity, encapsulation into 
hydrophobic carriers and administration with penetration enhancers which 
chemically or physically reduce the stratum corneum barrier. 89,96 
1.3.2 Optimisation of formulation and peptide characteristics 
1.3.2.1 Percutaneous Penetration Enhancers 
The most widely researched approach to enhance transdermal delivery of drugs is 
formulation with chemical penetration enhancers (sorption promoters or accelerants). 
These enhancers increase the diffusivity of the drugs by stratum corneum lipid 
fluidisation thus decreasing barrier function. This approach has been successful for 
enhancing the permeation of a wide range of small molecules but many of these 
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chemical penetration enhancers are of limited clinical application due to irritation. 
Magnusson and Runn97 reported enhanced transdermal penetration of M-TRH, an 
analogue of the endogenous tripeptide, thyrotrophin releasing hormone (TRH), in the 
presence of a terpene and ethanol vehicle. Steady state flux values for M-TRH across 
human epidermis from PBS were 0.34 mg/cm2/h. In the presence of 50% ethanol the 
flux increased threefold and a combination of 47% ethanol and 3% cineole resulted 
in a flux of 1.60 mg/cm2/h. Hence substantial enhancement was achieved for this 
small peptide but this approach is of limited value for larger peptides and care needs 
to be taken that enhancer chemicals do not denature the peptide. Karande et al 
reported the skin permeation enhancing properties of an anionic surfactant, sodium 
lauroylsarcosinate (NLS) and a non-ionic surfactant, sorbitan monolaureate (S20) in 
1:1 phosphate buffered saline (PBS):ethanol solvent. It was observed from the results 
that combinations of NLS and S20 exhibited significantly higher enhancement of 
skin permeability compared to that induced by individual surfactants. It was thus 
concluded based on the data generated from nuclear magnetic resonance (NMR) and 
fourier transform infra red (FTIR) studies that NLS acts as a strong extractor of 
stratum corneum lipids and S20 behaves as a weak fluidizer.98 The author also 
undertook a study to uncover the fundamental mechanisms that define the potency 
and irritation of chemical penetration enhancers and reported that the irritation 
behavior of chemical penetration enhancers is related to the ratio of hydrogen 
bonding to polar interactions.99 
1.3.2.2 Encapsulation 
Encapsulation involves the entrapment of a peptide drug within a polymeric, 
phospholipid or carbohydrate particulate delivery system such as microspheres, 
liposomes, or nanoparticles. Liposomes are phospholipid based vesicles which have 
been extensively investigated in transdermal delivery. It is generally acknowledged 
that whilst they are useful for local delivery to superficial skin layers they do not 
penetrate the epidermis intact. Encapsulation of interferon (IFN)-α into liposomes 
has been shown to increase deposition in the skin100 but increased penetration of 
macromolecules through the skin has not been demonstrated. A number of other 
liposome like vesicles with increased structural flexibility have been developed 
including transfersomes, niosomes and ethosomes. Ethosomes have been evaluated 
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with a number of small molecules and with insulin. When the effect of skin 
application of an ethosomal insulin formulation on blood glucose levels (BGL) in 
vivo in normal and diabetic rats was investigated, it was found that insulin delivered 
from the ethosomal patch significantly decreased (up to 60%) blood glucose level in 
both normal and diabetic rats. A prolonged plateau effect of at least 8h was also 
observed using the ethosomal insulin patch.101 Niosomes are vesicles composed of 
non-ionic surfactants that have been evaluated as carriers for a number of cosmetic 
and drug applications. Gupta et al studied the relative potential of transfersomes, 
niosomes and liposomes in non-invasive delivery of tetanus toxoid (TT). They 
observed that the entrapment efficiency, elasticity and topical effect with these 
encapsulated forms were higher than intramuscular administration of alum-adsorbed 
tetanus toxoid.102 In another study, conducted on trans-retinoic acid or tretinoin, the 
potential of niosomes as topical delivery systems capable of improving the cutaneous 
delivery of tretinoin was assessed. Tretinoin cutaneous delivery was strongly affected 
by vesicle composition and thermodynamic activity of the drug with negatively 
charged niosomal formulations showing higher cutaneous drug retention than both 
liposomes and commercial formulations.103 Transfersomes are composed of 
phospholipids such as phosphatidylcholine, but also contain surfactant which acts as 
an ‘edge activator’ conferring deformability on the vesicle.104, 105 However, in all 
cases scale up of these delivery systems to provide therapeutic peptide levels in 
humans is yet to be demonstrated. 
1.3.2.3 Chemical modification 
Lipophilic derivatives of peptides can be made either to increase the encapsulation 
efficiency into liposomes or directly increase their delivery through skin. The 
approach has been used successfully to enhance peptide permeability across 
intestinal and rectal barriers.106 Recently this approach has been applied to skin 
delivery. Foldvari et al100 reported cutaneous absorption of IFN-α with fatty acids 
with increasing chain length (C12, C14, C16, C18 and C18:1). The skin absorption 
of acylated IFNa derivatives was tested in a gel-type pharmaceutical formulation. 
The cutaneous and percutaneous absorption of acylated IFN-α was, overall, 2.5–5 
times greater than IFN-α. Increasing fatty acid chain length from 12 to 16 resulted in 
increased palmitoyl substitutions to lysine residues in the protein compared with the 
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parent IFN-α while further fatty acid chain increase lead to a decrease in absorption. 
In the early 1970’s it was shown that conjugating fatty acids to bovine serum 
albumin changed the immune response from humoral to a mainly delayed type 
hypersensitivity response. Subsequently, it was shown that dipalmitoyl-peptide 
conjugates in combination with Freund’s complete adjuvant were able to induce 
antibodies and cytolytic T cells (CTL) and lipopeptides were used.107 The major 
priority to improve the transmembrane absorption of poorly-absorbed compounds 
was to impart them with increased membrane-like character, by conjugation to 
lipidic amino acids and their oligomers. However, the resultant underivatised 
hydrophobic conjugates were often poorly soluble in water. The problem of 
maintaining the balance between the lipophilic and hydrophilic properties of the 
conjugates was addressed by modifying the lipidic amino acids themselves and 
secondly by conjugating the lipidic amino acids with hydrophilic molecules.108 
Lipoamino acid conjugated peptides and lipopeptides have been discussed in detail in 
section 1.5. 
1.3.2.4 Effect of hydration 
 
Figure 1.5 How hydration increases the fluidity of the stratum corneum lipids by insertion of 
water molecules between polar head groups109  
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The state of hydration of the stratum corneum may influence the percutaneous 
absorption of a drug. The stratum corneum water content at normal relative humidity 
is between 15 and 20% of dry weight. Increased water content results in increased 
elasticity and permeability of the stratum corneum, whereas reducing water content 
will lead to opposite effect.110 One of the proposed mechanisms for the increase in 
transport of the drug is by water being absorbed into the stratum corneum where it 
acts as a plasticiser in its bound state (Figure 1.5). Other studies suggest that the 
stratum corneum not only swells, but also develops multiple folds, resulting in a 37% 
increase in surface area.110 Increase in water content of the stratum corneum is 
associated with a decrease in lipid/protein phase transition temperature indicating 
lipid disruption and protein denaturation.111 Hydration does not always increase 
permeation and in case of molecules with strong lipophilic character there was no 
effect on the absorption rate.  
1.3.3  Physical Energy Application 
1.3.3.1 Iontophoresis 
Iontophoresis uses small voltage constant current (up to 0.5 mA/cm2) to push 
charged molecules into the skin. The main mechanism of enhancement is 
electrorepulsion whereby a solute with the same charge as an electrode placed on the 
skin surface is repelled into the skin.112 The applied current also has a direct effect on 
skin permeability and causes electroosmosis, the convective flow of water molecules 
which enhances the permeability of neutral solutes.113 Iontophoretic transdermal 
delivery of a number of peptides has been demonstrated, including luteinising 
hormone releasing hormone (LHRH), TRH, cyclosporin, nafarelin, arginine 
vasopressin (AVP), octreotide, calcitonin and insulin.105 
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Figure 1.6 Infosys system: patient controlled analgesia by iontophoresis enhanced 
transdermal fentanyl delivery (Alza corp) 
Iontophoretic delivery of peptides has been extensively investigated by Guy’s group 
who have generated an understanding of the primary mechanism of enhancement for 
peptides and attempted to develop peptide structure-penetration relationships. 
Computational studies that generated 3D quantitative structure-permeation 
relationships predicted that iontophoresis was favoured by peptide hydrophilicity and 
hindered by voluminous, localized hydrophobicity.114 This was particularly the case 
where the bulky lipophilic moiety was directly adjacent to a positively charged 
residue, as occurs in nafarelin and leuprolide. It has been suggested that this structure 
inhibits electroosmosis, thereby reducing iontophoretic transport.115 Interestingly, the 
molecular characteristics that favour electrotransport are the converse of those that 
favour passive diffusion. Combinations of iontophoresis with chemical enhancers 
and formulation modifications have been investigated. For example, Boinpally et 
al116 reported that the in vitro transport of cyclosporine from lecithin vesicles under 
anodal iontophoresis was greater than when applied in combination with a 
microemulsion. Pillai and coworkers117 have systematically investigated the 
iontophoretic delivery of insulin with a range of solvents and chemical penetration 
enhancers. Whilst increased skin penetration could be achieved this was frequently 
associated with increased skin irritation. To date, iontophoretic transdermal delivery 
of large peptides and proteins sufficient to achieve therapeutic outcomes in humans 
has not been demonstrated. However the technique may be useful for local delivery 
of small peptides (less than 10 kDa) in the treatment of skin conditions or lesions.105 
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1.3.3.2 Electroporation 
Electroporation involves the application of high voltages (100–1000 V) in short 
pulses (1–100 ms) to induce transient structural changes in the stratum corneum lipid 
bilayers which manifest as aqueous pores.118 The electrical pulses cause a transient 
drop in skin resistance of up to three orders of magnitude which is associated with an 
increase in permeability up to three to four orders of magnitude for small and 
macromolecules. Enhancement of peptide permeation by electroporation has been 
shown to be substantially greater than by iontophoresis. For example, Prausnitz et 
al119 demonstrated in vitro skin permeation of heparin by electroporation at amounts 
equivalent to therapeutic levels (100–500 mg/cm2 h). This was an order of magnitude 
greater than the heparin flux achieved with iontophoresis. Sen et al120 reported a 20-
fold increase in transport of fluorescence- labelled insulin across porcine epidermis 
when applied in the presence of an anionic phospholipid (1,2-dimyristoyl-3-
phosphatidylserine) with electroporation compared with electroporation alone. The 
main question associated with electroporation is patient tolerance. Many of the 
studies of electroporation to date have involved in vitro or animal experimentation 
with few clinical studies. In a study of electrochemotherapy of melanoma lesions, 
local injection of bleomycin followed by electroporation was applied to multiple 
lesions on 12 patients. All patients reported discomfort during electroporation with 
mild pain and/or muscle spasms.121 Recent studies have indicated that it may be 
possible to modify the applied electroporation parameters to reduce muscle spasms 
whilst maintaining electrochemotherapeutic efficacy. If these side effects can be 
overcome, the potential clinical applications of electroporation in transdermal 
delivery are worthy of further investigation.105 
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1.3.3.3 Sonophoresis 
 
Figure 1.7 The basic design of ultrasonic delivery devices (A) Drug is placed on the skin 
beneath the ultrasonic probe. Ultrasound pulses are passed through the probe and drug 
molecules are hypothesized to move into the skin through a combination of physical wave 
pressure and permeabilisation of intercellular bilayers. (B) The formation of bubbles in the 
intercellular lipid space caused by cavitation increases bilayer fluidisation and resultant 
permeability 96 
Ultrasound at therapeutic frequencies (1–3 MHz) as used in physical therapy was 
first applied to enhance the skin penetration of small drugs in the 1980s. More 
recently low frequency ultrasound (<100 kHz) has been used to provide greater 
enhancement and has been extended to the delivery of macromolecules across intact 
skin.122 The mechanism by which the acoustic waves enhance permeability through 
the skin is not fully understood but it is hypothesized that these waves cause 
microcavitation in the skin which disorders the stratum corneum lipid bilayers, 
thereby promoting drug diffusion (Figure 1.7). In addition, it has been reported that 
ultrasound causes stratum corneum lipid extraction which contributes to increased 
permeability.123 Ultrasound enhanced transdermal delivery of a number of peptides 
and proteins has been reported including insulin, erythropoietin, IFN-γ and 
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heparin.105 These studies utilised a range of ultrasonic transducers and baths. 
Recently, a miniaturised ultrasound system was developed and investigated. This 
system involves an array of ultrasound transducers and offers the potential of 
development as a transdermal patch. For example, following application of insulin 
with or without ultrasound to six pigs blood glucose decreased by 72±5 mg/dL at 60 
min (p<0.05) and 91±23 mg/dL at 90 min compared with an increase of 31±21 mg/ 
dL in the control animals (p<0.05) from baseline glucose level (146±13 mg/dL).124 
The authors concluded that their cymbal array ultrasound system has potential for 
noninvasive transdermal insulin delivery for diabetes management. Patient 
acceptance and safety of therapeutic ultrasound in physical therapy applications is 
well established. Short periods of low frequency ultrasound pulses as used for the 
SonoPrep local anaesthetic application (10 sec 55 kHz of ultrasound pretreatment) 
also seem to be well tolerated,125 however these very short pretreatments and low 
intensities are unlikely to be sufficient to generate therapeutically relevant 
transdermal delivery of large molecules. 
1.3.3.4 Photomechanical waves 
Photomechanical waves are generated by the impact of laser radiation on a target 
material (e.g., polystyrene) that is then directed towards the skin surface. Lee and 
coworkers126 have hypothesised that these stress waves cause transient 
permeabilisation of the stratum corneum sufficient to permit the diffusion of 
macromolecules. Delivery of insulin through the skin of diabetic rats by this 
technique caused a reduction in blood glucose of 80±3%, with the level maintained 
below 200 mg/dL for 3 h.127 Delivery of oligonucleotides, DNA and 100 nm 
microspheres has been reported, though the recently introduced technique has yet to 
be tested on human subjects. 
1.3.3.5 Magnetic energy 
Limited work has been undertaken to investigate the ability of magnetic fields to 
move diamagnetic substances through skin.128 Langer discussed the interesting idea 
of employing intelligent systems based on magnetism or microchip technology to 
deliver drugs in controlled, pulsatile mode.129 An alternative method for achieving 
pulsatile release involves using microfabrication technology to develop active 
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devices that incorporate micrometre- scale pumps, valves and flow channels to 
deliver liquid solutions.129  
 
 
Figure 1.8 Schematic of PEMF Dermaportation waveform 
In this study a novel physical skin penetration enhancement technology was 
investigated for peptide delivery. Dermaportation (OBJ Ltd) is a Pulsed Electro 
Magnetic Field (PEMF) platform technology that applies electromagnetic pulses to 
enhance skin permeation and push target molecules away from the field. The 
technique utilizes a time varying electromagnetic field that is believed to interact 
with the skin to enhance transdermal delivery. At the heart of the Dermaportation 
system is a low energy time varying quasi-rectangular PEMF. Each pulse has a 
rapidly rising and falling edge (Figure 1.8) that is hypothesised to induce localized 
electromagnetic field effects in the stratum corneum environment. Biological and 
therapeutic effects of electromagnetic fields and inductive effects on biological 
tissues have been widely reported, for example, enhancement of healing of venous 
ulcers and bone fractures and effects on a range of cellular functions.130, 131 
Dermaportation uses a low voltage (3V) and does not require direct physical contact 
with the skin to produce diffusion enhancement. This offers potential advantages, 
particularly in wound management and drug delivery into the skin. In addition, the 
fabrication of small self contained Dermaportation patches is possible due to the low 
energy requirements. The standard Dermaportation system (DP1001) generates a 
specific pattern of energy pulses that have been shown to induce transdermal flux 
increases during field exposure of a number of small molecules, such as 5-
aminolevulinic acid132, diclofenac diethylammonium salt133 and lidocaine 
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hydrochloride.134 . It is proposed that Dermaportation energy influences both the 
molecular movement of drug molecules in the epidermis and the ordered structure of 
the stratum corneum lipid bilayers but the precise mechanism of enhancement is an 
area of continuing investigation.  
1.3.4 Minimally invasive strategies for enhancing delivery 
1.3.4.1 Microneedles 
 
Figure 1.9 Images of microneedles used for transdermal drug delivery135 
Microneedles are an application of the microfabrication technology whereby an array 
of needles is used to pierce the skin in a minimally invasive manner to create a 
physical pathway for drug diffusion.136 The microneedle array (Figure 1.9) is applied 
to the skin surface so that the needles (usually about 150 mm in length) penetrate the 
epidermis to bypass the stratum corneum and deliver drug directly to the viable 
epidermis. As the epidermis is devoid of nociceptors and the microneedles do not 
penetrate to the nociceptors of the dermis, a pain sensation is not elicited. The 
microneedle technology has been applied to the transdermal delivery of a number of 
macromolecules. Martanto et al137 reported decreased plasma glucose levels of up to 
80% in diabetic rats following administration of insulin solution for 4 h preceded by 
a 10 min application of a 105 stainless steel solid microneedle array. However the 
insulin delivery levels achieved in laboratory animals are considerably lower than 
those required by humans and the technique has yet to be tested clinically. Safety has 
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been one of the main concerns raised since microneedles were first introduced. 
However it has been reported that breakage of silicon microneedles is minimal if the 
array is inserted gently and carefully.136  
1.3.4.2 Jet injectors 
A number of devices are commercially available which propel solid particles or 
liquid droplets into the skin at high velocity. They offer a needle-less alternative to 
the traditional injection. The current applications are for the administration of 
recombinant human growth hormone (hGH), insulin and vaccination. There has also 
been interest for small molecules, other proteins, gene delivery and 
immunotherapeutics. The premise that jet propulsion is less painful than 
conventional needles has not been substantiated.105 
1.3.5 Stratum corneum ablation 
It is well known that the stratum corneum is the main skin barrier therefore its 
removal will dramatically enhance skin penetration and water loss. A number of 
techniques have been developed to provide a controlled removal of the SC. These 
techniques are discussed below: 
1.3.5.1 Laser ablation 
A high energy laser directed at the skin surface can remove the stratum corneum to 
increase drug permeability to subsequently applied drugs. Nelson et al138 first 
described the technique in 1991 when they reported a 2.1 times increase in the 
permeability coefficient of IFN-γ across pig skin that had been exposed to a laser at 
2790 nm. The safety and reversibility of the technique is yet to be established and it 
is likely that laser ablation would be restricted to the clinical setting with limited 
application. Laser ablation is also widely used by beauticians to improve skin tone.  
1.3.5.2 Radiofrequency (RF) thermal ablation 
TransPharma Medical’s application of its RF-microchannel technology is the 
ViaDerm system which consists of a microarray of radiofrequency electrodes which 
create microchannels in the epidermis by cell ablation thereby permitting drug 
diffusion via the microchannels. The technology has been evaluated for transdermal 
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delivery of small hydrophilic drugs, peptides and genes. Bioavailability of hGH 
applied by ViaDerm to rats was 75% of the subcutaneous injection and recently the 
delivery of 100 nm nanoparticles and gene therapy vectors was demonstrated. The 
technique also appears to be well tolerated with only mild erythema reported and as 
the energy is restricted to the upper epidermis, dermal nociceptors are not affected 
therefore minimal pain would be expected.105  
1.3.5.3 Suction blister ablation 
A mechanical device exerts a vacuum to cause a small blister on the skin which is 
then removed to expose a site for drug application.139 According to Svedman et al 
only the epidermis is split off by this suctioning and it does not cause bleeding or 
discomfort because the effect is superficial to the dermal capillaries and nociceptors. 
They reported the application of the antidiuretic peptide 1-deamino-8-D-arginine 
vasopressin with close to 100% bioavailability in healthy human subjects with 
recovery of the skin spot to normal after 6 weeks. However, further research into this 
technique has been undertaken in the past 10 years or by other groups so it is 
unlikely that this technique will progress further for peptide delivery.105 
1.3.5.4 Thermal poration 
Thermal poration involves the application of pulsed heat to form micron scale 
aqueous pathways across the stratum corneum. Badkar et al140 recently demonstrated 
transdermal delivery of interferon alpha in hairless rats using thermal poration alone 
and a twofold increase when combined with iontophoresis. Iontophoresis alone and 
passive application did not result in transdermal flux of interferon. 
1.3.5.5 Combination of technologies 
The combination of two or more of these enhancement techniques to generate a 
synergistic enhancement effect has been extensively explored and offers promise for 
the future development of transdermal products.141 For example, Srinivasan et al142 
reported several-fold enhancement of transdermal leuprolide delivery by application 
with iontophoresis after a pretreatment with ethanol. Choi et al143 suggested that 
pretreatment with chemical enhancers dilated intercellular spaces and reduced skin 
impedance thereby increasing the effectiveness of iontophoresis of insulin. 
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Synergistic effects between physical enhancement techniques have also been 
reported. The application of a single electroporation pulse prior to iontophoresis 
increased the transdermal flux of LHRH by five to ten times as compared to 
iontophoresis alone. This combination also increased the transdermal flux of human 
parathyroid hormone (hPTH) up to 10 times greater than electroporation alone. 
These studies do raise the possibility of using combinations of enhancement 
approaches to achieve therapeutically relevant delivery of proteins and peptides to 
and across the skin. Whilst the safety and patient tolerability of these combinations 
must be fully established they do offer opportunities for effective delivery 
alternatives.105 
1.4 Lipopeptides and lipoamino acid conjugation approaches to 
enhance the stability and delivery of peptides across biological 
barriers 
The problem with most peptides is delivering them to the specific site, in an intact 
and biologically active form and without the peptide being integrated into other 
tissues.107 In order for a peptide to be of significant value as a drug, there are several 
potential problems that must be overcome as discussed in previous sections. Novel 
drug-delivery systems for the oral administration of drugs and peptides, which are 
normally poorly absorbed or biologically unstable have been developed by 
combining the peptide or drug with a lipoamino acid (LAA) or liposaccharide (LS), 
lipopeptides, liposomes and polyethylene glycol (PEG) conjugates which can act as a 
carrier.107  
Increasing lipophilicity by addition of long aliphatic chains or lipid moieties is an 
established method of increasing bioavailability. This technique increases the 
permeability across the epithelial barriers or can increase uptake by the lymphatic 
system. Passive diffusion is the major route for compounds crossing the epithelial 
barrier and so is the most important target for increasing bioavailability. Presence of 
lipid groups on peptides has been shown to significantly increase the biological half 
life of peptides.144 LAAs combine the properties of amino acids with those of lipids; 
thus combining them with a peptide or drug provides a means of transporting the 
compound into the body in a stable and biologically active form.145, 146 The linkage 
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between drug and lipidic unit may either be biologically stable (such that a new drug 
is formed) or possess biological or chemical instability (when the conjugate will be a 
pro-drug). In either case, the resulting conjugates would be expected to possess a 
high degree of membrane-like character, which may be sufficient to facilitate their 
passage across membranes. The long alkyl side chains may also have the additional 
effect of protecting a labile parent drug from enzymatic attack. The LAA system has 
also been used to increase the oral absorption of various drugs including peptides, β 
lactam antibiotics147 and benzoquinolizine alkaloids.108 Conjugation to lipidic 
peptides increased the half-life of LHRH and TRH with the peptides subsequently 
being released from Caco-2 cell homogenates. The released LHRH or TRH 
subsequently demonstrated a longer half-life than when present alone in the 
incubation mixture, suggesting that the cleaved lipidic peptide is capable of 
inhibiting enzymes.148 Table 1-2 lists some of the examples of peptides conjugated to 
lipoamino/fatty acids 
Research has been carried out to investigate the effect of lipoamino acid and 
liposaccharide conjugation on the activity of a somatostatin analogue TT-232.149 The 
combination of LAA’s with TT-232 resulted in bifunctional conjugates where the 
long alkyl side chains were lipophilic and the peptide part was hydrophilic (Table 1-
2). Conjugation with LAA’s resulted in higher lipophilicity which is essential for 
crossing biological membranes but the conjugate has to have a certain degree of 
water solubility for absorption through the gut. Sugars were hence conjugated to TT-
232 to increase the water solubility. This not only improved physicochemical 
properties of parent compounds, such as solubility, but also allowed the conjugate to 
utilize active transport uptake systems (e.g. the Na+-dependent D-glucose 
transporter) and help target the compound (e.g. sialyl Lewis-X sugars, elevated â-
glucuronidase expression in some tumours). The results indicated that there was no 
clear correlation between the biological activity and the length of the side chain of 
the LAA, or the presence of a spacer between the N-terminus of the molecule and the 
ligand, or the presence of an additional carbohydrate moiety. It was thus concluded 
that modification of the N- and C- termini of TT-232 with LAA or LS resulted in 
amphipathic surfactant-like molecules with higher bioavailability and stability.  
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Toth et al146 also synthesized and evaluated LAA and carbohydrate modified 
enkephalins. These centrally acting anti-nociceptive agents are ideal molecular 
templates for the development of novel analgesics which may not produce the 
undesired side effects exhibited by opioids currently utilised in the clinic. However, 
as with most other peptides, the native compounds are rapidly catabolised via 
enzymatic degradation following administration, and the amount remaining in the 
blood stream displays poor BBB permeation due to its highly polar nature. The in 
vitro data suggested that C- terminal modifications of the leu-enkaphalin structure 
were more favourably tolerated than the N- terminal modifications. The in vitro 
activities of the peptide conjugates were established using MVD (mouse vas 
deferens) and GPI (Guinea pig ileum) assays. However, C-terminal conjugation of 
one or two glucuronic acid analogues to the native peptide via amide linkages led to 
a dramatic increase in activity. Thus, it can be concluded that conjugation of the 
native peptide with a lipoamino acid did not lead to any significant decrease in the 
biological activity of the peptide (Table 1-2).146 In addition a novel  lipid core 
peptide (LCP) system was developed by incorporating lipid amino acids to the poly 
lysine system to enhance lipophilicity and membrane binding effects and the stability 
of the LCP system.150 
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Table 1-2 Lipoamino acid/lipophilic conjugation of peptides 
Peptide Experimental detail Outcome Reference 
Somatostatin 
analogue TT 32 
A somatostatin construct with lipid and sugar moieties at 
opposite ends was synthesized so that the entire molecule 
could be considered as an amphipathic surfactant 
Conjugation with LAA’s resulted in higher 
lipophilicity and the conjugated sugars increased water 
solubility and no loss of anti proliferative activity was 
observed 
149 
Enkephalins LAA and carbohydrate modified enkephalins were synthesized 
The C – terminal analogues of the LAA peptide 
conjugates displayed activity whilst the dimers were 
inactive. Inclusion of a glucose or glucuronic acid 
moiety into the lipopeptide structure decreased activity. 
144 
Methotrexate 
MTX was conjugated through one or both of its glutamate 
carboxyl groups to LAA with varying side chain lengths to 
alter the lipophilicity and solubility of the adducts 
The results indicated that the carboxylic conjugates 
showed higher encapsulation in neutral and positive 
liposomes whereas the DPPS-containing negative 
vesicles gave lower encapsulation 
151 
Thymogen 
(IM862) 
A library of eight novel derivatives of the dipeptide IM862 
was designed and synthesized by conjugating dodecanoic 
α-amino acid (C12) and/or β-D-glucuronic acid (GlcA). 
Nearly all the synthesized lipid and glycoside 
conjugates displayed greater permeation due to 
increase in lipophilicity 
152 
Endorphins 
(opoid peptides) 
Endo 1 and lipopeptides (C12 LAA-endo-1) loaded 
liposomes were examined for their stability and membrane 
permeability via Caco 2 cells 
Endo-1 was in a homogenate of Caco-2 cells with a 
short half life while a 3-fold increase in stability was 
observed with liposomal formulation. The apparent 
permeability of C12 LAA-Endo-1 was similar to that of 
Endo-1. An increase in apparent permeability was 
observed for shorter LAA conjugates (C8 and C10). 
 
153 
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Occludin peptide 
Lipopeptide derivatives of one of the active occludin 
peptides (OPs), were synthesized by adding a C14-LAA 
the N terminus. 
The L- and D-diastereomers of C14-OP 90–103 had 
distinctly different effects. The D-isomer, which 
released intact OP 90–103 from the lipoamino acid, 
displayed a rapid and transient increase in tight 
junction permeability. The L-isomer, which released 
OP 90–103 more rapidly, was seen to have a more 
sustained increase in tight junction permeability 
154 
Phenylalanine-
Glycine 
Butyric acid (C4), caproic acid (C6) and octanoic acid (C8) 
was conjugated to Phe-Gly 
No permeation of parent peptide observed and skin 
permeation of C6 acyl derivative was found to be 
highest. Acyl Phe-Gly derivatives increased the 
stability of the dipeptide 
155 
DADLE (Tyr-D-
Ala-Gly-Phe-D-
Leu) 
Derivatives were synthesized with various fatty acids by 
conjugation at the C terminus to increase their stability and 
permeability in the intestine. 
Higher permeability for DADLE-C2, DADLE-C4, and 
DADLE-C6 was observed in comparison to native 
DADLE, and DADLE-C4 showed the highest 
permeability across the jejunum and colon. The 
permeation of DADLE-C8 was lower than native 
DADLE despite being the most lipophilic derivative. 
156 
Cyclosporine 
(CsA) 
Arginine oligomers were conjugated to CsA to facilitate 
transdermal delivery 
The amount of conjugate delivered and the free drug 
released was therapeutically effective in an animal 
model of contact dermatitis in which preparations 
containing 1, 0.1 and 0.01% of a chemically releasable 
CsA conjugate reduced ear inflammation. 
157 
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Figure 1.10 Lipoamino acid conjugate of methotrexate151 
In 2003, Pignatello et al151 studied the effect of liposomal delivery on in vitro antitumor 
activity of lipophilic conjugates of methotrexate (MTX) with lipoamino acids (Figure 
1.10). In previously published studies, they had described the synthesis and preliminary 
biological evaluation of a series of conjugates of methotrexate with lipoamino acid 
residues (Table 1-2). The activity exhibited in vitro by the liposomal formulations was 
found to be comparable to or lower than that of one of the free drugs after the same 
times of incubation. Therefore, inclusion in the phospholipid vesicles did not further 
improve the penetration through cell membranes by passive diffusion of these lipophilic 
conjugates. The highest improvement of activity with respect to the free compounds was 
generally observed by encapsulating the conjugates in positively charged (Stearylamine 
containing) liposomes.  
Another study was undertaken to investigate the use of liposomes for the delivery of the 
lipopeptide antigens, with the intention of enhancing uptake and subsequent cellular 
expression of the entrapped antigen. Synthetic lipopeptides were synthesized by 
conjugating C8, C12 and C16 LAA to the antigens. This conjugation enhanced the 
immune stimulatory capacity of peptide antigen. However, encapsulation of lipopeptides 
within liposomes appears to compromise their immune stimulatory capacity at least at a 
loading of 10% when tested in cell culture. Only the C12 lipopeptide encapsulated in 
liposomes showed enhanced activity over unmodified peptide either alone or 
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encapsulated in liposomes.158 Research has also been undertaken on a naturally 
occurring thymic peptide, Thymogen, is a dipeptide shown to possess immuno-
modulating and anti-angiogenic properties. It is highly hydrophilic in nature and hence 
demonstrates low permeability across the gastrointestinal tract. The dipeptide L-Glu-L-
Trp-OH is under development for potential treatments of certain cancers and immuno-
deficiency disorders. Intestinal permeability was studied using Caco 2 cell layers and it 
was observed that the permeability of IM862 alone could not be determined as its 
concentration was below the limit of quantification, hence confirming the poor oral 
absorption of the dipeptide (Table 1-2). In comparison, nearly all the synthesized lipid 
and glycoside conjugates displayed greater permeation values.152  
 
Figure 1.11 Structure of Endo 1 and C12-LAA-Endo 1153 
Endorphins (opioid peptides) were isolated from mammalian brain tissue and are widely 
distributed in the human CNS. These peptides were not favourable drug candidates due 
to low stability and poor membrane permeability. To fulfill their potential as 
pharmaceutically relevant pain-modulating compounds, pharmacokinetics of these 
peptides must be improved. LAA residues (8,12,18 carbons) were introduced as a 
racemic mixture of both the L- and D-stereoisomers.153 These modified endorphin 
peptides overcame the poor metabolic stability and the low membrane permeability in 
vitro. In a follow on study the endo 1 and lipopeptides (C12 LAA-endo-1) (Figure 1.11) 
loaded liposomes were examined for their stability and membrane permeability and it 
was concluded that the liposomal formulation of endo 1 and C12 LAA-Endo-1 formed 
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stable emulsions in buffer and the liposomal preparation of the lipopeptide had higher 
metabolic stability than the liposomal formulation of the native peptide (Table 1-2). The 
permeability across Caco-2 cell monolayers of both peptides was also improved 2-fold 
with the liposomal formulation.159 Staffan et al also investigated the effect of LAA 
conjugation to long chain peptides such as occludin (Table 1-2). It was concluded from 
this study that their can be clear differences in the permeability/stability of the D- and L- 
diastereomers after conjugation to a peptide.154  
Polysaccharides have also been used for delivering drugs to colon. The rationale for 
using polysaccharides as a delivery system is the presence of a number of 
polysaccharidases in the colon which degrade the carrier and release the drug. Some of 
the polysaccharides that have been studied for delivering drugs to colon include 
chitosan, pectin, cyclodextrin, dextrans and inulin.160 One example of polysaccharides is 
dextrans which have varying molecular weights. These compounds have been used most 
widely to modify the pharmacokinetics of drugs. Examples of their use include the local 
delivery of anticancer and chemisensitiser drugs using biodegradable dextran ion-
exchange microspheres.161 
Fatty acid addition to peptides can enhance bioavailability and membrane permeability 
of peptides that are poorly absorbed.162 Whittaker et al163 used 2-amino-2-hydroxy-
methyl-1,3-propanediol (tris) a common laboratory reagent to link fatty acyl groups to 
peptides. Improvement in the transdermal delivery of tetragastrin by lipophilic 
modification with fatty acids (acetic acid and butyric acid) has also been studied. The 
flux of these acyl derivatives was in the order of acetyl > butyroyl > caproyl. The 
stability of tetragastrin in skin homogenate was also significantly improved by chemical 
modification with fatty acids. These results suggested that chemical modification of 
tetragastrin with fatty acids increases its lipophilicity, which makes it permeable across 
the skin. Moreover, it also reduced the degradation in the viable skin, resulting in 
increase in permeation of tetragastrin across the stratum corneum.164  
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R = C4, C6 or C8 
Figure 1.12 Phe-Gly and its acyl derivatives155 
Lipophilic derivatives of Phe-Gly have also been synthesized by chemical modification 
with butyric acid (C4), caproic acid (C6) and octanoic acid (C8) (Figure 1.12). The in 
vitro stability, permeability and accumulation of this peptide were investigated in rat 
skin. The native peptide rapidly degraded in the skin homogenates but the acyl-Phe-Gly 
derivatives were more stable than the parent peptide. Also no significant difference was 
observed in the stability of the acyl-Phe-Gly derivatives. All the three derivatives 
permeated across the skin and the permeation of the C6 acyl derivative was the highest. 
No permeation of the parent peptide was observed. These results thus, suggested that it 
was possible to adjust the lipophilicity of Phe-Gly derivatives by conjugating them with 
fatty acids and higher the carbon number of the fatty acids higher is the stability and the 
transdermal absorption (Table 1-2).155 Chemical modification of peptide and protein 
drugs is a potentially useful approach because it can alter the various physicochemical 
properties of peptides and proteins, such as an increase in their molecular weights and 
lipophilicity and alter their in vivo pharmacokinetic behaviour. Furthermore, Fujita et al 
found that acyl peptides were more permeable across the intestine than the native 
peptides while retaining their biological activities. They studied the intestinal absorption 
of chemically modified of hCT (human calcitonin) and investigated the synergistic 
effects of acylation and absorption enhancers on its intestinal absorption.165  
In a study conducted by Uchiyama et al DADLE (Tyr-D-Ala-Gly-Phe-D-Leu), an 
enkephalin analogue, was chosen as a model peptide, and new lipophilic derivatives of 
DADLE were synthesized by chemical modification (Table 1-2). It was found that the 
derivatives had at least 75% activity of the native DADLE. DADLE was also found to 
be relatively stable and is resistant to aminopeptidases, carboxypeptidases and 
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enkephalinases. The higher permeability of these derivatives across jejunum and colon 
in comparison with native DADLE might be accounted for by their lipophilicity.156  
Another interesting study was published by Rothbard et al where they studied the 
conjugation of arginine oligomers to cyclosporine to facilitate transdermal delivery 
through the skin. Orally administered CsA is effective against a broad range of 
inflammatory skin diseases, including widespread conditions such as psoriasis and 
atopic dermatitis; however, systemic administration is limited by considerable side 
effects, including nephrotoxicity and many drug interactions. Topical application of CsA 
has been proven ineffective in a range of inflammatory disorders due to poor topical 
absorption. Short oligomers of arginine efficiently cross biological membranes and can 
be used to facilitate the uptake of a variety of small molecules to which they are attached 
(Table 1-2). The results indicated that short oligomers of arginine facilitated transport 
across the cutaneous barrier when applied topically.157 Lipoamino acid and lipid 
conjugation thus, holds promise in modifying the properties of different therapeutic 
peptides by increasing their stability, lipophilicity, permeability across biological 
barriers and in some cases the activity of these molecules which are of therapeutic 
significance in the treatment of various diseases. 
1.5 Peptides as dermatological and cosmetic agents 
A number of small peptides have been identified for their therapeutic or cosmetic 
potential in the skin. In this project we have investigated the skin permeation of Alanine-
Tryptophan (Ala-Trp) as a model dipeptide.  
1.5.1 Small peptides as cosmeceuticals 
For example, carnosine (β-Ala-His), a widely researched peptide is implicated in 
biological activities such as wound healing and as an antioxidant. The native peptide has 
very low affinity for the skin and does not permeate beyond the first layer of the stratum 
corneum, the outermost region of the epidermis. However, when a palmitoyl chain is 
attached to the terminal –NH2 group the lipopeptide has been shown to diffuse into the 
stratum corneum, epidermal and dermal skin layers and remain localized without any 
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systemic activity.166 Lys-Thr and Lys-Ser dipeptides have been used in personal care 
compositions to improve the cosmetic appearance of skin, hair and nails.167 Lys-Thr and 
N-acyl derivatives and esters have also been used to treat or minimize signs of skin 
ageing such as wrinkles, skin lines and large pores.168 The dermatological use of the 
citrullinylarginine dipeptide as a skin and phanera care and treatment agent has also been 
studied and is said to have repairing and revitalizing properties.169 Acetyl-dipeptide-1 
cetyl ester is another such dipeptide which is used as a hair conditioning and skin 
conditioning agent.170 Dipeptide-2 consists of amino acids, valine and tryptophan and is 
believed to improve lymphatic circulation and is used in eye creams for dark circles and 
puffy eyes. The peptide’s structure resembles that of the lipid content of the epidermis 
and is considered to be a natural moisurizing factor as it helps in the skin’s healing 
process and prevents dermal irritation.171 A number of other small peptides are also 
formulated or under investigation for their anti-ageing potential.172  
1.5.2 Small peptides as dermatologicals 
Similarly dipeptides also have therapeutic potential in the treatment of Herpes simplex 
virus type 2 infection (HSV-2). These immunotherapeutic agents induce cytokine 
production that can lead to potent antimicrobial activity.173 Immunomodulating 
dipeptides such as muramyl dipeptides have shown antiviral activity against pathogens 
including murine cytomegalovirus and human immunodeficiency virus type 1 (HIV-
1).174, 175 In other work, a bacterially derived dipeptide, SCV-07 (gamma-d-glutamyl-l-
tryptophan), significantly increased the efficacy of antituberculosis therapy, stimulated 
thymic and splenic cell proliferation, and improved macrophage function.173 Two 
commercially available dipeptides of glutamine are DIPEPTIVEN™, which is an alanyl-
glutamine (Fresenius Laboratories, Germany) and GLAMIN™ (Pharmacia and Upjohn 
Laboratory, Sweden). Arginyl-glutamine dipeptide inhibits the over-proliferation of 
unwanted blood vessels and is advantageous in retinopathy because it is safe for human 
and animal use and can be readily formulated in an aqueous solution.176 Use of the 
dipeptides, alanyl-glutamine (Ala-Gln) and glycyl-glutamine (Gly-Gln) has also been 
suggested as an alternative to the use of free Gln as a supplement in total parenteral 
nutrition (TPN), owing to their better pharmaceutical properties.177 The antihypertensive 
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effects of dipeptides such as Ile-Tyr, Lys-Trp, Val-Tyr, and Ile-Trp have been 
demonstrated to be derived from their inhibitory effect on angiotensin-I-converting 
enzyme.178 In a study conducted by Lin et al, the penetration of various amino acids and 
dipeptides through porcine skin was measured in vitro to examine the effect of 
lipophilicity and molecular weight of the compounds on the permeability of passive 
diffusion. The results indicated that the effect of lipophilicity was a more dominant 
factor than the molecular weight. The permeability of Ala-Leu, Ala-Phe, Ala-Trp, Gly-
Gly and Trp-Ala was also predicted and the permeability was comparable to that of 
other experimental systems in the same molecular weight range.179 Abla et al studied the 
effect of charge and molecular weight on the transdermal delivery of peptides by 
iontophoresis. Two series of dipeptides were selected for this study: the first was a group 
of unblocked lysine-containing dipeptides, the second, a series of (unblocked and 
partially blocked) tyrosine-containing dipeptides. The results demonstrated that for the 
amino acids and dipeptides studied the transdermal flux was governed by the 
charge/MW ratio. It was also shown that ionic mobility decreases with increasing 
molecular weight.180 In a study by Babizhayev et al it was shown that, N -
acetylcarnosine may pass through the lipid membranes of the corneal and skin cells 
more easily than carnosine. N – acetylcarnosine can be gradually broken down to 
carnosine which then exerts its beneficial effects. N – acetylcarnosine containing eye 
drops have demonstrated efficacy in treating a variety of ophthalmic conditions 
including corneal diseases, cataracts and glaucoma. Due to its relative hydrophobicity as 
compared to L-carnosine, it might cross the cornea of the treated eye gradually and 
maintain the concentration of L- carnosine for a longer time in the aqueous humor. Data 
also demonstrated that the topical administration of 1% L-carnosine to the rabbit eye 
does not lead to the accumulation of this compound in the aqueous humor. It was thus 
concluded, that using N – acetylcarnosine or its pharmacologically acceptable salt in 
combination with a cellulose compound can be used to increase the intraocular (or 
transepidemal) permeation of L-carnosine in mammals upon ophthalmic or cosmetic 
application.181  
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1.6 Tetrapeptide conjugates as treatment options in psoriasis 
The second group of peptides we looked at in our project was the native tetrapeptide, 
Alanine-Alanine-Proline-Valine (Ala-Ala-Pro-Val) and its lipoaminoacid conjugates 
which act as Human neutrophil elastase (HNE) inhibitors.  HNE is a member of the 
chymotrypsin family of serine proteases and is primarily located in the azurophil 
granules of polymorphonuclear leucocytes. It can cause the degradation of a wide 
variety of biomacromolecules such as elastin, which plays a major structural function in 
the lungs, arteries, skin and ligaments, collagen types I, II, III, IV, VIII, IX and XI, 
fibrin, fibronectin, cartilage proteoglycans, cytokines, the platelet IIb/IIIa receptor and 
cadherins.182 Human neutrophil elastase (HNE; EC 3.4.21.37) has physiological 
functions in host defense against bacterial infections and extracellular matrix (ECM) 
remodeling following tissue injury.145 During acute inflammatory disorders, the local 
concentration of HNE exceeds those of its natural inhibitors such as α-proteinase 
inhibitor, leading to ECM degradation.145 Insufficient levels of protease inhibitors has 
been therefore suggested as a contributing factor in a number of diseases including, 
among others, acute lung injury, cystic fibrosis, ischemic reperfusion injury, rheumatoid 
arthritis, atherosclerosis, psoriasis, and malignant tumors.145 Active HNE is detected in 
psoriatic lesions and induces keratinocyte hyperproliferation via the EGFR signaling 
pathway.183 This imbalance can be restored by administration of natural inhibitor (α1Pi) 
or low molecular weight peptidic reversible or irreversible inhibitors.184, 185 Thus, the 
involvement of HNE in such pathological processes makes it an interesting target for the 
development of anti-inflammatory drugs. Attempts to develop useful therapeutic HNE 
and elastase inhibitors are therefore in progress.  
Hassall et al synthesized a new family of water soluble, reversible HLE inhibitors which 
had potential use in the treatment of inflammatory conditions.185  In another study done 
in the same year, Hornebeck et al synthesized fatty acid peptide derivatives as model 
compounds to protect elastin against degradation by elastases. Peptide sequences which 
fit the extended binding sites of porcine pancreatic elastase and human leukocyte 
elastase were covalently coupled to oleic acid. The coupling of a fatty acid moiety to the 
peptide greatly decreased its inhibitor constant (Ki) vs. human leukocyte elastase (Ki for 
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Oleoyl(Ala)2ProValine: 3.0 (10−6M). The modifications of the carboxylic end group of 
the peptide to an aldehyde further greatly enhanced the inhibition capacity of the 
compound towards leukocyte elastase (Ki for Oleoyl(Ala)2ProAlaninal: 0.7 μM). It was 
thus shown that, Oleoyl(Ala)2Pro-Valine was also capable of inhibiting elastases in their 
adsorbed form to insoluble elastin.186 The effect of oleoyl peptide, oleoyl-alanyl-alanyl-
prolyl-valine (Ol-Ala-Ala-Pro-Val-OH) conjugates against elastolysis by neutrophil 
elastase and kappa elastin-induced monocyte chemotaxis was investigated by 
Rasoamanantena et al. The results indicated that when the -COOH terminal of the oleoyl 
peptide was derivatized to amide forms, the compound lost its ability to interact with 
HNE while keeping its elastin-protecting function. In addition, the HNE-inhibitory 
capacity of Ol-Ala-Ala-Pro-Val-OH was only reduced 2-fold by using elastin as a 
substrate. This decrease was much lower than those determined with other HNE 
inhibitors of similar potency and could be accounted for by the ability of oleoyl peptide 
to bind to elastin.187   
The role of plant derived phenolics as HNE inhibitors was investigated by Hrenn et al. 
Several phenolics of different sizes were tested and it was found that the ellagitannins, 
agrimoniin and pedunculagin were the most potent direct HNE inhibitors (IC50 = 0.9 and 
2.8μM, respectively). Agrimoniin also showed anti-proliferative effects in the ATP 
assay (IC50 = 3.2 μM), suggesting that this type of tannin could have beneficial effects in 
the treatment of diseases such as psoriasis.188 In a study conducted on some Yemeni 
medicinal plants it was found that 14 extracts at various concentrations inhibited the 
activity of HNE182 Steinbrecher et al reported the binding affinity prediction, organic 
synthesis, and activity measurement for bornyl (3,4,5-trihydroxy)-cinnamate. This 
compound was a cinnamic acid ester derivative found to have IC50 value in the μM 
range. Free energy calculations predicted that the ligand would inhibit HNE with an IC50 
value in the nanomolar range.183 Many other studies have investigated compounds such 
as alpha-ketooxadiazole, for there role in HNE inhibition in psoriasis and in different 
disease states.189  
Peptidic HNE inhibitors have a common hydrophobic sequence which partially mimics 
certain amino acid sequences found in elastin. The Ala-Ala-Pro-Val sequence fits the P-
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P1 subsites of elastase and inhibits HNE competitively. Toth et al synthesized a series of 
lipopeptides of increasing lipophilic character keeping the peptide moiety (Ala-Ala-Pro-
Val) constant and their HNE inhibitory capacity was then analysed. Enzyme inhibition 
increased with increased lipophilicity of the substances; all compounds were more 
potent HNE inhibitors than N-oleoyl-(Ala)2Pro-Val-OH.145 We have investigated the 
approach of lipoamino acid conjugation to increase the lipophilicity of the tetrapeptide 
and assess its transdermal delivery and biological activity. In an earlier study we had 
assessed the effectiveness of coupling a short chain lipoamino acid (LAA) to enhance 
transepidermal delivery of a model HNE (human neutrophil elastase) inhibitor. HNE 
was coupled to a racemic mixture of a short chain LAA resulting in two diastereomers of 
the lipoamino acid modified tetrapeptide. The penetration of the lipopeptide mixture was 
assessed across human epidermis in vitro. The cumulative amount (µg: mean ± SEM; 
n=6) penetrating to the receptor over 8 h was approximately 80 µg/cm2 for the D-LAA 
conjugate, 30 µg/cm2 for the L-LAA conjugate, compared to 0 for the peptide. It was 
concluded that the D-diastereomer was more stable than the L-diastereomer and 
penetrated the human epidermis more than the L-diastereomer.190 The application of this 
approach to cutaneous delivery is relatively new and has merit on a scientific basis but 
may be less convenient from a regulatory viewpoint as chemical modification generating 
a new compound is involved. 
1.7 Anti-inflammatory peptides in skin diseases 
Inflammation is mediated by a series of events that are mediated by cellular and soluble 
components of the immune system.191 Lymphomononuclear cells play important role in 
inflammatory process. Intraepidermal localization of activated T-lymphocytes and 
dermal infiltration of monocytes are unique histologic features of psoriasis. These cells 
have important role in initiation and maintenance of the inflammatory process via 
several cascade mechanisms including cytokines (IL-2, IFN-γ) and chemokines (IL-8, 
RANTES).192 Extensive research has been undertaken to study the effects of anti-
inflammatory peptides on the proinflammatory cytokines and the T cell function.  In a 
study conducted by Rayachaudhri et al, the anti-inflammatory actions of peptide T were 
investigated. Peptide T (Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr) is a ligand for the CD3:T3 
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receptor and is a part of the HIV envelope protein gp120. The study reported that, 
peptide T analogue (DAPTA) inhibited the lymphocyte, monocyte chemotactic activities 
of RANTES and fmlp. Thus DAPTA may help to decrease the cellular infiltrates which 
in turn may decrease the intraepidermal chemokine and cytokine cascade activities.34 
Manlios et al193 explored the role of core peptide (CP; G-L-R-I-L-L-L-K-V) to inhibit 
IL-2 production in T cells following antigen recognition. This peptide had protective 
effects of induction on adjuvant induced arthritis in rats. In this study, the tris technology 
was used as a delivery system for core peptide. To increase biological availability of CP, 
the peptide was conjugated to tris-glycine-tripalmitate and then injected in rats. When 
tested in acute adjuvant induced arthritis the lipopeptide had a therapeutic effect on 
inflammation.194 Babu et al studied the in vitro permeation and distribution of spantide 
II with or without cysteine HCl (CH) as a penetration enhancer through hairless rat skin. 
The anti-inflammatory effect of spantide II was studied by measuring the reduction of 
allergic contact dermatitis (ACD) in C57BL/6 mice after application of spantide II as a 
topical solution. The in vitro permeation studies indicated no detectable levels of 
spantide II permeated through hairless rat skin. However accumulation of the peptide 
was seen in the different skin layers making it suitable for topical drug delivery. The 
anti-inflammatory activity of SP antagonist spantide II was also demonstrated by topical 
application. 191 
A new class of anti-inflammatory peptides being researched are the α-MSH (melanocyte 
stimulating hormone) and related peptides. α-MSH is a tridecapeptide which, upon 
proteolytic cleavage, is generated from its precursor ACTH. The anti-inflammatory 
effects of α-MSH which have been observed at subpicomolar, concentrations have been 
attributed to modulation of proinflammatory cytokine and adhesion molecule 
expression. α-MSH and related tripeptides have been shown to possess promising in 
vitro as well as in vivo anti-inflammatory effects. In particular the α-MSH-related 
tripeptides appear to be suited to being developed as anti-inflammatory drugs. Their 
small molecular size further provides advantages especially for local therapy of 
inflammatory diseases of skin and mucous membranes.195 Granulysin is another 
antimicrobial peptide that was modified by shortening the length of the peptide to 20 
amino acids. It was observed that even after chemically modifying the structure it 
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retained both antimicrobial and anti-inflammatory activity.196 The potential of an anti-
inflammatory peptide (antiflammin I) to reduce irritation when delivered transdermally 
by iontophoresis has been examined by Mize et al. These nonapeptides have been 
reported to have potent anti-inflammatory activity in vivo without any of the known side 
effects of corticosteroids. Transdermal delivery of antiflammin I significantly decreased 
drug-induced inflammatory response in hairless guinea pig skin, demonstrating retention 
of the peptides biological activity after delivery in vivo.197 In this project we have 
evaluated the transdermal delivery of 3 anti-inflammatory peptides, core peptide (CP) 
and two analogues that have demonstrated improved biological efficacy and specificity: 
a cyclic peptide sequence (C1) and its linear sequence counterpart (C1-L).  
1.8 Significance and objective 
An effective transdermal application is expected to provide a new therapeutic approach 
for psoriasis and other inflammatory disorders associated with the skin and underlying 
tissues.  In many cases these conditions are poorly controlled with currently available 
products.  Several peptides and synthetic small molecules are now available that can 
inhibit specific pathways in the development of psoriasis. 8, 9 Examples include peptide 
T, RNase 7, granulysin and psoriasin. An effective delivery system that targets 
therapeutic compounds to their sites of action, preferably following a convenient 
application to the skin surface, will provide a major advancement in the management of 
psoriasis and other skin related disorders.  
The overall objective of this research was to investigate novel technologies for the 
enhanced transdermal delivery of peptides, particularly those with therapeutic or 
cosmetic application in skin. The major objective of this research was to assess different 
enhancement strategies (Dermaportation and lipoamino acid conjugation) for the 
delivery of small and high molecular weight peptides for cosmetic and therapeutic uses. 
Our hypothesis is that Dermaportation and lipoamino acid conjugation will enhance the 
delivery of small and high molecular weight peptides through the skin. We also 
hypothesize that, the skin permeability of a core peptide (CP), which has anti-
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inflammatory activity will also increase upon cyclization. The project was divided into 
following parts: 
 Assessment of stability and skin permeability of a model dipeptide (Ala-Trp) 
across human epidermis with Dermaportation 
 Assess the stability, skin permeability, accumulation and biological activity of 
the native tetrapeptide (Ala-Ala-Pro-Val) and its lipoamino acid conjugates 
 Assess the skin permeability and accumulation of Acetyl hexapeptide 3 and its 
lipoamino acid conjugates 
 Assess the stability and skin permeability of the core peptide with anti-
inflammatory activity and two analogues, a cyclic peptide sequence (C1) and its 
linear sequence counterpart (C1-L) 
 50
 
 
 
 
 
 
Chapter 2.  
Permeability of a Model Dipeptide (Ala-Trp) Across 
Human Epidermis: Effect of Pulsed Electromagnetic 
Energy 
 
 
 
 
 
 
 
 
 51
2.1  AIM 
The aim of the present study was to assess the effect of pulsed electromagnetic field 
(PEMF) energy (Dermaportation DP1001; OBJ Ltd) on the permeation of a model 
dipeptide (Ala-Trp) through human epidermis using an in vitro skin diffusion model. 
The stability of the dipeptide was also assessed at different temperatures and conditions. 
As discussed in section 1.5 dipeptides have potential as cosmetic and therapeutic agents. 
To exert either of these actions, the peptide should permeate through the lipophilic 
stratum corneum and accumulate in the viable epidermis or dermis depending on its 
target site of action. Ala-Trp was selected as a small molecular weight model dipeptide 
to study the penetration enhancement effects of Dermaportation, which is a newly 
developed PEMF technology. 
2.2 Materials and Methods 
2.2.1 Chemicals 
Alanine-Tryptophan (Ala-Trp), a model dipeptide with a molecular weight 275.30 Da 
was purchased from Sigma Aldrich (USA). Acetonitrile, HPLC solvent was supplied by 
JT Baker (USA) and phosphate buffered saline solution (PBS) was prepared according 
to the United States Pharmacopoeia. 
2.2.2 HPLC instrumentation and conditions 
The samples were analysed by reverse phase HPLC Agilent 1100 system which 
consisted of a quaternary pump (G1311A), autosampler (G1313A), degasser (G1312A) 
and photo diode array detector (G1321A). Separation was achieved on a Phenomenex 
Jupiter C18, 300A column (5 μm, 4.6mm×150mm). Integration was undertaken using 
Chemstation software B.03.01 [317]. Elution was performed at ambient temperature 
using a mobile phase gradient at a flow rate of 1 mL/min and the wavelength of 
detection was 210 nm. Buffer A was 0.1% TFA and Buffer B was 0.1% TFA in 
acetonitrile. The dipeptide was eluted using a combination of isocratic and linear 
gradient protocol; Buffer B was held at 10% for 5 min followed by a linear gradient 
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from 10 to 100% over 10 min. All samples were analysed by HPLC using injection 
volumes of 20 μL. 
2.2.3 HPLC analysis and validation 
Calibration curves were obtained using 0.9, 1.9, 3.9, 7.81, 15.62 and 31.25 μg/mL of 
Ala-Trp standard solutions in PBS at pH 7.4. Linearity (quoted as R2) was evaluated by 
linear regression analysis, which was calculated by the least square regression method. 
The precision of the assay was determined by injecting three standard concentrations 
(0.9, 7.8 and 31.25 μg/mL Ala-Trp) six times on the HPLC column. The intra-day 
repeatability was assessed by injecting 7.8 and 15.62 μg/mL Ala-Trp standards six times 
at different times in a day. The inter-day repeatability was determined by injecting 7.8 
and 15.62 μg/mL Ala-Trp standards six times on 3 different days. The intra- and inter-
day repeatability were quoted as the coefficient of variance. The minimum detectable 
and quantifiable limits (LOD and LOQ) were measured by diluting Ala-Trp in PBS to 
give a concentration range from 0.9 to 31.3 μg/mL and then injected on the HPLC. 
Accuracy of the analytical method was determined for in vitro skin diffusion studies as 
follows. Two separate samples of PBS which had been incubated with human epidermis 
for 24h at 37°C were spiked with Ala-Trp standards to give final concentrations of 7.8 
and 15.6 μg/mL Ala-Trp. Each spiked sample and standard was injected six times on the 
HPLC column and the percentage difference between each standard and the 
corresponding spiked sample was calculated. 
2.2.4 Stability study 
The stability of Ala-Trp was determined at different temperatures and with having the 
dipeptide in contact with skin to provide an estimate of the stability of the drug during 
the skin diffusion experiments. The following temperatures were used: 37°C, room 
temperature (ambient light), room temperature (dark) and at 4°C. Vials containing 3 mL 
of 1 mg/mL dipeptide solution were stored under these conditions. 100 μL samples were 
withdrawn at 0, 20, 45, 60 min, 2h, 3h, 4h, 5h and 6h. The samples were then diluted to 
give a final theoretical concentration of 20 μg/mL and were analysed by HPLC. 
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2.2.5 Human skin preparation 
Full thickness human skin samples excised from female patients (30 year old female 
abdominal section was used in the present study) undergoing abdominoplasty at Perth 
hospitals were refrigerated immediately after surgery. Sampling was approved by the 
Human Research Ethics Committee of Curtin University (Approval numbers 
HR132/2001, HR 70/2007 and HR 129/2008) and was conducted in compliance with the 
guidelines of the National Health and Medical Research Council of Australia. The 
following procedure was used to obtain epidermal sheets. The subcutaneous fat was 
removed by dissection, the full thickness skin then immersed in water at 60°C for 1 min, 
allowing the epidermis to be teased off the dermis.198 The epidermis was placed onto 
aluminum foil, air dried, then placed in a zip-lock bag and stored at –20°C until 
required. 
2.2.6 Skin permeation of Ala-Trp 
In vitro permeation studies across human epidermis were performed in Pyrex glass 
Franz-type diffusion cells (enabling permeation across skin sections of cross sectional 
area 1.18 cm2; receptor volume approximately 3.5 mL: Figure 2.1). Epidermal 
membrane was placed between the donor and receptor compartments and allowed to 
equilibrate for 30 min with the receptor solution (PBS pH 7.4) which was stirred 
continuously with a magnetic stirrer bar. The receptor compartment of the cell was 
immersed in a water bath at 37±0.5°C. PBS (1 mL) was placed in the donor 
compartment, allowed to equilibrate for 30 min and the conductivity across the 
epidermis was measured using a digital multimeter to determine membrane integrity. 
The PBS solutions were then removed from the donor and receptor compartments and 
the receptor refilled with approximately 3 mL of fresh pre-warmed PBS. The donor 
solution, which consisted of 1mL of 1mg/mL Ala-Trp in PBS was added. 200 μL 
samples of the receptor phase were withdrawn and replaced with an equal volume of 
fresh pre-warmed (37°C) PBS over an 8 h period to maintain sink conditions. The Ala-
Trp content in the samples was determined using HPLC. 
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Figure 2.1 Schematic of skin diffusion experimental cell with Dermaportation coil in place 
Dermaportation coils were added to the exterior of the donor compartment and energy 
applied for 8 h (Dermaportation cells), whilst other cells had no external Dermaportation 
energy applied. 9 replicates were conducted for passive and Dermaportation 
experimental protocols. The cumulative amount of drug permeated through the 
epidermis (μg/cm2) versus time (h) was plotted. The cumulative amount was calculated 
by taking into account the amount of peptide present at the previous time points plus the 
amount present in the 200 μL sample and the amount present at the time point at which 
the cumulative amount is calculated. The flux of Ala-Trp through the human epidermis 
for both passive and Dermaportation cells was determined from the slope of the plot of 
cumulative amount versus time and expressed as μg/cm2/h. Permeability coefficients 
(cm/h) were calculated for Ala-Trp for both passive and Dermaportation using the 
following equation: 
Permeability coefficient Kp (cm/h) = Flux (J) / Concentration in the donor (C)… (Eq 1)             
2.2.7 Extraction of Ala-Trp from the epidermis and mass balance 
The uptake of Ala-Trp into the epidermis was also investigated. To validate the 
extraction procedure a 1 mg/mL solution of Ala-Trp was allowed to equilibrate with the 
epidermis for 8 hours. After 8 hours the epidermis was removed, four water washes were 
completed and 50 L from each extract was analysed by HPLC. This extraction 
procedure was undertaken on each epidermal membrane on termination of the skin 
 55
diffusion experiment. The donor solution was removed from the donor compartment and 
the skin sample soaked in 1 mL water. Four water washes were completed and 50 L 
from each extract was analysed by HPLC. The donor solution was also diluted 10 times 
and the diluted solution analysed by HPLC to quantify the amount of the peptide left in 
the donor at the end of the experiment.   
2.2.8 Statistical Analysis 
The cumulative amount of target drug in the receptor chamber was determined over the 
entire period of testing, and the differences between the diffusion by passive and 
Dermaportation were analyzed using ANOVA with the Factors Treat and Time (GLM 
procedures, SAS Institute). Further, flux rates (μg/cm2.h) were calculated from the slope 
of the linear relationship between the cumulative amount and time per group. Two 
separate flux rates were calculated, (i) the rate of the active drug diffusion or transport in 
the first 20 min, and (ii) the average diffusion rate over the first 2 h. An ANOVA with 
Fisher LSD post hoc comparisons on the Factors Treat and Experiment was used for the 
flux rates. A result was considered significant with p < 0.05. Enhancement Ratios with 
respect to passive diffusion were calculated from statistically significant flux values 
only. 
2.3  Results and Discussion 
2.3.1 Chromatography 
Ala-Trp was analysed by UV detection using HPLC. The dipeptide eluted without any 
interfering peaks at a retention time of 9.1 min. The linearity obtained by the HPLC 
method was 0.9999 over the range of the calibration curve (0.975-31.25 μg/mL) for Ala-
Trp standard solutions. Figure 2.2 is a typical HPLC chromatogram of Ala-Trp analysed 
8 h after (a) passive and (b) Dermaportation administration to human epidermis. 
A calibration curve was obtained by plotting the peak area versus concentration of 
standards injected. The coefficient of variation (CV) for precision, determined from the 
relative standard deviation (n = 6), was 0.27% for 0.98 μg/mL, 0.15% for 7.80 μg/mL 
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and 0.13% for 31.25 μg/mL Ala-Trp standard solutions in PBS. The intraday variation 
was 0.69% and 0.43% and the interday variation was 0.55% and 0.38% at 7.80 and 
15.63 μg/mL Ala-Trp standard solutions in PBS, respectively. These are within the 
acceptable criteria for intra and inter-day repeatability of R.S.D. < 2%. 
(a) 
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(b) 
 
Figure 2.2 Chromatograms for Ala-Trp analyzed after 8h (a) Dermaportation (96.49μg/cm2) and 
(b) Passive (2.77μg/cm2) 
The limit of detection (LOD), calculated as greater than three times the baseline noise 
level in the assay, was 49 ng/mL. The limit of quantitation (LOQ), calculated as greater 
than 10 times the baseline noise level in the assay, was 165 ng/mL. The suitability of the 
assay with a simulated diffusion cell receptor solution (PBS solution which had been in 
contact with skin for 4 h) was demonstrated, with no interfering peaks detected. The 
HPLC method permitted the detection of 7.8 μg/mL of Ala-Trp sample with 92.11% 
accuracy and 15.63 μg/mL of Ala-Trp sample with 93.16% accuracy. 
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2.3.2 Stability of the dipeptide in solution 
The degradation profile of Ala-Trp at different temperatures is shown in Figure 2.4. The 
stability data was presented as the percent peptide remaining over time at varying 
temperatures and conditions. It was observed that when the dipeptide solution was 
placed at 37ºC in contact with the skin about 11% of the peptide was lost in 6 h. This is 
in agreement with previous reports that lysine and tyrosine containing dipeptides are 
unstable when in contact with the skin.180 This compares with only 4.6% loss of 
dipeptide in the same conditions but without skin present. In our experiment the skin 
was previously frozen therefore much of the enzymatic activity was lost, yet substantial 
degradation was still observed. It is expected that the dipeptide would be more 
extensively degraded where the cutaneous enzymes were preserved. The dipeptide was 
most stable at 4ºC with 3% degraded over the 6 h period, and was relatively stable at 
room temperature in dark and light conditions with 4% loss over the 6 h period. A 
separate preliminary study was conducted to assess the stability during Dermaportation 
and passive diffusion and it was found that the dipeptide collected from the receptor was 
relatively stable during the time of the experiment. No significant amounts of 
degradation products, which were present in samples in contact with the skin, were 
detected. Figure 2.2 is a typical HPLC chromatogram of Ala-Trp analysed 8 h after (a) 
passive and (b) Dermaportation suggesting that either Dermaportation does not alter the 
Ala-Trp structure or the degraded products may have a very strong affinity to the skin 
therefore may not diffuse through the skin. The possibility of the latter is under further 
investigation. 
Dipeptides have previously been shown to degrade in the skin due to the presence of 
cutaneous enzymes.179 Skin proteases have been isolated and characterized however it is 
not known which peptide sequences or peptides are most susceptible to enzymatic 
degradation in human skin.199,200 Previous studies have suggested that peptides can 
undergo extensive enzymatic metabolism in the viable skin and hence it is particularly 
desirable to increase the rate and extent of permeation of these drugs across the skin and 
thereby reduce the potential effects of skin enzymes.201 
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Figure 2.3 Chromatogram for Ala-Trp and degradation product analyzed after 3h when the 
sample was incubated with skin 
In the stability study the rate of degradation of the dipeptide at 37°C without skin was 
about 9.4 times lower than the rate of degradation at 37°C when the dipeptide solution 
was left in contact with skin. Figure 2.3 is a typical chromatogram of Ala-Trp and the 
degradation product analysed after 3h.  At lower temperatures (i.e. at room temperature, 
room temperature and dark and at 4°C) the mechanism of degradation was different than 
at higher temperatures and it was assumed to follow a biphasic degradation pattern 
(Figure 2.4). The amount of product that eluted at about 7.5 min, which was suspected to 
be the degradation product, steadily increased till about 6 h. The total amount of the 
dipeptide and the percentage of degradation product were plotted against time and the 
rate was determined from the slope of the linear portion of the curve from 0.33 to 3 h. 
The rate of degradation as determined in both studies, showed a higher level in the 
stability study than that of the skin diffusion experiment with Dermaportation. This may 
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be because the samples in the skin diffusion studies were collected from the receptor 
compartment that has a lower concentration of the dipeptide and is affected by the skin 
permeability of the dipeptide and degradation product. A lower percentage of 
degradation product was detected with passive diffusion since very low amounts of the 
dipeptide actually traversed the skin, which led to a lower amount of both dipeptide and 
degradation products in the receptor chamber.  
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Figure 2.4 Ala-Trp degradation profile in solution at varying conditions 
Previous studies on the characterization of aminopeptidases showed that Ala-Trp was 
susceptible to hydrolysis by aminopeptidase–I but no definite structures of the 
degradation products were reported.202 Although tryptophan was suspected to be one of 
the likely degradation products, tryptophan residues in peptides or proteins can also 
undergo oxidation. Few studies have focussed on identification of compounds formed 
from these peptides. Simat et al attempted to identify tryptophan degradation 
compounds by subjecting the amino acid itself and peptides containing tryptophan to an 
oxidising agent.203 Comparing the transepidermal flux values in this study, it was seen 
that the permeation of the degradation product is lower than that of the native dipeptide. 
We have speculated that Ala-Trp may undergo hydrolysis or enzymatic degradation 
which results in the formation of a degradation product which could be an alanine or 
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tryptophan related compound. This compound was detected after the diffusion of the 
native peptide through human epidermis at a lower level than expected, suggesting that 
this degradation product may have a tendency to remain in the skin. In addition, it was 
also observed that its permeation through the skin was enhanced by Dermaporation. Fast 
permeation of the dipeptide by Dermaportation could also mean less contact time for the 
peptide with the skin enzymes and more rapid delivery to the target site, both of which 
would benefit the therapeutic outcome. 
2.3.3 Permeation of Ala-Trp through human epidermis with Dermaportation 
In this study the influence of the novel penetration enhancement technology, 
Dermaportation on epidermal penetration of Ala-Trp in vitro was determined. 
Dermaportation appears to permit a substantial amount of native dipeptide to penetrate 
through the skin structure over the 8 h application period. The cumulative amount of 
Ala-Trp penetrating the human epidermis to the receptor solution over time for 
Dermaportation and passive application is demonstrated in Figure 2.5. We used the 
general guideline of accepting skin sections which had conductivity lower than 20kΩ. 
The conductivity was measured at the start and end of the experiment and cells which 
had a high conductivity value were not included in cumulative amount calculation. The 
cumulative amount of dipeptide permeated after 8 hours with Dermaportation was 96.5 
μg/cm2 and the amount permeated with passive diffusion was 2.77 μg/cm2. The results 
indicated an increase in the rate and extent of Ala-Trp diffusion through human 
epidermis over 8 h in cells where Dermaportation was applied, as compared to cells 
where the dipeptide solution was applied without Dermaportation (Treat: F1,16 = 23.97, 
p < 0.001; Treat by Time interaction: F13,208 = 10.33, p < 0.001). An analysis per time 
point, demonstrated that the Dermaportation-treated cells had already a significantly 
higher amount of the dipeptide in the receptor compartment at 10 min (Treat=10m: 
F1,16 = 12.93; p < 0.005). At t = 0, all groups were equal (Treat=0: F1,16 = 0, p < 
0.001), demonstrating that no dipeptide was present in the receptor compartment before 
the experiment was started. The lag time was approximately 0.33h with Dermaportation. 
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Figure 2.5 Cumulative penetration of dipeptide (1 mg/mL) across human epidermis for passive 
(▲) or Dermaportation (●) applied from 0-4h (mean ± SEM: n=9)  
The estimated transdermal flux was calculated over the linear portion (0.33-2h) of the 
curve as 19.427 μg/cm2/h for Dermaportation and 0.778 μg/cm2/h for passive diffusion. 
Approximately 35 fold enhancement was observed with Dermaportation as compared to 
passive diffusion. The estimated permeability coefficient for Ala-Trp was 1.94 x 10-2 
cm/h with Dermaportation and 7.7 x 10-4 cm/h with passive diffusion (Table 2-3). The 
transdermal permeability coefficient (kp) of the dipeptide in porcine skin when 
measured for passive diffusion has been reported to be 1.39 × 10-2 cm/h by Lin et al179, 
in comparison with the current study value of 7.7 × 10-4 cm/h. However it is not valid to 
directly compare the two permeability coefficients since they were determined using 
different skin models. In the current study Dermaportation was applied for the first 4 h 
and a steep increase in cumulative amount permeating to the receptor was observed in 
20 mins (38.23 and 1.02 μg/cm2 for Dermaportation and passive application 
respectively). This difference may be due to an initial push into the skin due to the 
applied electromagnetic field. There was a steady increase in the amount of dipeptide 
permeating over the entire period of the experiment (Figure 2.5). Over the first 20 mins, 
the first 2 h, the first 4 h, and the entire 8 h period, the Ala-Trp diffusion flux in 
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Dermaportation diffusion cells was larger than for the passive cells (TreatFlux20: F1,16 
= 12.93, p < 0.005; TreatFlux120: F1,33 = 20.79, p < 0.005; TreatFlux4hr: F1,16 = 
13.50, p < 0.005; TreatFlux8hr: F1,16 = 12.58, p < 0.005). Dermaportation enhanced the 
permeability of Ala-Trp in the first 20 min by up to 37.3-fold over the passive diffusion 
rate. This finding is in agreement with previous reports in which Dermaportation was 
shown to increase the transdermal diffusion of a low molecular weight hydrophilic 
compound, 5-aminolevulinic acid and the local anaesthetics lignocaine and tetracaine 
hydrochloride in similar in vitro experiments with human epidermis.132, 133 Tables 2-1 
and 2-2 list the flux and correlation coefficients for the stability study and the skin 
diffusion experiments.  
The efficiency of the solvent extraction method used to recover the peptide from the 
epidermal membrane at the conclusion of each experiment was approximately 85%. The 
amount of dipeptide remaining in the epidermis after 8h application period was 
approximately 0.85 µg/cm2 (± 0.07) with passive diffusion and 0.54 µg/cm2 (± 0.06) 
with Dermaportation. The comparably lower amount in the skin with Dermaportation as 
compared to passive diffusion may be due to the increased delivery of the dipeptide to 
the receptor compartment after 8h. 
There have been limited reports on skin penetration enhancement of dipeptides. 
Altenbach et al observed no iontophoretic and passive transport of Tyr-Phe across 
human skin in vitro without the addition of an enzyme inhibitor at 37 °C.204 Human 
cadaver skin of postmortem biopsies excised within 24 h of death from the abdominal 
region of female donors was used in this study. Epidermal membrane including the 
stratum corneum and the viable epidermis was isolated from the underlying dermis by 
heat treatment and mechanical separation. The results indicated that there was 
substantial metabolism of Tyr-Phe in human cadaver epidermis during permeation. The 
metabolism of Tyr-Phe was potentially catalyzed by enzymes such as dipeptidase, 
carboxypeptidase and aminopeptidase that have been found in the epidermis. Metabolic 
degradation of Tyr-Phe at both pH values was found to be completely suppressed at 
4 °C. Tyr and Phe were found in the receiver solution and recovered from the epidermis. 
Also, Tyr-Phe permeation was measurable and the amount of intact Tyr-Phe extracted 
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from the tissue was larger compared to the experiments at 37 °C at the same pH where 
no permeation of the dipeptide was observed.  
We cannot directly compare the transdermal flux values from this study to literature data 
since there has been very limited work done on Ala-Trp as a model dipeptide. This 
preliminary study indicates that the delivery rate of the peptide can be enhanced with 
Dermaportation when compared to passive diffusion. Dermaportation may provide an 
effective means of delivering molecules that are highly susceptible to degradation like 
dipeptides, in higher amounts and in a relatively short duration. 
2.4 Conclusion 
Dermaportation significantly enhanced the delivery of Ala-Trp through human 
epidermis in vitro over an 8 h period when compared to passive diffusion. The dipeptide 
was shown to be unstable on exposure to human epidermis with an increasing amount of 
degradation product evident in the receptor phase over the 8 h period. Given the 
susceptibility of peptides to degradation in the skin it is essential that they are delivered 
rapidly across the skin in order to maximise the opportunity for delivery of the native 
peptide. Dermaportation offers a potential new delivery method for skin delivery of 
peptides for dermatological and cosmetic applications. 
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Table 2-1 Rate of degradation of Ala-Trp at different temperatures and conditions 
 
 
Dipeptide Degradation product 
 
Room 
temperature 
37°C 
without 
skin 
37°C 
with 
skin 
Room 
temperature 
and dark 
4°C 37°C with skin 
% of Degradation 
product 
Rate (µg/cm2/h) 4.9 2.98 28.34 10.64 1.89 6.61 0.66 
Correlation 
coefficient (R2) 
0.643 0.981 0.981 0.679 0.115 0.982 0.983 
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Table 2-2 Rate of permeation of dipeptide and degradation product with 
Dermaportation and passive diffusion. Data are mean ( SEM, n=9)  
 
Table 2-3 Skin permeation of Ala-Trp with Dermaportation and passive 
diffusion over 2h 
Treatment 
Cumulative 
amount 
(µg/cm2) 
Transdermal 
flux (µg/cm2/h) 
Permeability 
coefficient (kp) 
(cm/h) 
Enhancement 
ratio (0-2h) 
Dermaportation 96.49 19.42 1.94×10-2 34.67 
Passive 2.77 0.77 7.7×10-4  
 
 
 
 
Dipeptide Degradation product % of degradation product 
 Dermaportation Passive Dermaportation Passive Dermaportation Passive
Flux 
(µg/cm2/h) 
19.42 0.77 2.36 0.13 2.39 0.021 
Correlation 
coefficient 
or rate 
(slope)  
(R2) 
0.978 0.940 0.993 0.931 0.996 0.001 
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Chapter 3.  
Skin Permeability and Biological Activity of a Therapeutic 
Peptide and its Lipoamino Acid Conjugates 
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3.1  Aim and Brief Background 
This study was designed to investigate the lipoamino acid (LAA) conjugation approach 
for enhanced skin permeability of small peptides, particularly those with therapeutic 
application in skin diseases. The choice of the Human Neutrophil Elastase (HNE) 
inhibitor peptide offers the potential for application as a new therapeutic approach for 
psoriasis and other inflammatory disorders associated with the skin. The effectiveness of 
coupling a short chain LAA to enhance transepidermal delivery of a model HNE 
inhibitor tetrapeptide (Ala-Ala-Pro-Val or AAPV) was assessed. The optimal conjugate 
structure for skin penetration and biological activity of this therapeutic peptide with anti-
inflammatory activity was also determined.  When HNE inhibitor was coupled to a 
racemic mixture of a short chain LAA, two diastereomers of the LAA modified 
tetrapeptide were formed. Preliminary in vitro skin penetration studies with C8-LAA 
conjugated AAPV had shown that, in general, the delivery through the skin of the D-
diastereomer was higher than the L-diastereomer. In this study the effect of conjugation 
of C6, C8 and C10 LAAs was assessed on the skin permeation, stability and biological 
activity of the native HNE inhibitor. Accumulation of these peptides in the skin was 
quantified using solvent extraction and recovery (mass balance) was calculated. 
Permeability coefficients were calculated for each peptide and conjugate and HNE 
inhibition studies were undertaken to determine the differences in activity of the 
conjugates on elastase enzyme as compared to the parent peptide. Preliminary 
investigations to elucidate the mechanism for enhanced permeation of these conjugated 
peptides in the skin were also conducted.  
3.2 Materials and Methods 
3.2.1 Chemicals 
AAPV (MW 355.4) (Figure 3.1), C6(D)-LAA-AAPV (MW 468.6), C6(L)-LAA-AAPV 
(MW 468.6) (Figure 3.2), C6(D,L)-LAA-AAPV (MW 468.6), C8(D,L)-LAA-AAPV 
(MW 496.6) (Figure 3.3) and C10(D,L)-LAA-AAPV (MW 524.4) (Figure 3.4) were 
supplied by our collaborators in University of Queensland (Brisbane, Australia) and 
GLS Biochem (Shanghai, China). Propylene glycol (PG) and dimethyl sulphoxide 
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(DMSO) were obtained from BDH Chemical Pvt Ltd and Ajax FineChem respectively. 
HPLC grade acetonitrile and methanol were used and all other chemicals were of 
analytical grade. Phosphate buffered saline solution (PBS) was prepared according to the 
United States Pharmacopoeia.  
3.2.2 Peptide synthesis 
3.2.2.1 General 
The following information describing the synthesis, purification and validation of the 
peptides was supplied by Professor Toth’s group at the University of Queensland. 
Dimethylformamide (DMF) and trifluoroacetic acid (TFA) of peptide synthesis grade 
were purchased from Auspep (Parkville, Australia). HPLC grade acetonitrile was 
purchased from Labscan Asia Co. Ltd. (Bangkok, Thailand). Fmoc-protected amino 
acids (Ala, Pro, Val, NIe) and Rink amide MBHA resin (100-200 mesh, 0.78 mmol/g 
loading) were obtained from Novabiochem (Melbourne, Australia).  Piperidine was 
purchased from Auspep.  All other chemicals were purchased from the Aldrich 
Chemical Company unless otherwise stated.   
3.2.2.2 Lipoamino acid synthesis 
N-tert-Butoxycarbonyl-2-amino-D,L-octanoic acid (C8-LAA) and N-tert-
Butoxycarbonyl-2-amino-D,L-dodecanoic acid (C10-LAA) were synthesized from 
diethyl acetamido malonate and the appropriate alkyl bromide followed by N-Boc 
protection using published procedures and the spectral data for these compounds 
matched the reported data. 
Peptide synthesis 
The parent peptide, AAPV and C8- and C10-LAA derivatives were assembled on Rink 
amide MBHA resin (100-200 mesh, 0.78mmol/g loading) on a 0.5 mmol scale using 
HBTU/DIPEA activation and the in situ neutralization protocol. The efficiency of each 
amino acid coupling was determined by the quantitative ninhydrin reaction and 
couplings repeated until an efficiency > 99.6% was achieved. When construction of the 
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peptide was complete, the resin was washed with DMF, dichloromethane and methanol 
and dried. The peptide was deprotected and cleaved from the resin by treatment with 
TFA:water:triisopropylsilane (TIS) (95:2.5:2.5 v/v, 25 mL) for 6 hours. The resin was 
removed by filtration and washed with TFA. The solvent was removed from the peptide 
solution under a stream of nitrogen and the crude peptide precipitated with cold diethyl 
ether, collected and dissolved in 20% acetonitrile and lyophilized.  
The purification of peptide analogues was achieved by preparative RP-HPLC on a Grace 
Vydac C18, 25 cm preparative column using a Shimadzu SCL-10AVP controller and 
pump with an SPD 10AVP UV-Vis detector set at a wavelength of 214nm.  The peptides 
were purified using a gradient elution profile from 100% Solvent A (0.1% TFA in H2O) 
to 90% solvent B (90% CH3CN in water with 0.1% TFA) over 35 minutes at a flow rate 
of 5mL/min.  The peptides were purified to a single peak in the case of AAPV and two 
peaks in the case of the C8-LAA and C10-LAA-derivatives corresponding to the two 
diastereomers of the peptide, by analytical RP-HPLC.  The purity of peptide analogues 
was determined by analytical RP-HPLC on a Vydac C18, 25cm analytical column using 
the Shimadzu SCL-10AVP system described above and a gradient of 100% Solvent A to 
90% Solvent B over 30 minutes at a flow rate of 1 mL/min, electrospray ionization MS 
(ESI-MS; Perkin-Elmer Sciex API 3000) and LC/MS (Shimadzu LC-10AT HPLC, 
Perkin-Elmer Sciex API 3000). 
3.2.2.3 Synthesis of Nle(C6-Laa)-Ala-Ala-Pro-Val-NH2 
Both D- and L-norleucine (C6-LAA) were coupled to purified AAPV peptide in a 
solution phase coupling procedure described below: 
Solution Phase Coupling of Fmoc Protected Lipoamino acids 
Fmoc-D-Nle-OH (27.14 mg, 0.077 mmol) was activated by HBTU (30.28 mg, 0.08 
mmol) and hydroxybenzotriazole (HOBt) (14.89 mg, 0.11 mmol) in DMF (5mL).  This 
solution was stirred for 25 min before being added to a stirred solution of AAPV (22.28 
mg, 0.063 mmol), N,N-Diisopropylethylamine (DIPEA) (40 μL, 0.23 mmol) in DMF 
(10 mL) under anhydrous conditions. The reaction was stirred at room temperature for 
21 hr.  The solution was concentrated to dryness in vacuo at 40°C with residual DMF 
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azeotropically removed using toluene to give a dark yellow oil.  The residue was 
dissolved in water (10 mL), the product extracted with ethyl acetate (3 × 25 mL) and 
combined layers successively washed with 10% citric acid (2 × 20 mL), 10% sodium 
bicarbonate (2 × 20 mL), brine (3 × 20 mL), dried magnesium sulfate (MgSO4), filtered, 
and concentrated to dryness in vacuo at 35°C. 
Fmoc deprotection: 
20% Piperidine solution (20% in DMF) (40 mL) was added to the crude lipoamino acid 
and stirred at room temperature for 3 hr.  The resultant solution was concentrated to 
dryness in vacuo at 35°C to give a yellow oil and dissolved in 1:1 CH3CN/H2O, filtered 
and lyophilized overnight to afford crude C6-AAPV. 
Purification of C6-AAPV 
Crude lipoamino acid was purified on strata-X-C 33 um polymeric strong cation 200 
mg/ 3mL sep-pack.  The crude lipoamino acid was dissolved in H2O (2 mL).  Sep-pack 
was flushed with 2 mL H2O before crude lipoamino acid was loaded.  Sep-pack was 
successively flushed with H2O (4 mL) and fractions collected and lyophilized from the 
following gradients; 20% CH3CN /H2O (6 mL), 50% CH3CN /H2O (6 mL) and 100% 
CH3CN /H2O (6 mL) to give purified C6-AAPV 1 as a white solid: LRESIMS m/z 1457 
[M + H+]+; HRESIMS m/z 1456.8700 (M + H+, C62H114N21O19 requires 1456.8594).   
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 Figure 3.1 Chemical structure of AAPV 
NH2
O
NH
CH3
NH
O
CH3
O
N
O
NH
CH3CH3
O
NH2
CH3  
Figure 3.2 Chemical structure of L-C6-LAA-AAPV conjugate 
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Figure 3.3 Chemical structure of L-C8-LAA-AAPV conjugate 
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Figure 3.4 Chemical structure of L-C10-LAA-AAPV conjugate 
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Figure 3.5 Molecular models of (a) (R) C6-LAA-AAPV, (b) (S) C8-LAA-AAPV and (c) (R) C10-
LAA-AAPV 
3.2.3 HPLC instrumentation and conditions 
The general HPLC method for the analysis of the tetrapeptide and lipophilc conjugates 
was supplied by our collaborators but it had to be modified according to the available 
HPLC instrument. The experimental samples were analysed by reverse phase HPLC 
(Agilent 1200 system) which consisted of a binary pump (G1312A), autosampler 
(G1329A), degasser (G1379B) and diode array detector (G1365B). Separation was 
achieved on a Phenomenex C18 column (5 µm, 4.6 mm×50 mm) using a mobile phase 
gradient. Calibration curves of tetrapeptide and lipopeptides in PBS were obtained to 
ensure consistency with samples from the in vitro permeation experiments. Buffer A was 
0.1% TFA and buffer B was 0.1% TFA in acetonitrile. Elution was performed at a flow 
rate of 1.0 ml/min with the column temperature held at 25°C and the injection volume 
was 50 µL. The tetrapeptide and lipopeptides were eluted using a combination of 
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isocratic and linear gradient protocol; buffer B was held at 10% for 5 min followed by a 
linear gradient from 10 to 100% B over 10 min for C8(D,L)-LAA-AAPV, C10(D,L)-
LAA-AAPV and C6(L)-LAA-AAPV. For C6(D,L)-LAA-AAPV, buffer B was held at 
10% for 5 min followed by a linear gradient from 10 to 20% over 10 min. For C6(D)-
LAA-AAPV, buffer B was held at 10% for 2.5 min followed by a linear gradient from 
25 to 100% over 12.5 min.  Each sample analysed was automatically followed by a post-
wash for 5 min. Absorbance was simultaneously monitored at 205, 210 and 214 nm 
using a photo diode array detector. All calculations were carried out in comparison with 
external standards using areas acquired at 210 nm.  
3.2.4 HPLC analysis 
3.2.4.1 Linearity 
A 1 mg/mL stock solution of the parent peptide, AAPV and conjugated peptides [C6(L), 
C6(D), C6(D,L), C8(D,L) and C10(D,L)] was prepared by dissolving 5 mg peptide in 5 
mL propylene glycol. Linear dilution was performed using PBS and calibration curves 
were obtained using 3.9, 7.81, 15.62, 31.25, 62.5 and 125 μg/mL for AAPV, C6 (D)-
LAA-AAPV, C6(D,L)-LAA-AAPV and C10(D,L)-LAA-AAPV; 3.12, 6.25, 12.5, 25, 50 
and 100  μg/mL for C6(L)-LAA-AAPV; 1.95, 3.9, 7.81, 15.62, 31.25, 62.5 and 125 
μg/mL for C8(D,L)-LAA-AAPV obtained from UQ; 3.67, 7.34, 14.68, 29.36, 58.72 and 
11.5 μg/mL for C8(D,L)-LAA-AAPV obtained from GLS Biochem solutions in PBS at 
pH 7.4. Linearity (quoted as R2) was evaluated by linear regression analysis, which was 
calculated by the least square regression method.  
3.2.4.2 Precision 
The precision of the assay was determined by injecting three standard concentrations of 
7.80 and 31.25 5 μg/mL AAPV, 1.95, 15.625 and 62.5 μg/mL C6(D,L)-LAA-AAPV and 
C8(D,L)-LAA-AAPV from UQ; 0.975, 7.80 and 31.25 μg/mL C6(D)-LAA-AAPV; 
6.25, 50.0 and 100.0  μg/mL C6(L)-LAA-AAPV; 7.34, 29.37 and 117.50 μg/mL 
C8(D,L)-LAA-AAPV from UQ; 3.06, 12.50 and 50 μg/mL C10(D,L)-LAA-AAPV from 
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GLS Biochem and 3.90, 15.62 and 62.50  μg/mL C10(D,L)-LAA-AAPV from UQ six 
times on the HPLC. 
3.2.4.3 Intra-day repeatability 
The intra-day repeatability was assessed by injecting 7.80 and 31.25 μg/mL AAPV; 1.95 
and 62.5 μg/mL C6(D,L)-LAA-AAPV; 1.95 and 15.62 μg/mL C8(D,L)-LAA-AAPV 
from UQ; 7.80 and 31.25 μg/mL C6(D)- LAA-AAPV; 6.25 and 50.0 μg/mL C6(L)-
LAA-AAPV; 7.34 and 29.37 μg/mL C8(D,L)-LAA-AAPV from GLS Biochem; 3.90 
and 15.62 μg/mL C10(D,L)-LAA-AAPV from UQ and 3.06 and 50.0 μg/mL C10(D,L)-
LAA-AAPV from GLS Biochem standards six times at different times in a day. 
3.2.4.4 Inter-day repeatability 
The inter-day repeatability was determined by injecting 7.80 and 31.25 μg/mL AAPV; 
1.95 and 62.5 μg/mL C6(D,L)-LAA-AAPV; 1.95 and 15.62 μg/mL C8(D,L)-LAA-
AAPV from UQ; 7.80 and 31.25 μg/mL C6(D)-LAA-AAPV; 6.25 and 50.0 μg/mL 
C6(L)-LAA-AAPV; 3.90 and 15.62 μg/mL C10(D,L)-LAA-AAPV from UQ and 3.06 
and 50.0 μg/mL C10(D,L)-LAA-AAPV from GLS Biochem standards six times on 3 
different days. The intra- and inter-day repeatabilities were quoted as the coefficient of 
variance. 
3.2.4.5 Lower limit of detection (LOD) 
The minimum detectable and quantifiable limits (LOD and LOQ) were measured by 
diluting the stock solution of AAPV and conjugated peptides with PBS to give a 
concentration range from 3.9 to125 μg/mL and then injected on the HPLC. The LOD 
was calculated as greater than 3 times the baseline noise level by the following formula: 
LOD = 3 × SD of peak area of standard / slope. 
3.2.4.6 Lower limit of quantification (LOQ) 
The LOQ was calculated as 10 times the baseline noise level. The LOQ was calculated 
by the following formula: LOQ = 10 × SD of peak area of standard / slope. 
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3.2.5 Formulation approaches and duration of skin hydration 
3.2.5.1 Selection of vehicle and effect of concentration 
Based on the preliminary data for C8 (D,L) conjugated AAPV, it was decided to use 
propylene glycol as the vehicle. Due to limited availability of the peptides it was first 
decided to assess the effect of a lower concentration on the delivery of the peptide across 
the skin. Experiments were also conducted using a 75:25 mixture of propylene glycol: 
PBS as the donor vehicle and 25:75 propylene glycol: PBS as the receptor for C6(D,L)-
LAA-AAPV, C8(D,L)-LAA-AAPV and C10(D,L)-LAA-AAPV. Based on this 
preliminary study 3 mg peptide dissolved in 300 µL propylene glycol was used as the 
vehicle and phosphate buffered saline as the receptor medium for the skin diffusion 
studies. To asses the effect of concentration on skin permeation of the native and 
conjugated peptides a comparison was also made by using 6 mg peptide in 300 µL 
propylene glycol in the donor.  
3.2.5.2 Skin hydration 
As discussed in the introduction, skin hydration can improve the delivery of drugs across 
the continuous stratum corneum. This hypothesis was investigated by hydrating the 
epidermal membranes to be used in the diffusion study with phosphate buffered saline 
(receptor medium) for 1h and overnight.  Before the start of the experiment, the receptor 
medium was withdrawn and a fresh sample of pre-equilibrated PBS at 35°C was 
replaced in the receptor compartment. 
3.2.6 Skin Stability (metabolism) experiment 
The influence of human skin on the stability of the native tetrapeptide and the lipoamino 
acid conjugates of the tetrapeptide was determined by placing skin in a vial containing 
peptide solution to provide an estimate of their stability during the skin diffusion 
experiments. Vials containing 2 mL of 20 µg/mL AAPV, 250 µg/mL C6(D)-LAA-
AAPV, 10 µg/mL C6(D,L)-LAA-AAPV, 100 µg/mL C8(D,L)-LAA-AAPV and 30 
µg/mL C10(D,L)- LAA-AAPV solutions were stored at 37°C. The concentrations of 
each peptide for the stability study were chosen based on the amount of peptide found in 
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the receptor after skin permeation. 150 μL samples were withdrawn at 0, 2, 4, 6 and 24h. 
In the case of C6(D,L)-LAA-AAPV the samples were diluted to give a final theoretical 
concentration of 125 µg/mL and were analysed by HPLC. The percentage of intact 
peptide was calculated as follows: 
Intact peptide =  Final amount of peptide ×100 % 
     Initial amount of peptide 
3.2.7 Human skin preparation 
Full thickness human skin samples excised from female donors undertaking 
abdominoplasty surgery at Perth hospitals were refrigerated immediately after surgery. 
Sampling was approved by the Human Research Ethics Committee of Curtin University 
(Approval numbers HR132/2001, HR 70/2007 and HR 129/2008) and was carried out 
under the Guidelines of the National Health and Medical Research Council of Australia. 
The subcutaneous fat was removed by dissection and whole skin was frozen at -20°C 
within 24 h of surgery. When required for a permeation study the skin samples were 
thawed at room temperature. Epidermis was detached from the dermis by heat separation 
as described previously.198 Permeation of the tetrapeptide and lipoamino acid conjugates 
of the tetrapeptide was assessed across epidermis prepared by heat separation from the 
dermis.  
3.2.8 Skin permeation of tetrapeptide and lipoamino acid conjugates 
The epidermal membrane was mounted on a Franz-type diffusion cell (effective 
diffusion surface area approximately 1 cm2 and receptor volume approximately 3 ml) 
with the stratum corneum layer facing the donor compartment. The receptor 
compartment was filled with phosphate buffered saline pH 7.4 (PBS) or 25:75 propylene 
glycol: PBS and allowed to equilibrate in a 35°C water bath with the receptor phase 
stirring continuously for approximately 1h or overnight depending on the experimental 
protocol. 35°C was used for the diffusion experiments because water bath temperature of 
35°C will give a skin surface temperature of 32°C. The donor compartment was loaded 
with 300 µL of either propylene glycol or propylene glycol and PBS mixture containing 
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3 mg or 6 mg of peptide (tetrapeptide or lipoamino acid conjugated tetrapeptide) and 
sealed with Parafilm. These amounts were completely soluble at these concentrations. 
The apparatus was maintained at 35°C throughout the 24 h duration of the experiment. 
200 µL aliquots were taken from the receptor compartment at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 
and 24 h and replaced immediately with 200 µL of receptor medium pre-equilibrated at 
35°C to maintain skin conditions. At the termination of the experiment (24 h) samples 
were also taken from the donor compartment. Samples collected were kept at 4°C in the 
injecting tray for analysis by reverse phase HPLC. All samples from individual 
experiments were assayed together in the same run. The D- and L-diastereomers of the 
lipopeptide were identified by comparison with synthesised standards of the individual 
diastereomers of known configuration. 
3.2.9 Mass balance and recovery 
The uptake of peptide and conjugates in the epidermis was also investigated. Different 
solvents were tested for their extraction efficiency of the peptide and conjugates from 
the skin. As C6(L)-LAA-AAPV and C6(D)-LAA-AAPV were available in greatest 
amount, these conjugates were used for testing extraction efficiency with a number of 
solvents. DMSO, methanol and propylene glycol were compared as extraction solvents 
for the peptides and conjugates from the skin. The protocol for DMSO and methanol 
extraction was as follows: 
1. The absolute recovery of C6(D)-LAA-AAPV and C6(L)-LAA-AAPV from skin 
tissue was determined by spiking skin sections with the conjugates in propylene 
glycol. The skin sections were allowed to rest in 500 µL methanol and agitated 
for 2 min.  
2. The sample was then transferred to a second Eppendorf tube containing 500 µL   
methanol and agitated for another 2 min. 
3. The skin sample was then extracted with 1 mL 50:50 DMSO: water for 2 hours 
with agitation.  
4. After 2 hours the methanolic and DMSO extracts with skin were centrifuged at 
10,000 RPM for 10 mins. The supernatants were withdrawn and injected on 
HPLC to quantify the amount of peptide in the skin. 
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The protocol for propylene glycol and methanol extraction was as follows: 
1. The absolute recovery of AAPV, C6(D,L)-LAA-AAPV, C8(D,L)-LAA-AAPV 
and C10(D,L)-LAA-AAPV from skin tissue was determined by spiking skin 
sections with the conjugates in propylene glycol. The skin sections were allowed 
to rest in 500 µL methanol and vortexed for 2 min. 
2. The skin section was then transferred to a second Eppendorf tube containing 500 
µL methanol and vortexed for another 2 min. 
3. The skin sample was then placed in 1 mL propylene glycol for 2 hours with 
agitation. 
4. After centrifuging each extract at 10,000 × g for 10 min, the resultant 
supernatants were diluted appropriately and quantified by HPLC. 
The extraction method using methanol and propylene glycol was most efficient and 
therefore used for experimental samples. 
To determine mass balance/recovery purpose in the skin permeation experiments, the 
donor solution was removed from the donor compartment and diluted appropriately to 
quantify the amount of peptide in the donor at the end of the experiment. The donor 
compartment with the skin was rinsed with 300 µL PBS and the wash was collected. The 
receptor compartment was emptied and washed with 500 µL PBS. Samples from both 
washes were injected on HPLC to quantify the peptides and conjugates present in the 
washes. 
3.2.10 Surface tension measurement 
The surface tension of AAPV, C6(D,L)-LAA-AAPV, C8(D,L)-LAA-AAPV and 
C10(D,L)-LAA-AAPV was measured by the ring method using a Du Nouy ring 
tensiometer at room temperature. A 1 mg/mL standard solution of each peptide was first 
prepared by dissolving 10 mg of peptide in 10 mL PBS. Linear dilution was carried out 
to give final concentrations of 0.5, 0.25, 0.125 and 0.0625 mg/mL in PBS. The surface 
tension was first measured for PBS and it was used as a control. The surface activity of 
the peptides and conjugates was compared to the control. 
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3.2.11 Elastase inhibition assays 
Inhibition of HNE by the synthesized conjugates and the parent tetrapeptide was 
assessed using an EnzChek® Elastase Assay Kit (E-12056, Molecular Probes). The 
native peptide, AAPV was used as a standard to which the lipoamino acid conjugates 
were compared. The kit contained DQ™ elastin (component A) from bovine neck 
ligament that was labeled with BODIPY® FL, a 10 times concentrated reaction buffer 
containing 1 M Tris-HCL at pH 8 and 2mM sodium azide (component B) and elastase 
from pig pancreas (component C). Digestion products from the DQ elastin substrate had 
absorption maxima at approximately 505 nm and fluorescence emission maxima at 515 
nm.  
3.2.12 Assay optimization 
The activity of the tetrapeptide and its LAA conjugates from both the sources 
(University of Queensland and GLS Biochem, China) was assessed at 2 different 
concentrations of the elastin substrate and porcine elastase. The activity of the peptides 
at different concentrations was tested at a final concentration of 6.25 and 25 µg/mL DQ 
elastin substrate and 0.25 and 0.5 U/mL elastase. A two hour incubation period and a 
fluorescence microplate reader equipped with standard fluorescein filters were used to 
detect the activity of elastase from porcine pancreas down to a final concentration of 5 × 
10-3 U/mL (40 ng protein/mL). Because the assay is continuous, kinetic data can be 
obtained easily and a comparison was made between 0.5 and 0.25 U/mL elastase at a 
specific concentration of the substrate. 
3.2.12.1 Dilution of reaction buffer 
To prepare a 1X reaction buffer, 6 mL of the 10X reaction buffer was diluted in 54 mL 
deionized water (dH2O). This 60 mL volume of working 1X reaction buffer was 
sufficient to prepare working solutions of elastase and inhibitors. 
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3.2.12.2 Preparation of standard concentration of the Inhibitors 
A 1 mM solution of inhibitor standards was prepared by dissolving 0.354 mg AAPV, 
0.468 mg C6(L)-LAA-AAPV and C6(D,L)-LAA-AAPV, 0.497 mg C8 (D,L)-LAA-
AAPV and 0.534 mg C10 (D,L)-LAA-AAPV in 1 mL propylene glycol. Further linear 
dilution was carried out with 1X reaction buffer to give 0.5, 0.25, 0.125, 0.062, 0.031 
and 0.015 mM working standard concentrations. 
3.2.12.3 Preparation of DQ elastin working standard solution 
A 1.0 mg/mL stock solution of the DQ elastin substrate was prepared by adding 1.0 mL 
of deionized water (dH2O) directly to a vial containing the lyophilized substrate. It was 
mixed thoroughly to dissolve. A 100 μg/mL working solution of the DQ elastin substrate 
was prepared by diluting the DQ elastin stock solution ten-fold in 1X Reaction Buffer. 
Appropriate concentrations of the substrate were prepared by linearly diluting the 100 
μg/mL solution with 1X Reaction Buffer.  
3.2.12.4  Preparation of enzyme working solution 
A 100 U/mL stock solution by of porcine pancreatic elastase was prepared by dissolving 
the contents of the vial (Component C) in 0.5 mL dH2O. A 1 U/mL solution was 
prepared by diluting the 100 U/mL stock solution 100 times with 1X Reaction Buffer. A 
0.5 U/mL solution can be prepared by linearly diluting the 1 U/mL solution with 1X 
Reaction Buffer. 
3.2.12.5 Reaction mixture 
1) 50 μL of the diluted inhibitors in the concentration range of 0.031 to 1mM (or no-
inhibitor control) was added to each assay well. 
2) Either 50 μL of 100 μg/mL or 25 μg/mL DQ elastin working solution was then added 
to each assay well. This gave a final concentration of 25 and 6.25 μg/mL DQ elastin in 
the final reaction mixure. 
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3) Porcine pancreatic elastase was diluted in 1X Reaction Buffer. 100 μL of the diluted 
enzyme, or 100 μL of 1X Reaction Buffer as a blank, was added to the sample wells 
preloaded with substrate and inhibitor. 
4) The samples were incubated at room temperature, protected from light, for an 
appropriate time, e.g. 1–2 hours. Because the assay is continuous (not terminated), 
fluorescence may be measured at multiple time points. 
5) The fluorescence intensity was measured in a fluorescence microplate reader 
equipped with standard fluorescein filters. 
6) Correction was made for background fluorescence by subtracting the values derived 
from the no-enzyme control. 
3.2.13 Statistical analysis 
Differences in the permeation of AAPV and the lipoamino acid conjugates were 
analysed for statistical significance (p < 0.05) using an Analysis of Variance (ANOVA) 
at each of the prescribed time points. The ANOVA model was implemented using the 
GENMOD procedure in the SAS software system, with the control group being the 
reference group in each model.  Because of the skewness in the concentrations, the 
regression model was applied to the log-transformed data (in order to obtain the p-values 
for comparison of treatments). The overall p-values were found to be significant for 
most of the comparisons.  
3.3 Results and discussion 
3.3.1 Chromatography 
3.3.1.1 AAPV 
The current HPLC method was an extension of that established previously in our 
laboratory.205 The method provided good selectivity and specificity and the tetrapeptide 
eluted at approximately 2.8 min. The linearity shown by the HPLC method was 1.00 and 
the precision was 0.22% for 31.25 µg/mL and 0.56% for 7.8 µg/mL.  The lowest amount 
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of AAPV that could be detected (LOD) by this method was 200 ng and the amount that 
could be quantified (LOQ) accurately was 700 ng. The method showed intra-day 
repeatability of 0.40% for 31.25 μg/mL and 0.60% for 7.8 µg/mL (both within the 
acceptable criteria for intraday repeatability which is RSD < 5%) and the inter-day 
repeatability of 0.76 % for 31.25 µg/mL and 1.05 % for 7.8 µg/mL. Thus the method 
was validated to be used as a detection method for AAPV after permeation through skin. 
A typical chromatogram for AAPV is shown in Figure 3.6 below. 
 
Figure 3.6 Chromatogram of 125 µg/mL standard of AAPV 
3.3.1.2 C6(D), C6(L) and C6(D,L)-LAA-AAPV 
The HPLC method developed for AAPV enabled co-analysis of both the tetrapeptide 
and the lipopeptide diastereomers in the same run. The retention time for the lipopeptide 
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[C6(D)-LAA-AAPV] was approximately 9.1 min. This peptide was obtained from 
University of Queensland and stating the source was important since there are minor 
differences in the chromatographic conditions of the same peptides from 2 different 
sources. The linearity shown by the HPLC method was 1.0 and the precision was 0.74% 
for 0.975 µg/mL, 0.63% for 7.8 µg/mL and 0.24% for 31.25 µg/mL. The LOD and LOQ 
of C6(D)-LAA-AAPV was 0.3 µg and 0.99 µg respectively. The method showed intra- 
day repeatability of 0.68% for 7.8 μg/mL and 0.37% for 31.25 µg/mL (both within the 
acceptable criteria for intra-day repeatability which is RSD < 5%) and the inter-day 
repeatability of 0.85% for 7.8 µg/mL and 0.40% for 31.25 µg/mL. A typical 
chromatogram for C6(D)-LAA-AAPV is shown in Figure 3.7 below. 
 
Figure 3.7 Chromatogram of 15.62 µg/mL standard of C6(D)-LAA-AAPV 
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The retention time of C6(L)-LAA-AAPV was 4.6 min. The linearity obtained by the 
HPLC method was 0.9994 and the precision was 0.90% for 6.25 µg/mL, 0.46% for 50 
µg/mL and 0.47% for 100 µg/mL.  The LOD and LOQ of C6(L)-LAA-AAPV was 0.11 
µg and 0.38 µg respectively. The method showed intra-day repeatability was 1.04% for 
6.25 μg/mL and 0.61 % for 50 µg/mL and the inter-day repeatability was 1.09% for 6.25 
µg/mL and 0.62% for 50µg/mL. A typical chromatogram for C6(L)-LAA-AAPV is 
shown in Figure 3.8 below. 
 
Figure 3.8 Chromatogram of 25 µg/mL standard of C6(L)-LAA-AAPV from UQ 
The HPLC method for the racemic mixture of C6(D,L)-LAA-AAPV obtained from GLS 
Biochem varied in comparison to the method used for C6(D) and C6(L) individual 
diastereomers, in terms of the mobile phase gradient used to elute the two peaks 
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corresponding to the D- and L- diastereomers. The lipopeptide gave a twin peak, which 
is typical of diastereomeric mixtures; the L-diastereomer peak eluted at approximately 
11.2 min and the D-diastereomer at 11.5 min. The linearity obtained by the HPLC 
method was 0.9999 for the D- isomer and 1.00 for the L- diastereomer. For the D- 
diastereomer the precision was 0.74% for 1.95 µg/mL, 0.25% for15.625 µg/mL and 
0.17% for 62.5 µg/mL; LOD was 44 ng and LOQ was 147 ng. The method showed 
intra-day repeatability of 1.10% for 1.95 μg/mL and 0.16 % for 62.5 µg/mL and inter-
day repeatability of 1.10% for 1.95 µg/mL and 0.18% for 62.5µg/mL. For the L- 
diastereomer the precision was 0.86% for 1.95 μg/mL, 0.19% for 15.625 μg/mL and 
0.19% for 62.5 μg/mL, the LOD was 34 ng and the LOQ was 113 ng. The method 
showed intra-day repeatability of 1.10% for 1.95 μg/mL and 0.10 % for 62.5 µg/mL and 
the inter-day repeatability of 1.22% for 1.95 µg/mL and 0.18% for 62.5µg/mL. A typical 
chromatogram for C6(D,L)-LAA-AAPV is shown in Figure 3.9 below. 
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Figure 3.9 Chromatogram of 30 µg/mL standard of C6(D,L)-LAA-AAPV 
3.3.1.3 C8(D,L)-LAA-AAPV 
C8(D,L)-LAA-AAPV was obtained from two sources. C8(D,L) from UQ gave a twin 
peak after HPLC analysis (Figure 3.10) whereas the C8(D,L) from GLS Biochem, eluted 
as a single sharp peak under the same chromatographic conditions. The HPLC method 
was validated for C8(D,L) obtained from both the sources. For the UQ sourced 
lipopeptide L-diastereomer peak eluted at approximately 10.2 min and the D-
diastereomer at approximately 10.4 min. The linearity for the L- diastereomer and the D-
diastereomer was 0.9998 and 0.9999 respectively. For the C8(L) diastereomer the 
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precision was, 1.35% for 1.95 μg/mL; 0.38% for 15.625 μg/mL and 0.11% for 62.5 
μg/mL. The LOD was 88 ng and the LOQ was 293.23 ng. The method showed intra-day 
repeatability of 2.40% for 1.95 μg/mL and 0.61 % for 15.625 µg/mL and inter-day 
repeatability of 2.12% for 1.95 µg/mL and 0.83% for 15.625µg/mL. For the C8(D)-
LAA-AAPV diastereomer, the precision was 1.40% for 1.95 μg/mL, 0.56% for 15.625 
μg/mL and 0.33% for 62.5 μg/mL. The LOD was approximately 67.90 ng and the LOQ 
was 226.34 ng. The method showed intra-day repeatability of 2.0% for 1.95 μg/mL and 
0.94 % for 15.625 µg/mL and the inter-day repeatability of 2.28% for 1.95 µg/mL and 
0.90% for 15.625µg/mL.  
 
Figure 3.10 Chromatogram of 100 µg/mL standard of C8(D,L)-LAA-AAPV from UQ 
C8(D,L)-LAA-AAPV obtained from GLS Biochem eluted at approximately 10.7 min 
and variation of the HPLC conditions did not permit elucidation of two peaks 
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corresponding to the diastereomers. The linearity by this method was 1.0 and the 
precision was 0.94% for 7.34 μg/mL, 0.25 % for 29.37 μg/mL and 0.21% for 117.5 
μg/mL. The LOD was approximately 30 ng and the LOQ was 102 ng. The method 
showed intra day repeatability of 0.68% for 7.34 μg/mL and 0.51 % for 29.37 µg/mL 
and the inter day repeatability of 0.63% for 7.34 µg/mL and 0.40% for 29.37 µg/mL. A 
typical chromatogram for C8(D,L)-LAA-AAPV is shown in Figure 3.11 below. 
 
Figure 3.11 Chromatogram of 62.5 µg/mL standard of C8(D,L)-LAA-AAPV from GLS Biochem 
3.3.1.4 C10 (D,L)-LAA-AAPV 
C10(D,L)-LAA-AAPV obtained from UQ eluted as twin peaks, one corresponding to 
the L- diastereomer and the other D- diastereomer while the same compound obtained 
from GLS Biochem eluted as a single peak. The peak corresponding to the L- 
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diastereomer eluted at 11.3 min and the peak corresponding to the D- diastereomer 
eluted at 11.6 mins (Figure 3.12). The linearity obtained by the HPLC method for 
C10(D,L) from UQ was 0.9996 for the L- distereomer and 0.9998 for the D- 
diastereomer. For C10(L)-LAA-AAPV the precision of the assay was 1.31% for 3.9 
μg/mL, 0.52% for 15.625 μg/mL and 0.22% for 62.5 μg/mL, and the LOD and LOQ 
were 61.68 ng and 205.60 ng respectively. The intra-day repeatability was 1.05% for 3.9 
μg/mL and 0.33% for 15.625 μg/mL and the inter-day repeatability was 1.05 % for 3.9 
μg/mL and 0.28% for 15.625 μg/mL. For C10(D)-LAA-AAPV, the precision was 1.51% 
for 3.9 μg/mL, 0.76% for 15.625 μg/mL and 0.13% for 62.5 μg/mL. The intra-day 
repeatability was 1.27% for 3.9 μg/mL and 0.35% for 15.625 μg/mL and the inter-day 
repeatability was 1.26% for 3.9 μg/mL and 0.46% for 15.625 μg/mL. The LOD and 
LOQ were approximately 30 ng and 100 ng respectively.  
 
Figure 3.12 Chromatogram of 100 µg/mL standard of C10(D,L)-LAA-AAPV from UQ 
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C10(D,L)-LAA-AAPV obtained from GLS Biochem eluted as a single peak at 11.3 min 
and variation of the HPLC conditions did not permit elucidation of two peaks 
corresponding to the diastereomers. The linearity by the assay method was 1 and 
precision was 1.02% for 3.06 μg/mL, 0.41% for 12.5 μg/mL and 1.64% for 50 μg/mL. 
The LOD of C10(D,L)-LAA-AAPV was approximately 120 ng and the LOQ was 400 
ng. The method showed intra-day repeatability of 0.70% for 3.06 μg/mL and 0.63 % for 
50 µg/mL and the inter day repeatability of 0.82% for 3.06 µg/mL and 0.56% for 
50µg/mL. A chromatogram for C10(D,L)-LAA-AAPV  is shown in Figure 3.13 below. 
 
 
Figure 3.13 Chromatogram of 50 µg/mL standard of C10(D,L)-LAA-AAPV from GLS Biochem 
We evaluated several validation parameters to demonstrate that the analytical procedure 
is suitable for analyzing AAPV and its lipoamino acid conjugates in skin samples. The 
HPLC method described in the study also has the advantage of a rapid and sensitive 
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quantification of AAPV and its conjugates in the skin. Validation parameters such as 
linearity and assay precision of the peptides obtained from UQ and GLS Biochem were 
found to be similar with minimal difference in the correlation coefficient and coefficient 
of variance (Table 3-1 and 3-2). The only difference between C8(D,L)-LAA-AAPV and 
C10(D,L)-LAA-AAPV obtained from GLS Biochem as compared to UQ was that it was 
not possible to separate them into individual diastereomers chromatographically. In-vitro 
skin diffusion studies were conducted on the peptides from both sources and similar 
results were obtained verifying that peptides from both the sources showed similar 
permeation characteristics. The only drawback was that we were not able to compare the 
diffusion of the individual diastereomers in the diffusion studies undertaken with the 
peptides from GLS Biochem.  
Table 3-1 Correlation coefficient of tetrapeptide and its conjugates 
Peptide 
Correlation coefficient 
(r2) 
Linear range(µg/mL) 
AAPV 1.000 3.9-125 
C6(D)-LAA-AAPV-UQ 1.000 3.9-125 
C6(L)-LAA-AAPV-UQ 0.9994 3.12-100 
C6(D,L)-LAA-AAPV- GLS 
Biochem 
0.999 –D disastereomer 
1.000- L diastereomer 
3.9-125 
3.9-125 
C8(D,L)-LAA-AAPV- UQ 
0.9999 –D disastereomer 
0.9998- L diastereomer 
1.95-125 
1.95-125 
C8(D,L)-LAA-AAPV- GLS 
Biochem 
1.000 3.67-117.5 
C10(D,L)-LAA-AAPV- UQ 
0.9998 –D disastereomer 
0.9996- L diastereomer 
3.9-125 
3.9-125 
C10(D,L)-LAA-AAPV- GLS 
Biochem 
1.000 3.06-100 
 95
Table 3-2 Assay precision, Intra-day and Inter-day variations of AAPV and its lipoamino acid conjugates 
Peptide Precision (n=5) 
Intra-day variation 
(n=5) 
Inter-day variation (n=9) 
Coefficient of 
Variance (CV,%) 
7.8 µg/mL 31.25 µg/mL 7.8 µg/mL 31.25 µg/mL 7.8 µg/mL 31.25 µg/mL
AAPV (%) 0.56 0.22 0.60 0.40 0.76 1.05 
0.975 
µg/mL 
7.8 µg/mL 
31.25 
µg/mL 
7.8 µg/mL 31.25 µg/mL 7.8 µg/mL 31.25 µg/mL
C6(D)-LAA-
AAPV,UQ 
(%) 0.74 0.63 0.24 0.68 0.37 0.85 0.40 
6.25 µg/mL 50 µg/mL 100 µg/mL
6.25 
µg/mL 
50 µg/mL 6.25 µg/mL 50 µg/mL 
C6(L)-LAA-AAPV, 
UQ (%) 
 0.90 0.46 0.47 1.04 0.61 1.09 0.62 
1.95 µg/mL
15.62 
µg/mL 
62.5 
µg/mL 
1.95 
µg/mL 
62.5 µg/mL 1.95 µg/mL 62.5 µg/mL C6(D,L)-LAA-
AAPV,GLS Biochem, 
D diastereomer (%) 0.74 0.25 0.17 1.10 0.16 1.10 0.18 
1.95 µg/mL
15.62 
µg/mL 
62.5 
µg/mL 
1.95 
µg/mL 
62.5 µg/mL 1.95 µg/mL 62.5 µg/mL C6(D,L)-LAA-
AAPV,GLS Biochem, 
L diastereomer (%) 0.86 0.19 0.19 1.10 0.10 1.22 0.18 
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1.95 µg/mL
15.62 
µg/mL 
62.5 
µg/mL 
1.95 
µg/mL 
15.62 µg/mL 1.95 µg/mL 15.62 µg/mLC8(D,L)-LAA-
AAPV, UQ, D 
diastereomer (%) 1.40 0.56 0.33 2.00 0.94 2.28 0.90 
1.95 µg/mL
15.62 
µg/mL 
62.5 
µg/mL 
1.95 
µg/mL 
15.62 µg/mL 1.95 µg/mL 15.62 µg/mLC8(D,L)-LAA-
AAPV,UQ, L 
diastereomer(%) 1.35 0.38 0.11 2.40 0.61 2.12 0.83 
7.34 µg/mL
29.37 
µg/mL 
117.5 
µg/mL 
7.34 
µg/mL 
29.37 µg/mL 7.34 µg/mL 
29.37 µg/  
mL 
C8(D,L)-LAA-
AAPV, GLS 
Biochem, (%) 0.94 0.25 0.21 0.68 0.51 0.63 0.40 
3.9 µg/mL 
15.62 
µg/mL 
62.5 
µg/mL 
3.9 µg/mL 15.62 µg/mL 3.9 µg/mL 15.62 µg/mLC10(D,L)-LAA-
AAPV, UQ, D 
diastereomer (%) 1.51 0.76 0.13 1.27 0.35 1.26 0.46 
3.9 µg/mL 
15.62 
µg/mL 
62.5 
µg/mL 
3.9 µg/ 
mL 
15.62 µg/mL 3.9 µg/mL 15.62 µg/mLC10(D,L)-LAA-
AAPV, UQ, L 
diastereomer (%) 1.31 0.52 0.22 1.05 0.33 1.05 0.28 
3.06 µg/mL 12.5 µg/mL 50 µg/mL 
3.06 
µg/mL 
50 µg/mL 3.06 µg/mL 50 µg/mL C10(D,L)-LAA-
AAPV, GLS 
Biochem, (%) 1.02 0.41 1.64 0.70 0.63 0.82 0.56 
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3.3.2 Skin stability of tetrapeptide and lipoamino acid conjugates of the 
tetrapeptide 
The degradation profiles of AAPV, C6(D,L)-LAA-AAPV, C8(D,L)-LAA-AAPV and 
C10(D,L)-LAA-AAPV are shown in Figure 3.14. The stability data was presented as the 
percentage of the peptide remaining at 37ºC over time.  
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Figure 3.14 Degradation profile of tetrapeptide and its lipoamino acid conjugates 
It was observed that when the tetrapeptide and its conjugates were placed at 37ºC in 
contact with human skin about 70% of the native peptide was lost in 24 h while the 
stability of all the conjugated peptides was higher in comparison. (Table 3-3) 
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Table 3-3 Percent degradation of AAPV and its lipoamino acid conjugates 
(Mean, n=3, ± SEM) 
Time % AAPV 
% C6(D) 
diastereomer
% C6(L) 
diastereomer % C8(D,L) 
% C10(D) 
diastereomer 
% C10(L) 
diastereomer
0 100.00 100.00 100.00 100.00 100.00 100.00  
2 97.43 (±2.06) 93.56 (±2.60) 95.06 (±5.31) 99.23(±0.05) 98.39 (±1.69 ) 96.71 (±0.23 
4 95.85 (±1.62) 83.96 (±5.30) 84.21 (±6.52) 97.38 (±0.05) 97.53 (±0.49) 97.57 (±) 
6 88.31(±4.63) 84.81 (±6.40) 81.58 (±5.64) 97.24 (±0.03) 91.93 (±2.40) 88.54 (±0.68) 
24 31.93 (±7.73) 76.43 (±5.0) 73.60 (±3.88) 94.30 (±0.02) 79.37 (±7.78) 75.57 (±7.43) 
C6(D)-LAA-AAPV, C6(L)-LAA-AAPV, C10(D)-LAA-AAPV and C10(L)-LAA-
AAPV diastereomers showed similar degradation profiles whereas C8(D,L)-LAA-
AAPV was the most stable of the conjugated peptides with just 6% loss in activity at the 
end of 24h period. The rank order of peptides from most to least stable was C8(D,L)-
LAA-AAPV > C10(D)-LAA-AAPV > C6(D)-LAA-AAPV>C10(L)-LAA-AAPV > 
C6(L)-LAA-AAPV though there was no significant difference in the stability between 
these conjugates. A significant difference (p<0.0001) was observed when stability of 
each of these conjugates was compared to AAPV at 24h. It has been reported in the 
literature that conjugation of a native peptide with long alkyl side chains may protect a 
labile parent drug from enzymatic attack. This was demonstrated for the enzymatically 
labile model peptides LHRH and TRH which when conjugated to various lipidic 
peptides showed increased metabolic stability during incubation with Caco 2 cell 
homogenates.108 
3.3.3 In-vitro skin diffusion of tetrapeptide and lipoamino acid conjugates 
across human epidermis 
In this study lipoamino acid conjugation was used as an enhancement strategy to 
improve transdermal delivery of the HNE inhibitor, AAPV.  LAAs are α-amino acids 
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with a hydrocarbon side chain. They are a convenient method of incorporating lipid 
groups into peptides as they can be coupled to the peptide during solid phase synthesis 
using standard coupling techniques and can be incorporated at any place in the sequence. 
The results of all human skin permeability experiments were plotted as cumulative 
amount of conjugated peptide/tetrapeptide permeated through the epidermis (μg/cm2) 
versus time (h). The steady-state flux of each of these conjugated/native peptide through 
the human epidermis was determined using equation 2 and expressed as μg/cm2.h. 
Permeability coefficients (cm/h) were calculated for each of these peptides using the 
equation 1 in section 2.2.6 
3.3.3.1 Preliminary experiments to determine final protocol 
Preliminary investigations were carried out on C6(D)-, C6(L)-, C6(D,L)-, C8(D,L)- and 
C10(D,L)-LAA-AAPV lipoamino acid conjugates. It is important to note that 
experiments were conducted based on the availability of these peptide conjugates. 
Synthetic procedures are time consuming and expensive therefore we were only able to 
get very small and limited quantities of peptides. In some cases experiments could not be 
repeated if a portion of the available compound was required for other assessment 
procedures. Experiments were undertaken to determine the final donor concentration, 
donor vehicle, receptor vehicle and period of epidermal membrane hydration.  
The first set of studies was carried out with racemic mixture of C6(D,L)-LAA-AAPV. A 
solubility study was first undertaken with racemic mixture of C6(D,L)-LAA-AAPV 
where 2 mg C6(D,L)- LAA-AAPV was dissolved in four different solvent mixtures 
(100% PG, 75:25 PG:PBS, 50:50 PG:PBS and 25:75 PG:PBS). The results indicated that 
the racemate had good solubility in both 100% PG and 75:25 PG: PBS mixture.  For the 
purpose of formulation optimization to assess the effect of a particular donor 
vehicle/receptor medium on the skin diffusion of C6 (D,L)-LAA-AAPV a 75:25 mixture 
of propylene glycol: PBS was used as the donor vehicle and 25:75 PG:PBS was used as 
the receptor medium. In preliminary work done in our laboratory on stereoselective 
permeation of C8(D,L)-LAA-AAPV, a concentration of 3mg peptide in 300 µL PG was 
applied to epidermal sections which had been hydrated with PBS for 1h before starting 
the experiment. Keeping in line with this study, we decided to use a donor concentration 
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of  3 mg. 3 mg peptide was dissolved in 300 µL vehicle (75:25 PG:PBS) and the 
epidermis was hydrated for 1 h before starting the experiment.  The receptor 
compartment contained 25:75 PG: PBS. 
 
0
1
2
3
4
5
6
7
8
9
0 5 10 15 20 25 30
Time (h)
C
um
ul
at
iv
e 
am
ou
nt
 (μ
g/
cm
2 )
C6(D)-LAA-AAPV
C6(L)-LAA-AAPV
AAPV
 
Figure 3.15 Permeation profile of cumulative amount vs. time of C6(D,L)-LAA-AAPV (racemic 
mixtures) vs. APPV across human epidermis. Results are expressed as mean (±SEM), n=8 
The results showed that there was decreased permeation of the racemic mixture as 
compared to the individual diastereomers across the human epidermis (Figure 3.15). 
Significant difference was not found in the permeation of the D- and the L- 
diastereomers except at 24 h where the cumulative amount of D- and L- diastereomers in 
the receptor compartment was 4 μg/cm2 and 2.24 μg/cm2. A large variability was also 
observed in the data which may be due to considerable intra-donor differences. Based on 
these studies it was thus decided to evaluate the permeation of C6(D,L)-LAA-AAPV 
using the same (3mg) donor concentration dissolved in 100% propylene glycol. 
After evaluation of skin permeation with C6-LAA-AAPV, higher carbon chain length 
lipoamino acids conjugated to AAPV were evaluated. Skin permeation of C8(D,L)-
LAA-AAPV was assessed at different conditions by altering the donor vehicle, receptor 
medium and concentration of the peptide in the donor. A preliminary study was then 
conducted by changing the donor vehicle to 75:25 PG:PBS and the receptor to 25:75 
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PG:PBS. However there was no observed permeation of the lipopeptide across the 
human epidermis under these conditions.  
The last set of lipoamino acid conjugates we investigated was a racemic mixture of C10-
(D,L)-LAA-AAPV. In an initial study, 3mg of C10(D,L)-LAA-AAPV was dissolved in 
300 µL propylene glycol. 
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Figure 3.16 Cumulative amount vs. time of AAPV and its C10 lipoamino acid conjugate across 
human epidermis at a donor concentration of 3 mg in 300 µL propylene glycol. Results are 
expressed as mean (±SEM: n=6).  
The above results suggest that there was a steady increase in the permeation of the D- 
diastereomer of the lipopeptide till 8h (Figure 3.16). The permeation of the L-
diastereomer started to decrease after approximately 2h and this may be due to the 
stability of the L- diastereomer as observed for C6(D,L)-LAA-AAPV. The maximum 
cumulative amounts in the receptor for C10(D)-LAA-AAPV and C10(L)-LAA-AAPV 
diastereomers were approximately 7 and 6 µg/cm2 respectively. Interestingly, the 
amount of D- diastereomer and the native peptide at 24h was almost similar, with the 
tetrapeptide being marginally higher than the lipopeptide. Also, a large variability was 
observed in skin sections from the same donor which may have contributed to the above 
results and hence this study was considered inconclusive. In the next set of optimization 
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studies, experiments were conducted at donor concentration of 3mg and 6 mg peptide in 
300µL of propylene glycol. 
Based on the preliminary data obtained for all the LAA conjugates a final protocol for 
the skin permeation studies was designed. It was decided to assess the skin permeation at 
two different peptide concentrations (3mg and 6 mg in 300µL) wherever possible. The 
donor vehicle was fixed as 100% propylene glycol as this permitted adequate solubility 
of all LAA conjugates at the required donor concentration and the receptor medium as 
PBS (pH 7.4) 
3.3.3.2 AAPV, C6(L)-LAA-AAPV, C6(D)-LAA-AAPV and C6(D,L)-LAA-AAPV 
Conjugation of the tetrapeptide to a C6-LAA substantially enhanced the ability of the 
tetrapeptide to cross the epidermis (Figure 3.17). We evaluated the skin permeation of 
C6(L), C6(D) individual diastereomers and its racemic mixture C6(D,L)-LAA-AAPV.  
The skin permeation of individual diastereomers of C6(D) and C6(L) was compared to 
determine if there were differences in permeation of the lipopeptide diastereomers across 
human epidermis.  
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Figure 3.17 Permeation profiles for individual C6(D) and C6(L) diastereomers (3 mg in 300 μL 
propylene glycol) across human epidermis from 0-24h. Results are expressed as mean (±SEM: n=3).  
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Permeation of L- diastereomer was substantially lower than that of D-diastereomer and 
was consistent with our earlier work with C8(D,L)-LAA-AAPV racemate where the D- 
diastereomer was found to permeate the epidermis to a greater extent than the L-
diastereomer. The cumulative amount of C6(D)-LAA-AAPV and C6(L)-LAA-AAPV 
penetrated across skin was plotted against time. The pseudo-steady state flux was 
determined from the gradient of the linear portion over 8 and 24h of the cumulative 
amount-time plot by equation 2.  
J = V(C/t)/A …………………………(Equation 2) 
where J is the steady-state flux (μg/cm2/h), V is the receptor volume (ml), C is the 
concentration of peptide in the receptor (μg/ml), t is the time (h), and A is the active 
diffusional area (cm2). Over the 24h experimental period the transdermal flux of C6(D)- 
LAA-AAPV was calculated to be 58.5 µg/cm2/h as compared to 15.37 µg/cm2/h for 
C6(L). Over 8h the flux increased to 157.69 µg/cm2/h for C6(D)-LAA-AAPV and 26.22 
µg/cm2/h for C6(L)-LAA-AAPV. This may be due to higher stability of both the 
diastereomers at the 8h time period. A significant difference was observed in the 
permeation of C6(D)-LAA-AAPV and C6(L)-LAA-AAPV as compared to AAPV at 8h 
and 24h with p<0.0001 for C6(D)-LAA-AAPV and C6(L)-LAA-AAPV at 8h and p< 
0.0001 for C6(D)-LAA-AAPV and p<0.05 for C6(L)-LAA-AAPV at 24h. The 
permeability coefficient was also found to be higher (5.25×10-2 and 1.94×10-2 cm/h over 
8 and 24h) in case of C6(D)-LAA-AAPV as compared to C6(L)-LAA-AAPV (8.7×10-3 
and 1.9×10-2 cm/h over 8 and 24h). The approximate lag times for both the diastereomers 
were 0.5h. There was variability in permeation of each compound between the cells as 
shown by the standard error of the mean. The variability may be due to the intra-donor 
differences in skin permeation.  The passive permeation of native tetrapeptide AAPV 
without conjugation to lipoamino acid was found to be very low (Figure 3.18). 
Conjugation with C6(D) (p<0.0001) and C6(L) (p<0.05) diastereomers enhanced the 
permeation of the tetrapeptide approximately 104 and 27-fold over 24h and 349 and 58 
fold over 8h respectively.  
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Figure 3.18 Comparison of cumulative permeation of C6(L)-LAA-AAPV and C6(D)-LAA-AAPV 
vs. AAPV across human epidermis. Mean (±SEM: n=3) 
The current data demonstrates stereo selective permeation of the lipopeptide 
diastereomers across human epidermis (Figure 3.18). These observations of 
diastereoselective permeation of the lipopeptide across human epidermal sections are in 
line with other reports of stereoselective percutaneous permeation of enantiomers and 
racemates. The components of the stratum corneum are proposed to serve as potential 
sources of chiral discrimination that may result in differential diffusion rates, dependent 
on the stereochemistry of the solute 206. Furthermore, the stereochemistry of drug 
molecules can influence physicochemical properties such as solubility and melting 
point.207 and such differences can affect skin permeability. The results from the stability 
study also showed that there is approximately 25% loss in the activity of the C6(L) 
diastereomer i.e. 5% more than the C6(D) diastereomer. This combined with less 
permeation of the L- diastereomer could be a factor contributing to decreased flux of the 
C6(L) diastereomer. We therefore hypothesise that the observed decreased trans-
epidermal delivery of the L-diastereomer, in comparison with the D-diastereomer, may 
be related to increased degradation of the L-diastereomer in the receptor and/or 
stereoselective permeability of the diastereomers. The percentage of applied dose 
penetrating to the receptor over 24 h following administration was 4.67% for the D-
diastereomer conjugate and 1.23% for the L-diastereomer, compared to 0.04% for the 
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peptide. We envisage that these concentrations will be sufficient to inhibit HNE activity 
since this tetrapeptide may also show an increased inhibitory capacity with lipidation.145  
In the next set of experiments, diffusion of the racemic mixture of C6(D,L)-LAA-AAPV 
was investigated. The skin diffusion studies were conducted on 2 different skin donors 
and the data was pooled to calculate the cumulative amount permeating the receptor at 
the end of 24 hours. The donor concentration used in the study was 3mg peptide in 300 
µL propylene glycol and the epidermis was hydrated for 1 h before starting the 
experiment.  
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Figure 3.19 Cumulative amount vs. time of C6(D)-LAA-AAPV, C6(L)-LAA-AAPV (racemic 
mixture) and AAPV across human epidermis. Results are expressed as mean (±SEM: n=9).  
The results showed that in accordance with the individual diastereomer there was more 
permeation of the D-diastereomer from the racemic mixture as compared to the L-
diastereomer. The estimated transdermal flux was calculated over 24h using equation 2 
as 2.29 μg/cm2/h for the C6(D) and 0.5 μg/cm2/h for the C6(L) isomer. The flux of the 
D-diastereomer in the racemate was approximately 4.6-fold higher than the L- 
diastereomer. In comparison with the individual diastereomers it was found that the 
permeation of the racemate across the epidermis was lower (Figure 3.20).  
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Figure 3.20 Comparison of cumulative permeation of C6(D) and C6(L) individual diastereomers 
(n=3) vs. C6(D,L)-LAA-AAPV racemic mixture (n=9) and AAPV (n=7) across human epidermis at a 
donor concentration of 3 mg in 300 µL propylene glycol.  Results are expressed as mean (±SEM). 
The major barrier to transdermal drug delivery is the outermost layer of the skin, the 
stratum corneum. Drug-skin interactions may be of a stereo selective nature since the 
stratum corneum components form essentially a chiral environment 208. Considering the 
intercellular diffusion pathway, an interaction with ceramides is possible. Ceramides are 
chiral substances having two (ceramides 1 and 2), three (ceramides 3, 4 and 5) or four 
chiral carbons (ceramide 6) within the polar head. Stereo selective interaction with 
ceramides has been shown in ephedrine enantiomers 208, although not connected with 
differences in permeation ability. In addition, in the case of intracellular permeation, an 
interaction with keratin can take place. Various stereo selective processes in the skin 
have been investigated. 209 Significant differences in rates of skin transport between a 
racemate and pure enantiomers have previously been demonstrated from saturated 
solutions. This phenomenon has been attributed to the crystallinity of the solid: the 
greater solubility and hence greater flux relative to the racemate. One important reason 
for higher permeation of the pure enantiomers is the inherent differences in 
physicochemical properties of the two.210 For example, stereoselective skin permeation 
of organic nitrates was reported to be due to differences in solubility, lipophilicity and 
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diffusivity and these properties were closely related to the stereochemistry of the 
diastereomers.190 
Miyazaki et al reported different permeation rates of propanolol enantiomers through rat 
skin, indicating a stereoselective interaction with the stratum corneum.211 The in vitro 
human skin permeation of racemic and enantiomerically pure R- and S-propranolol HCl 
from topical formulations containing a chiral cellulose derivative as excipient was 
determined. In the case of the pure enantiomers, there was a significant difference 
between the penetration rates of R- and S-propranolol. The flux of the R- and D- isomers 
was 1.20 and 0.58 µg/cm2/h respectively and flux ratio was 2.06. In the case of racemic 
propranolol, however, the flux of the R- and S- isomers was 0.59 and 0.49 µg/cm2/h 
respectively and the flux ratio was decreased to 1.2. 210  The more lipophilic pro-drugs of 
propranolol appear to show more notable stereoselective permeation profiles. In full 
thickness skin, (R)- caproyl-propranolol showed the highest permeability which was 
about 52-fold greater than that of propranolol.212  
3.3.3.3 C8(D,L)-LAA-AAPV  
We had previously determined that the stratum corneum acts as a barrier to the delivery 
of the N-acetylated tetrapeptide (Ac-AAPV-NH2) across human skin.205 The current 
research was aimed at enhancing the transepidermal delivery of this potentially 
therapeutically useful tetrapeptide. We also demonstrated that coupling of a tetrapeptide 
to a short chain C8-LAA enhanced its trans-epidermal delivery.190 The lipopeptide was 
present as a mixture of the D- and L-diastereomers of the LAA with greater sub-
epidermal availability of the D-diastereomer. This is in agreement with the results for 
C6(D,L)-LAA-AAPV.  
We replicated the published study using a new batch of C8(D,L)-LAA-AAPV supplied 
by University of Queensland and by using a different skin donor. The donor 
concentration of C8(D,L)-LAA-AAPV was 3mg in 300µL propylene glycol and the 
epidermis was hydrated for 1h. The skin diffusion of C8(D,L)-LAA-AAPV was then 
compared to the native tetrapeptide. Based on the preliminary studies done with 
C6(D,L)-LAA-AAPV in different solvents and receptor medium propylene glycol was 
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used as a vehicle to dissolve the peptide and PBS as the receptor medium. The data was 
plotted as the cumulative amount (µg/cm2) of the peptide permeating in the receptor vs. 
time. Transdermal flux was calculated using equation 2. 
0
10
20
30
40
50
60
70
80
90
0 10 20 30
Time (h)
C
um
ul
at
iv
e 
am
ou
nt
 (g
/c
m
2 )
C8(D)-LAA-AAPv
C8(L)-LAA-AAPV
AAPV
 
Figure 3.21 Permeation profiles of the tetrapeptide and lipotetrapeptide [C8(D,L)-LAA-AAPV] 
racemic mixture across human epidermis at a donor concentration of 3 mg in 300 µL propylene 
glycol. Results are expressed as mean (±SEM: n=3 for C8(D,L)-LAA-AAPV and n=7 for AAPV) 
The results indicated that conjugation of the tetrapeptide to a C8-LAA enhances the 
ability of the tetrapeptide to cross the epidermis (Figure 3.21). The percentage of applied 
dose penetrating to the receptor over 24 h following administration was approximately 
2% for the D-LAA conjugate and 0.36% for the L-LAA conjugate, compared to 0.12% 
for the peptide. The estimated transdermal flux for the D- diastereomer and L- 
diastereomer was 7.42 µg/cm2/h and 1.37 µg/cm2/h respectively. The cumulative amount 
of the D- distereomer increased linearly in the receptor with the maximum of 60 µg at 
the end of 24h. The permeation of C8(D)-LAA-AAPV diastereomer was significantly 
increased as compared to AAPV permeation over the time period of the experiment 
(p<0.05). With regards to C8(L)-LAA-AAPV a significant difference in permeation as 
compared to AAPV was observed at 4h and 8h (p<0.05).  The approximate lag times for 
both the diastereomers were 0.5h. The amount obtained for the D- diastereomer was 
comparable to our previously published results though the values for the L- diastereomer 
were substantially lower. No degradation peak was observed for the L- diastereomer in 
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spite of a slight downward trend over the 24h experimental period. The reason may be 
attributed to stereo selective permeation across the epidermis and to a different skin 
sample used in the present study.  
The hydration time was increased from 1 to 24h and the donor concentration was kept 
constant (3mg in 300 µL PG). The peptide was dissolved in propylene glycol and the 
receptor medium was PBS. Results were expressed as mean (±SEM) of sections taken 
from two different female volunteers comparing tetrapeptide to lipotetrapeptide.  
 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
Time (h)
C
um
ul
at
iv
e 
am
ou
nt
 (µ
g/
cm
2 )
C8(D,L)-LAA-AAPV
AAPV
 
Figure 3.22 Cumulative permeation of C8(D,L)-LAA-AAPV (n=7) and AAPV (n=4) across human 
epidermis with 24h hydration. Mean (±SEM) 
The data suggests that, there was a marginal increase in the amount of lipidated peptide 
traversing the skin with skin hydrated for 24 h compared to 1 h hydration (Figure 3.22). 
The maximum cumulative amount of the tetrapeptide and lipo-tetrapeptide was 
approximately 80 µg/cm2 and 4 µg/cm2 (p<0.05). The estimated transdermal flux 
calculated over the linear portion of the curve was 10.08 µg/cm2/h for the lipo-
tetrapeptide while 0.5 µg/cm2/h for the native peptide. The amount of C8(D)-LAA-
AAPV increased from 60 to 80 μg/cm2 for skin hydrated for 24h but this effect was not 
seen with a racemic mixture of C10 (D,L)-LAA-AAPV.  
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The effect of increasing concentration was also assessed on skin permeation of C8(D,L)-
LAA-AAPV and the native peptide. A donor concentration of 6 mg native/lipo-peptide 
in 300µL propylene glycol was used and the skin was hydrated/equilibrated was 24h. 
Cumulative amount of lipopeptide and native peptide permeating to the receptor was 
calculated and the results showed that increase in concentration did not have a major 
impact on skin permeation (Figure 3.23). The cumulative amount at 24h for C8(D,L)-
LAA-AAPV and AAPV were approximately 60.0 µg/cm2 and 2.0 µg/cm2 respectively 
(p<0.05). These values were similar to those obtained at lower concentration and shorter 
equilibration time. 
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Figure 3.23 Permeation profiles of C8(D,L)-LAA-AAPV racemic mixture and AAPV at a donor 
concentration of 6 mg in 300 µL PG. Results are expressed as mean (±SEM:n=4) 
Acylation of peptides and proteins has been investigated for drug delivery via a number 
of routes of administration including transdermal. Yamamoto and colleagues examined 
the transdermal delivery of acyl derivatives (C4, C6 and C8) of a dipeptide (Phe–Gly) 
across full-thickness abdominal skin excised from a male rat and reported that the 
stability and permeability of the dipeptide was improved by the chemical conjugation 
with short chain fatty acids. The permeability of the C6-Phe–Gly across intact skin was 
the highest and the amount of C8-Phe–Gly remaining in the intact skin was highest of all 
the acyl derivatives studied, likely due to its high binding characteristics to the skin.155 
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Although the transfer characteristics of many compounds have been investigated, 
differences that may exist in the transfer rates of individual stereoisomers of chiral 
compounds have received scant attention. Stereoselective processes have also been 
reported within the viable epidermis and dermis, including those involved in contact 
dermatitis and skin metabolism. It is also possible that inter conversion of stereoisomers 
could occur due to enzyme activity. However, as the rate-limiting step in percutaneous 
penetration is diffusion across the stratum corneum, the significance of these sub-
stratum corneum effects is difficult to assess.208  
In this study, the tetrapeptide sequence was synthesised to generate the active 
conformation (using all L-amino acids) and the addition of the LAA is what generated 
the two stereoisomer’s, therefore we do not expect a decrease in activity for either of the 
lipopeptide isomers generated but possibly a difference in efficacy which will be 
discussed in the following section. 
3.3.3.4 C10(D,L)-LAA-AAPV and C10(D)-LAA-AAPV 
This conjugate was more lipophilic than the C6-LAA-AAPV and C8-LAA-AAPV 
conjugated peptides. The skin permeation of this lipopeptide was compared with the 
native peptide. The effect of donor concentration and time of hydration on skin 
permeability of peptides was also evaluated.  
Based on the low skin permeation results obtained in the preliminary study with donor 
concentration of 3 mg in 300 µL, it was then decided to increase the donor concentration 
and study its effect on skin permeability. A concentration of 6 mg peptide in 300 µL 
propylene glycol was used in the donor and the equilibration period was 1 h. From the 
skin permeation studies (Figure 3.24), the human epidermis was more permeable to the 
lipopeptide than to the less lipophilic native tetrapeptide but there was a longer lag time 
seen than with the shorter LAA conjugates. 
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Figure 3.24 Cumulative amount vs. time permeation of C10(D,L)-LAA-AAPV and AAPV at a 
donor concentration of 6 mg in 300 µL PG across human epidermis. Results are expressed as mean 
(±SEM, n=4) 
The flux value for AAPV was 0.24 µg/cm2/h compared to 8.92 µg/cm2/h for the 
lipopeptide. The C10(D,L)-LAA conjugate thus increased the permeation of the native 
peptide 37-fold. The cumulative amounts for AAPV and C10(D,L)-LAA-AAPV 
transported after 24 hours were approximately 2.2 and 71.43 µg/cm2. The difference in 
permeation between C10(D,L)-LAA-AAPV and AAPV was significant at the 24h time 
point  (p<0.05). 
The next objective was to study the effect of increasing skin hydration on transdermal 
delivery of this lipopeptide. Experiments were conducted at donor concentration of 6 mg 
in 300 µL propylene glycol and the skin hydration/equilibration period was increased 
from 1 to 24h.  
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Figure 3.25 Cumulative penetration of C10(D,L)-LAA-AAPV and AAPV across human epidermis 
with 24h hydration. Results are expressed as mean (±SEM: n=4) 
It can be concluded from these experiments that a higher donor concentration improved 
the skin permeability of a high molecular weight and more lipophilic peptide, C10 
(D,L)-LAA-AAPV. Initially the skin permeation of the lipopeptide was slow due to its 
high molecular weight and lipophilic nature. But, after 24 h the cumulative amount in 
the receptor was approximately 106 µg/cm2 as compared to 2.13 µg/cm2 for the 
tetrapeptide. C10(D,L)-LAA-AAPV permeation was significantly increased as 
compared to AAPV permeation at 24h (p<0.0001). The rate of permeation of the 
lipopeptide and native tetrapeptide was 13.25 and 0.26 µg/cm2/h respectively. The 
permeability coefficient for lipopeptide and native tetrapeptide was 2.2×10-3 cm/h and 
4.5×10-5 cm/h respectively. Conjugation with C10(D,L)-LAA-AAPV thus resulted in 
48-fold enhancement in the transdermal delivery of the tetrapeptide when used at a 
higher concentration (Figure 3.25). On comparison of this data with the results obtained 
with a donor concentration of 6 mg and skin hydration of 1 h it was observed that a 1.5 
fold enhancement in the delivery of C10(D,L)-LAA-AAPV was observed with longer 
period of hydration The data follows the same pattern where minimal permeation was 
observed till 8h and the amount increased at the 24h time period.  The only concern 
though is its lipophilic nature due to which the skin permeation begins only after 8 h in 
contrast to the other lipoamino acid conjugates investigated. Skin hydration/equilibration 
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also may have played a role in increasing transport of this lipophilic peptide across the 
lipid barrier.  
3.3.3.5 Consolidated comparison of skin permeation enhancement by lipoamino 
acid conjugated tetrapeptide 
The skin delivery results clearly indicate that, at a lower concentration of 3mg 
peptide/lipopeptide in 300µL in propylene glycol the order of permeation was 
C6(D)>C6(L)>C8(D)>C8(L)>C6(D)>C6(L)>C10(D)>C10(L).  
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Figure 3.26 Permeation profiles of AAPV and its lipoamino acid conjugates across human 
epidermis. Results are expressed as mean (±SEM) 
The D- distereomers of each of these peptides showed higher flux as compared to the L- 
distereomers. Permeation of native AAPV across intact skin was very low during the 
period of observation. In contrast, the three derivatives, C6-LAA-AAPV, C8-LAA-
AAPV and C10-LAA-AAPV permeated through the epidermis, with the individual 
diastereomers of C6-LAA-AAPV as the most permeable (Fig 3.26, Table 3-4). When the 
concentration was increased to 6 mg in 300µL propylene glycol with 1 h hydration, the 
amount of C10(D,L) permeating the skin increased. 
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Table 3-4 Comparison of permeation parameters of the native and conjugated 
peptides (flux calculated till 8 and 24 h for C6(D) and C6(L)-LAA-AAPV 
individual diastereomers) 
Peptide 
Cumulative 
amount (µg/cm2) 
Transdermal 
flux (µg/cm2/h) 
Permeability 
coefficient 
Kp(cm/h) 
AAPV (3mg in 300µL) 3.70 (± 1.09) 0.46 1.50 × 10-3 
C6(D)-LAA-AAPV (3mg in 300µL) 467.94 (± 192.6) 
157.69 – 8 h 
58.50- 24 h 
5.25 × 10-2- 8 h 
1.94 × 10-2- 24 h 
C6(L)-LAA-AAPV (3mg in 300µL) 123.04 (± 48.89) 
26.22- 8 h 
15.37- 24 h 
8.70 × 10-2- 8 h 
5.70 × 10-2- 24 h  
C6(D,L)-LAA-AAPV (3mg in 300µL) 
C6(D)-LAA-AAPV 
C6(L)-LAA-AAPV 
 
18.32 (± 7.40) 
3.93 (± 1.32) 
 
2.29 
0.50 
 
2.29 × 10-3 
4.90 × 10-3 
C8(D,L)-LAA-AAPV (3mg in 300µL) 
C8(D)-LAA-AAPV  
C8(L)-LAA-AAPV  
 
59.38 (± 19.14) 
10.99 (± 5.20) 
 
7.42 
1.37 
 
1.90 × 10-2 
4.50 × 10-4 
C8(D,L)-LAA-AAPV (6mg in 
300µL)- 1h 
60.00 (± 15.71) 7.50 1.20 × 10-3 
C10(D,L)-LAA-AAPV (6mg in 
300µL) 
106.03 (± 15.74) 13.25 2.2× 10-3 
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Overall, the permeability of the lipoamino acid conjugates of Ala-Ala-Pro-Val was 
much higher than the native tetrapeptide, Ala-Ala-Pro-Val. The permeability of the more 
lipophilic conjugates such as C10-LAA was less than that of native peptide in the initial 
time period of transport studies, but was higher than that of native at the end of the 
transport studies. These results for the skin permeability experiments are in good 
agreement with previous finding that the transdermal absorption of tetragastrin was 
enhanced by its chemical modification with fatty acids.164 Similar results were also 
observed in the intestinal absorption of various acyl derivatives of peptides and proteins 
including insulin, calcitonin and DADLE, an enkephalin derivative. 213 The lack of 
permeability of native Ala-Ala-Pro-Val across the epidermis maybe mainly attributed to 
its metabolism in the skin and low lipophilicity. The reason why the permeability of C6 
(D)-LAA-AAPV distereomer was the highest of all the lipoamino acids used in the study 
is not clearly understood but it may be due to the intrinsic stereoselectivity of the skin 
for enantiomers of chiral molecules and extrinsic factors such as differences in 
physicochemical properties between enantiomers and racemate.214  
It has also been demonstrated previously that the permeability of the acyl-tetragastrin 
derivatives was not correlated with their lipophilicity. That is, the permeability of acetyl-
tetragastrin was higher than that of butyroyl- and caproyl-derivatives across the intact 
and stripped skin.164 Therefore, the low initial permeability of higher lipophilic 
derivatives of Ala-Ala-Pro-Val [C10(D,L)-LAA-AAPV] in certain experimental 
conditions may be due to its strong partitioning and binding to the stratum corneum. 
From these findings, it may be considered that there is an optimal lipophilicity (length of 
lipoamino acid chain) of the derivatives for improving their transdermal delivery. 
3.3.4 Recovery of tetrapeptide and lipoamino acid conjugates from skin 
Figures 3.27, 3.28 and 3.29 indicates the amounts of native tetrapeptide and its 
lipoaminoacid conjugates in the skin after the permeation experiments. As shown in this 
figure, the amount of AAPV in the skin increased as the carbon number of fatty acid 
attached to the AAPV molecule increased in the intact skin. Initially extraction was 
carried out with DMSO and methanol for C6 (D)-LAA-AAPV and C6 (L)-LAA-AAPV. 
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The recovery of C6(D)-LAA-AAPV with DMSO was approximately 60% whereas 70% 
in case of C6(L)-LAA-AAPV. It was thus decided to optimize the extraction procedure 
by substituting DMSO with propylene glycol. The recovery of AAPV, C6(D,L), 
C8(D,L) and C10(D,L) was validated using the extraction procedure with PG and 
methanol. After three successive extractions with methanol and propylene glycol the 
recovery was 97%, 93 %, 90%, 96% and 95% for AAPV, C6(D)-LAA-AAPV, C6(L)-
LAA-AAPV, C8(D,L)-LAA-AAPV and C10(D,L)-LAA-AAPV respectively of the 
theoretical input. The possible loss of about 5–10% of tetrapeptide and its conjugates 
might be due to skin enzyme activity, metabolism and handling of the skin tissue, and 
other processes in the experiment. These peptide accumulation data further attest to the 
suspected strong interaction between the peptide and lipophilic structures present in the 
skin. The accumulation may also be the result of peptide to peptide interactions, which 
result in aggregation of these molecules in the skin and eventually in peptide deposition 
in the transport pathways.215 Figures 3.27, 3.28 and 3.29 shows the amount of peptide in 
the epidermis in different experimental conditions. 
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Figure 3.27 Amount of AAPV and its lipoamino acid conjugates in the skin after the permeation 
experiments (Donor concentration of 3mg peptide/lipopeptide in 300 µL PG) and 1 h hydration. 
Results are expressed are mean (±SEM: n=4) 
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Figure 3.28 Amount of AAPV and its lipoamino acid conjugates in the skin after the permeation 
experiments (Donor concentration of 3mg peptide/lipopeptide in 300 µL PG) and 24 h hydration. 
Results are expressed are mean (±SEM: n=4) 
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Figure 3.29 Amount of AAPV and its lipoamino acid conjugates in the skin after the permeation 
experiments (Donor concentration of. 6mg peptide/lipopeptide in 300 uL PG) and 24 h hydration. 
Results are expressed are mean (±SEM: n=4) 
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The amount of drug remaining in the epidermis at 24 h (Figure 3.27) increased as the 
number of carbons in the fatty acids that were chemically attached to the native Ala-Ala-
Pro-Val increased. As expected, the amount of C10(D,L)-LAA-AAPV was the highest 
of all the lipoamino acid derivatives. Therefore, an optimum lipophilicity (the carbon 
number of the fatty acids) is thought to exist for the drug accumulation in the skin. For 
example, Walter and Kurz (1988) reported good correlation between the partition 
coefficient of 10 different drugs with different physicochemical properties and their skin 
binding affinity. They concluded that these drugs might bind with skin components such 
as proteins, but binding with lipids was less likely as their binding was not affected 
when skin lipids were removed.216 These findings were in good agreement with our 
present finding of the highest accumulation of C10(D,L)-LAA-AAPV. Therefore, we 
speculate that the longer lag time of C10(D,L)-LAA-AAPV permeation is due to its high 
binding characteristics to the skin, since C10(D,L)-LAA-AAPV had the highest 
molecular weight and lipophilicity of all the lipoamino acid derivatives investigated.  
3.3.5 Surface activity  
A preliminary study was undertaken to assess if lipophilic conjugates of the tetrapeptide 
possess surface active properties which may be important in determining their 
permeability. The surface tension activity of tetrapeptide and its lipophilic conjugates 
was determined in aqueous solutions in the range of 0.0625-1 mg/mL by the ring method 
using a Du Nouy tensiometer at room temperature. An approximate critical micelle 
concentration (CMC) was obtained from the graph of surface tension in dyne/cm versus 
concentration (Figure 3.30). There was a significant decrease in surface tension of 
phosphate buffered saline with the addition of the AAPV coupled lipopeptides and the 
tetrapeptide (p<0.0001). In addition a significant difference (p<0.0001) in the surface 
tension lowering capacity between the lipoamino acid conjugates was also observed with 
C8 and C10 (D,L)-LAA-AAPV causing highest decrease followed by C6(D,L)-LAA-
AAPV and AAPV. The estimated CMC for AAPV, C6(D,L)-LAA-AAPV, C8(D,L)-
LAA-AAPV and C10(D,L)-LAA-AAPV was approximately 0.125, 0.25, 0.5, 0.5 
mg/mL. This is preliminary data to indicate that the tetrapeptide and its conjugates 
possess surface activity but more work is required to establish reliable CMC values. 
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Bio-based surfactants are synthetic amphipathic structures based on natural structures of 
biosurfactants. Among them, lipoamino acid/peptide and glycolipid analogues have 
become increasingly important because of their chemical simplicity, surface activity, 
aggregation properties and broad biological activity.217 A well-known example of a 
biosurfactant is surfactin, a cyclic lipopeptide  and powerful surfactant commonly used 
as an antibiotic.218 It has been found to exhibit effective characteristics like anti-
bacterial, anti-viral, anti-fungal, anti-mycoplasma and haemolytic activities.  
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Figure 3.30 Surface tension measurement of the native tetrapeptide and the conjugated 
lipopeptides.  Results are expressed as mean (± SEM) of 3 measurements 
Surfactant analogues of lipoamino acid/peptides have received a great deal of attention 
due to their multifunctionality, i.e. high efficiency, good aggregation properties and 
broad biological activity. These properties make them good alternatives for a wide range 
of applications in personal care, pharmaceutical and food sectors. In a study undertaken 
by Ashton et al the effects of a series of surfactants on the permeability of human skin in 
vitro using methyl nicotinate as a model drug was investigated. It was found that while 
the ionic surfactants exerted a greater effect on the flux of methyl nicotinate, the non-
ionic surfactants had a smaller but more immediate effect on the flux.219 We hypothesize 
that the LAA coupled peptides may have surfactant like properties which aid in skin 
permeation. They can interact with the stratum corneum by either increasing the local 
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water concentration with consequent swelling of the tissue. They may also interact with 
the stratum corneum through electrostatic and hydrophobic links or may interact with 
the protein fractions of the stratum corneum through hydrophobic interactions with 
keratin.220  
3.3.6 Enzyme inhibitory activity 
The main objective of this study was to assess the biological activity of the LAA 
conjugates and compare it to the native tetrapeptide. The elastase inhibitory activity of 
these peptides was assessed at two different substrate (6.25 µg/mL and 25 µg/mL) and 
enzyme concentrations (0.25 and 0.5 U/mL). Figure 3.31 showed that the ability of 
elastase to digest the substrate decreased as the concentration of each of the inhibitors in 
the reaction mixture increased. The inhibition caused by synthesised conjugates and the 
parent tetrapeptide was fairly similar. It was observed that there was approximately 70% 
reduction in the activity of elastase with the lipopeptides and tetrapeptide at 0.25mM. 
C6(L)-LAA-AAPV caused an overall inhibition of 55% when the assay was carried out 
at a lower concentration of elastase and substrate. At a higher concentration of substrate 
and elastase the results were fairly similar to those obtained at a lower concentration. It 
was observed that there was approximately 55% reduction in activity with the 
tetrapeptide and lipopeptides at 0.25mM. In comparison with the control tetrapeptide 
only C10(D,L) caused a higher level of inhibition at 0.25mM. As the two sets of 
experiments were carried out on different days there might be differences in the 
observed percentage of inhibition though the trends are similar. A comparison could not 
be made with C6(D)-LAA-AAPV since we did not have sufficient compound. In a 
separate study done earlier, the activity of C6(L)-LAA-AAPV and C6(D)-LAA-AAPV 
was compared with AAPV and it was observed that the activity of the conjugates was 
comparable to the tetrapeptide, at concentrations of 0.031, 0.062 and 0.125mM (Figure 
3.31). A significant difference was not found in the inhibitory capacity of the 
tetrapeptide by itself as compared to the LAA conjugates at all experimental conditions.  
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Figure 3. 31 Percent inhibition of elastase by tetrapeptide and its lipoamino acid conjugates. (a) and 
(C) inhibition at 6.25 µg/mL of substrate and 0.25 U/mL elastase, (B) inhibition at 25 µg/mL of 
substrate and 0.5 U/mL elastase 
Peptidic HNE inhibitors have a common hydrophobic peptide sequence, which partially 
mimics certain amino acid sequences found in elastin. The Ala-Ala-Pro-Val sequence 
fits the P-P1 subsites of elastase and inhibits HNE competitively with Ki approx. 10-4 M. 
The covalent coupling of lipophilic moieties as long chain cis unsaturated fatty acids has 
been found to increase considerably the inhibitory capacity of the substance, in keeping 
with the presence of an unusual hydrophobic binding site in HNE located near its active 
centre.186 In this project a series of lipopeptides of increasing lipophilic character were 
synthesized, keeping the peptide moiety (Ala-Ala-Pro-Val) constant and their HNE 
inhibitory capacity was then analysed. These lipidic peptides combine the 
physicochemical and biological properties of peptides and proteins with those of lipids 
and membranes and can also confer protection against enzyme degradation to 
biologically labile compounds and behave as bifunctional inhibitors.108  It can be 
concluded from these elastase inhibition studies that the biological activity of the 
tetrapeptide is not affected considerably by lipoamino acid conjugation. Indeed the 
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activity of C10(D,L)-LAA-AAPV was approximately 4.5% higher than the tetrapeptide 
control but the difference was not statistically significant.  
3.4 Conclusions 
We have demonstrated that coupling of a tetrapeptide to a short chain LAA enhances its 
trans-epidermal delivery. The lipopeptide was present as a mixture of the D- and L-
diastereomers of the LAA with greater sub-epidermal availability of the D-diastereomer. 
The stability of the LAA conjugates was found to be higher than the native tetrapeptide 
with only 20-25% degradation of the conjugates as compared to approximately 40% for 
the parent peptide. The transepidermal delivery of C6(D)-LAA-AAPV was found to be 
highest when the experiments were done using a donor concentration of 3 mg in 300 µL 
propylene glycol and hydration period of 1 hour. On increasing the hydration period to 
24h the flux and permeation rate of C8(D,L)-LAA-AAPV, in particular the C8(D) 
diastereomer was found to be highest. When the donor concentration was increased to 6 
mg in 300 µL propylene glycol and the hydration period was 24h, the permeability of 
the most lipophilic conjugate, C10(D,L)-LAA-AAPV was found to be highest. The 
permeability of this peptide up to 8 h was minimal and this lag time may be due to 
binding to the stratum corneum lipids. The amount of peptide remaining in the skin 
increased with the increase in carbon chain length that was chemically attached to the 
native tetrapeptide and C10(D,L)-LAA-AAPV was found to be present in the skin in 
highest amount.  We hypothesize that the skin permeation enhancement with the LAA 
conjugates may be due to the increase in lipophilic nature of the conjugates. In addition, 
the interfacial properties conferred by the LAA-peptide structure may also contribute to 
their skin permeability (lowering of surface tension). The preliminary surface activity 
study indicated that the LAA conjugates decreased the surface tension indicating that the 
coupled peptides may have surfactant like properties which aids in skin permeation. 
Importantly, the elastase inhibition studies concluded that the biological activity was 
retained after coupling of the tetrapeptide to C6, C8 and C10 (D,L)- LAA. 
In conclusion, we have shown that the stability and permeability of Ala-Ala-Pro-Val 
across the skin was improved by the chemical modification with lipoamino acids. This 
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chemical modification approach may be useful for the transdermal delivery of peptide 
drugs as well as the topical delivery of these drugs to the skin in the treatment of skin 
disorders such as psoriasis and dermatitis. 
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Chapter 4.  
Trans-epidermal Permeation of a Cosmetic Peptide and its 
Lipoamino Acid Conjugate 
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4.1 Aim and Background 
Wrinkles represent the more evident outcome of cutaneous ageing. Their onset is linked 
to a variety of events, among which are dermo-epidermal junction thinning due to 
decrease of laminine and loss of collagen.221 Acetyl hexapeptide-3 (Ac-EEMQRR) is a 
six-amino-acid peptide derived from SNAP-25 that has been shown to produce the 
desired interference with the neurosecretion. Ac-EEMQRR is described as a mimic of 
botulinum neurotoxin (Botox), which functions by inhibiting neurotransmitter release, 
thus exerting muscle relaxing effects involved in defining facial wrinkles.222 This 
hexapeptide is marketed under the name Argireline® (Lipotec, Barcelona, Spain). The 
objective of this study was to investigate the in vitro skin permeation of acetyl 
hexapeptide-3 and its C12 lipoamino acid conjugate. The cosmetic peptide was coupled 
to individual diastereomers of C12 (A)-LAA-hexapeptide-3 and C12 (B)-LAA-
hexapeptide-3. This preliminary study was designed to assess the effect of coupling of a 
LAA of higher molecular weight on the transepidermal permeation and accumulation of 
this hexapeptide. Accumulation of these peptides in the skin was also quantified. 
4.2  Materials and methods 
4.2.1 Chemicals 
Acetyl hexapeptide-3 (MW-889.99), C12(A)-LAA-Glu-Glu-Met-Gln-Arg-Arg (MW 
1044.27) and C12(B)-LAA-Glu-Glu-Met-Gln-Arg-Arg (MW 1044.27) (Figure 4.1) were 
synthesised by Professor Toth’s group at the University of Queensland (Brisbane, 
Australia). Propylene glycol (PG) was obtained from BDH Chemicals Pty Ltd. HPLC 
grade acetonitrile and methanol were used and all other chemicals were of analytical 
grade. Phosphate buffered saline solution (PBS) was prepared according to the United 
States Pharmacopoeia. 
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Figure 4.1 Chemical structure of acetyl hexapeptide-3 and C12-LAA conjugates 
4.2.2 HPLC instrumentation and conditions 
The samples were analysed by reverse phase HPLC (Agilent 1200 system) on a Grace 
Vydac C18 column (4.6 mm×250 mm) using a mobile phase gradient. Calibration 
curves of hexapeptide and its LAA conjugate in PBS were obtained to ensure 
consistency with samples from the in vitro permeation experiments. Buffer A was 0.1% 
TFA and buffer B was 0.1% TFA in 90% acetonitrile and 10% water. Elution was 
performed at a flow rate of 1.0 ml/min with the column temperature held at 25°C and the 
injection volume was 50 µL. The hexapeptide and its LAA conjugate were eluted using 
a combination of isocratic and linear gradient protocols; buffer B was held at 10% for 5 
min followed by a linear gradient from 10 to 100% B over 10 min. Each sample 
analysed was automatically followed by a post-wash for 5 min. Absorbance was 
simultaneously monitored at 205, 210 and 214 nm using a photo diode array detector. 
All calculations were carried out in comparison with external standards using areas 
acquired at 214 nm.  
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4.2.3 HPLC analysis 
4.2.3.1 Assay precision 
Stock solutions were prepared by accurately weighing the peptides and dissolving in 
75:25 propylene glycol: PBS. Working solutions of the three peptides were freshly 
prepared from their stock solutions. 
 Working solution for C12(A)-LAA-hexapeptide-3 was prepared by a 1:5 dilution 
of the stock with PBS. Appropriate dilution of this working solution gave 
concentrations of 1.56 to 100 µg/mL.  
 C12 (B)-LAA-hexapeptide-3 working solution was prepared by 1:20 dilution of 
the stock with PBS. Appropriate dilution of this working standard gave 
concentrations of 5.20 to 166.5 µg/mL. 
 Acetyl hexapeptide-3 working solution was prepared by 1:20 dilution of the 
stock with PBS. Appropriate dilution of this working standard gave 
concentrations of 4.55 to 145.8 µg/mL 
The entire procedure was repeated on three different days to test inter-day variation and 
repeated six times at low and high concentrations to test intra-day variation. Volumes of 
50 µL of the standards were used for the assay. 
4.2.3.2 Minimum detectable limits and low limit of quantitation 
The LOD and LOQ were measured by diluting C12(A)-LAA-hexapeptide-3, C12(B)-
LAA-hexapeptide-3 and acetyl hexapeptide-3 in 75:25 PG:PBS to give a concentration 
range from 1.56 to 50 μg/mL, 5.20 to 166.5 µg/mL and  4.55 to 145.8 µg/mL 
respectively and then injected on the HPLC. The LOD was calculated by the following 
formula: LOD = 3 × average height of noise / slope. The LOQ was calculated by the 
following formula: LOQ = 10 × average height of noise / slope. 
4.2.4 Preparation of human skin 
Ethical approval was obtained from the Curtin University Human Research Ethics 
Committee (Approval numbers HR132/2001, HR 70/2007 and HR 129/2008) for the 
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collection and use of human skin obtained from abdominoplasties. The in vitro 
transdermal experiments for acetyl hexapeptide-3, C12(A)-LAA-hexapeptide-3 and 
C12(B)-LAA-hexapeptide-3 were performed by using heat separated human epidermis 
prepared following the method of Kligman and Christophers198 as previously described.  
4.2.5 In-vitro skin permeation of acetyl hexapeptide-3 and its lipoamino acid 
conjugate 
Skin samples were allowed to thaw at room temperature. The epidermal membrane was 
mounted on a Franz-type diffusion cell (effective diffusion surface area approximately 1 
cm2 and receptor volume approximately 3 ml) with the stratum corneum layer facing the 
donor compartment. The receptor compartment was filled with 25:75 propylene glycol: 
PBS and allowed to equilibrate in a 35°C water bath with the receptor phase stirring 
continuously for approximately 1h before the addition of the peptide to the donor 
compartment. The donor compartment was loaded with 300 µL of propylene glycol and 
PBS mixture containing 2 mg peptide (acetyl hexapeptide-3 or lipoamino acid 
conjugated hexapeptide) and covered with Parafilm. These amounts were completely 
soluble at these concentrations. The apparatus was maintained at 35°C throughout the 
48h duration of the experiment. Aliquots (200 µL) were taken from the receptor 
compartment at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 and 48 h then replaced immediately with 
200 µL of receptor medium pre-equilibrated at 35°C. At the termination of the 
experiment samples were also taken from the donor compartment and analysed. Samples 
collected were kept at 4°C in the injecting tray while awaiting analysis by reverse phase 
HPLC.  
4.2.6 Skin accumulation, mass balance and recovery of peptides from the skin 
A suitable method for recovery of peptide remaining in the epidermal membrane at the 
conclusion of the experiment was developed and validated as follows. Human epidermal 
membranes were immersed in 2 mL of standard solution of peptides for 48h at 35°C. At 
the end of 48h, the skin samples were placed in 500 µL methanol in an Eppendorf tube 
and agitated for 2 min. The sample was then transferred to a second Eppendorf 
containing 500 µL methanol and agitated for another 2 min. The skin sample was then 
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extracted with 1 mL 75:25 PG:PBS for 2 hours with agitation. After 2 hours the 
methanolic and PG: PBS extracts with skin were centrifuged at 10,000 RPM for 10 min. 
The supernatants were withdrawn and injected on HPLC to quantify the amount of 
peptides in the skin. For mass balance/recovery purposes, the donor solution was 
removed from the donor compartment and diluted appropriately to quantify the amount 
of peptide in the donor at the end of the experiment. The donor compartment with the 
skin was rinsed with 300 µL PBS and the wash was collected. The receptor 
compartment was emptied and washed with 500 µL PBS. Samples from both the washes 
were injected on HPLC to quantify the peptides present in the washes. 
4.3  Results and discussion 
4.3.1  Chromatography and resolution 
HPLC chromatograms of the parent hexapeptide and its lipoamino acid conjugates are 
shown in Figure 4.2. Good resolution of the peptides on the column was achieved with 
elution times of 9.82, 12.15 and 13.23 mins for acetyl hexapeptide-3, C12(A)-LAA-
hexapeptide-3 and C12(B)-LAA-hexapeptide-3 respectively. 
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(a) 
 
(b) 
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(c) 
 
Figure 4.2 Typical chromatograms of (a) acetyl hexapeptide-3 (10.4 µg/mL in PBS) eluted at 9.8 
min (b) C12(A)-LAA-hexapeptide-3 (83.3 µg/mL in PBS) eluted at 12.1 min and (c) C12(B)-LAA-
hexapeptide-3 (83.3 µg/mL in PBS) eluted at 13.2 min 
4.3.1.1 Linearity 
Excellent linearity was obtained for all the three peptides over the concentration range 
studied (Table 4-1). 
Table 4-1 Correlation coefficients of the native peptide and its lipoamino acid 
conjugates 
Peptide 
Correlation 
coefficient (r2) 
Linear range (µg/mL) 
Acetyl hexapeptide-3 0.9999 4.55-145.8 
C12(A)-LAA-hexapeptide-3 0.9997 1.56-100 
C12(B)-LAA-hexapeptide-3 0.9999 5.20-166.5 
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4.3.1.2 Assay precision 
Calibration graphs were constructed by plotting the peak area versus concentration of 
standards injected. The best-fit straight lines were determined using the method of least 
squares. All plots passed through the origin. To obtain a satisfactory UV response for all 
peptides, the detection wavelength was selected at 214 nm. The intra-day and inter-day 
precision of the assay are summarised in Table 4-2. Intra and inter day coefficients of 
variation (C.V.) of the assay for the three peptides were below 5% 
Table 4-2 Intra-day and Inter-day variations of acetyl hexapeptide-3 and its 
lipoamino acid conjugates 
Peptide Intra-day variation (n=5) Inter-day variation (n=9) 
Acetyl hexapeptide-3 4.55 µg/mL 72.91 µg/mL 4.55 µg/mL 72.91 µg/mL
C.V.(%) 1.24 0.84 1.57 1.11 
C12(A)-LAA-
hexapeptide-3 
3.125 µg/mL 50 µg/mL 3.125 µg/mL 50 µg/mL 
C.V. (%) 1.80 0.13 2.38 0.52 
C12(B)-LAA-
hexapeptide-3 
10.40 µg/mL 83.25 µg/mL 10.40 µg/mL 83.25µg/mL 
C.V. (%) 1.04 0.85 0.95 0.83 
4.3.1.3 LOD and LOQ 
The LOD calculated as greater than 3 times the baseline noise in the assay was 25 ng for 
acetyl hexapeptide-3, 31 ng for C12(A)-LAA-hexapeptide-3 and 44.80 ng for C12 (B)-
LAA-hexapeptide-3. The LOQ calculated as greater than 10 times the baseline noise in 
the assay was 83ng for acetyl hexapeptide-3, 103.6 ng for C12(A)-LAA-hexapeptide-3 
and  149 ng for C12 (B)-LAA-hexapeptide-3. 
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4.3.2 Permeation of acetyl hexapeptide-3, C12(A) and C12(B) conjugated 
hexapeptide across human epidermis 
In this study, the effect of lipoamino acid (C12-LAA) conjugation on the skin 
permeation of acetyl hexapeptide-3 was studied. The cumulative amount of acetyl 
hexapeptide-3 penetrating the human epidermis to the receptor solution over time is 
demonstrated in Figure 4.3.  
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Figure 4.3 Permeation profile of acetyl hexapeptide-3 (donor concentration of 2mg in 300μL 
propylene glycol) across human epidermis. Results are expressed as mean (±SEM: n=5) 
No skin permeation was observed for the C12(A) and C12(B) lipoamino acid 
conjugates. The maximum cumulative amount of acetyl hexapeptide-3 in the receptor 
was 8 µg/cm2 after 48 h and there was considerable variability between cells. The 
estimated transdermal flux was calculated using equation 2 (Section 3.3.3.2) as            
2.5 x 10-4 μg/cm2/h. The estimated permeability coefficient for acetyl hexapeptide-3 was 
1.26 x 10-7 cm/h. The lack of permeation of the conjugates may be due to the chain 
length of the lipoamino acid attached to the peptide. The molecular weight of 
hexapeptide-3 is 889 and it increases to 1044.27 with the addition of a C12 lipoamino 
acid chain. The high molecular weight of the conjugated peptides may be one of the 
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reasons for its poor transepidermal delivery.  In addition, the low permeability of higher 
lipophilic derivatives of acetyl hexapeptide may be due to its strong partitioning into and 
binding to the stratum corneum. Yamamoto et al investigated the skin permeation and 
distribution of fatty acid conjugates of Phe-Gly and observed that the epidermal 
diffusion of C8-Phe-Gly was very low as compared to C4 and C6-Phe-Gly but the 
amount of C8-Phe-Gly in the skin was much higher than the native Phe-Gly and the 
other acyl derivatives. We can thus speculate from these findings that there is an optimal 
lipophilicity (length of acyl chain) of the acyl derivatives for improving their 
transdermal delivery. It may be that the optimal chain length is dependent on balancing 
desired lipophilicity with not markedly increasing molecular weight.153 
4.3.3 Recovery and skin extraction of acetyl hexapeptide-3 and C12-LAA from 
the epidermis 
Figure 4.4 indicates the amounts of native hexapeptide and its lipoamino acid conjugates 
in the skin after the permeation experiments. Native acetyl hexapeptide-3, C12(A)-LAA-
hexapeptide-3  and C12(B)-LAA-hexapeptide-3  were recovered from the epidermis at 
the end of the experiment. The epidermal extraction procedure was validated and the 
recovery of acetyl hexapeptide-3, C12(A)-LAA-hexapeptide-3 and C12(B)-LAA-
hexapeptide-3 was 96%, 93% and 94% respectively. 
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Figure 4.4 Amount of native peptide and conjugates remaining in epidermal membrane at 48 h  
The results indicate that the amount of C12(B)-LAA-hexapeptide-3 (59.92 µg/cm2 ± 
10.64) was found to be highest in the skin followed by C12(A)-LAA-hexapeptide-3 
(33.06 µg/cm2 ± 3.70) and acetyl hexapeptide-3 (12.64 µg/cm2 ± 1.48). This peptide 
accumulation data suggests that there is a strong interaction between the lipoamino acid 
conjugates of the hexapeptide and lipidic bilayers of the skin as previously described by 
Schuetz et al.215 Thus of the applied amount of each compound 2.99% of C12(B)-LAA-
hexapeptide-3, 1.65% of C12(A)-LAA-hexapeptide-3 and 0.63% of acetyl hexapeptide-
3 permeated into and remained in the epidermis over 48h. 
To increase the transepidermal delivery of acetyl hexapeptide-3, C12-LAA was 
conjugated to the parent peptide. Drug delivery is always a delicate balance between 
adequate lipophilicity to cross lipid bilayers and water solubility to aid in formulation. 
An important challenge though, is delivery into skin because peptides are poorly 
penetrating, especially as the number of amino acid residues increases.222 Because 
human skin functions as a physicochemical barrier, it has been historically assumed that 
molecules over 500 MW are unable to traverse the stratum corneum223 and this is further 
compounded if the molecule is polar in nature. An approach to this problem of poor 
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epidermal delivery is the addition of a lipophilic chain (eg, palmitate), which can 
increase skin penetration several fold over the underivatized peptide.224 However in our 
study, coupling of the peptide with individual diastereomers of C12-LAA-hexapeptide-3 
did not increase their permeation across the human epidermis. Due to availability of 
limited quantity of peptides (only 18 mg of each was supplied) we were not able to 
assess the effect of donor concentration, skin hydration and other formulation 
parameters on the transdermal delivery of these compounds. The skin diffusion of acetyl 
hexapeptide-3 was found to be fairly low which may be due to the donor concentration 
used in the study. A study recently published in the International Journal of Cosmetic 
Science reported that acetyl hexapeptide-3 at a 10% concentration reduces the depth of 
wrinkles. Skin topography analysis was performed to determine the effectiveness of an 
O/W emulsion containing 10% acetyl hexapeptide-3 using silicon imprints from the 
lateral preorbital area in healthy women volunteers. A concentration of 10% acetyl 
hexapeptide-3 caused a 30% reduction in wrinkle depth in the lateral preorbital area of 
healthy human volunteers in vivo when applied topically. 225 In vitro skin permeation of 
the peptide was also evaluated. It was reported that 30% of the applied amount was 
found in the receptor compartment but cumulative amount or transdermal flux have not 
been stated. This makes comparison with the present study difficult but it clearly 
indicates that higher amount of acetyl hexapeptide-3 was found traversing the skin 
which may be due to a higher applied concentration of the peptide. In the current study a 
donor concentration of 2 mg hexapeptide-3 and its lipoamino acid conjugates was used 
which is approximately 30 times less than the dose used by Blanes-Mira et al. This data 
is a preliminary indication of the effect lipoamino acid conjugation has on the 
transdermal delivery of acetyl hexapeptide-3. Even though, there was negligible 
permeation of the conjugates through the epidermis, C12-LAA-hexapeptide-3 retained 
in the skin was higher than acetyl hexapeptide-3. The amount in the skin was highest for 
C12(B)-LAA-hexapeptide-3 followed by C12(A)-LAA-hexapeptide-3 and the native 
hexapeptide. The poor permeation of the lipoamino acid conjugates may be attributed to 
its lipophilicity and chain length as discussed in earlier sections 3.3.3.4 and 3.3.3.5.  
Drugs with higher molecular weight are poor candidates for delivery by transdermal 
route. However, for topical drug delivery, accumulation of drug in the skin with minimal 
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permeation is desired. The target site for these peptides is the dermo-epidermal 
junction.191 Hence, drugs with moderate and low permeability can also be considered for 
topical use. Unlike transdermal delivery, an optimal accumulation in the skin with little 
or no flux through the skin to systemic uptake is desirable.  
Koda et al reported a similar finding with C8 lipophilic chain conjugates of 
endomorphin.159 An increase in apparent permeability of endomorphin was observed for 
N-terminus analogues bearing shorter LAA (C8 and C10) but the higher molecular 
weight of C12-LAA resulted in poor permeation across the human epidermis. A similar 
result was also observed for acyl tetragastrins where the permeation of tetragastrin 
across the intact skin was improved by chemical modification with acetic acid and 
butyric acid. However, caproyl-tetragastrin did not permeate across the intact skin up to 
the end of the experiment and a bell shaped profile between the permeability of acyl 
tetragastrins was observed.164 We therefore speculate that similar to our previous study 
on AAPV, the permeability of C12-LAA- Glu-Glu-Met-Gln-Arg-Arg through human 
epidermis may be inhibited due to its high binding characteristics to the lipidic stratum 
corneum region. The higher lipophilicity of the conjugate and the effect of conjugation 
of lower chain length LAAs such C6 and C8 should be investigated. 
4.4 Conclusions 
In summary we demonstrated that the epidermal permeation of acetyl hexapeptide-3 was 
low. Detectable amounts of C12(A)-LAA-hexapeptide-3 and C12(B)-LAA-hexapeptide-
3 were not found in the receptor solution but higher quantities of these conjugates were 
found to be retained in the skin. The amount of C12(B)-LAA-hexapeptide-3 in the 
epidermis was highest followed by C12(A)-LAA-hexapeptide-3 and acetyl hexapeptide-
3. This might be due to higher lipophilicity of these conjugated peptides due to the 
longer chain length. Thus, chemical modification approach may be more useful for small 
peptides with fewer amino acid residues or by conjugating peptides to smaller chain 
length lipoamino acids.  
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Chapter 5.  
Skin Permeation of an Anti-inflammatory Peptide and 
Analogues Exhibiting Improved Biological Efficacy and 
Specificity 
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5.1 Aim 
Peptides hold considerable promise in the management of dermatological conditions if 
they can be delivered in active form to their target sites within the skin. Peptides consist 
of chains of amino acids which can be modified to increase receptor binding, increase 
specificity, decrease toxicity and increase skin penetration, stability and solubility. 
Technological advances have created newer peptides capable of targeting many aspects 
of dermal health.220 Psoriasis and contact dermatitis are skin disorders that are 
characterized by long-term inflammation. These disorders are commonly treated with 
topical corticosteroids that target a variety of pathways of the inflammation cascade.189 
However corticosteroid therapy is associated with local side effects and there is a need 
for new therapies and delivery systems to overcome some of the limitations imposed by 
chronic steroid therapy. The purpose of this study was to evaluate the skin permeability 
and in skin stability of an anti-inflammatory peptide (core peptide: CP) and two 
analogues that have demonstrated improved biological efficacy and specificity: a cyclic 
peptide sequence (C1) and its linear sequence counterpart (C1-L). 
5.2 Materials and methods 
5.2.1 Chemicals 
Core peptide, CP (MW 1024), linear sequence of C1 (MW 1137) and cyclic peptide, C1 
(MW 1119) sequences (Table 5-1) were synthesized by Dr Marina Ali from Associate 
Professor Manolios’ group at Westmead Hospital, Sydney. Dimethyl sulphoxide 
(DMSO) was obtained from Ajax FineChem Pvt Ltd. HPLC grade acetonitrile and 
methanol was used and all other chemicals were of analytical grade. Phosphate buffered 
saline solution (PBS) was prepared according to the United States Pharmacopoeia. 
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Table 5-1 Peptide sequences and code 
Sequence Name Code 
LDRLDLLDLLDKVDG Cyclic peptide 1 CP1 or C1 
LDRLDLLDLLDKVDG Linear sequence of C1 CP1-L or C1-L 
GLRILLLKV Core peptide CP 
5.2.2 HPLC instrumentation and conditions 
The samples were analysed by reverse phase HPLC (Agilent 1200 system) on a Grace 
Vydac C18 column (4.6 mm×250 mm) using a mobile phase gradient and assay 
conditions were modified from an assay provided by Associate Professor Manolios’ 
group. Calibration curves of CP, C1 and C1-L in PBS were obtained to ensure 
consistency with samples from the in vitro permeation experiments. Solvent A was 0.1% 
TFA, and solvent B was 0.1% TFA in acetonitrile. Elution was performed at a flow rate 
of 1.0 ml/min with the column temperature held at 25°C and the injection volume was 
50 µL. The core peptide and its analogues were eluted using a combination of isocratic 
and linear gradient protocol; buffer B was held at 2.5 % for 2.5 min followed by a linear 
gradient from 2.5 to 60% B over 23.5 min. Each sample analysed was automatically 
followed by a post-wash for 5 min. Absorbance was simultaneously monitored at 210 
and 220 nm using a photo diode array detector. All calculations were carried out in 
comparison with external standards using areas acquired at 220 nm.  
5.2.3 HPLC analysis 
5.2.3.1 Assay precision 
Stock solutions were prepared by accurately weighing the peptides and dissolving in 
DMSO. Working solutions of the three peptides were freshly prepared from their stock 
solutions. 
 Working solution for C1 was prepared by serially diluting the stock with PBS. 
Appropriate dilution of this working solution gave concentrations of 1.90 to 
121.86 µg/mL.  
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 For C1-L working solution was prepared by serial dilution of the stock with PBS. 
Appropriate dilution of this working standard gave concentrations of 4 to 129 
µg/mL. 
 A core peptide working solution was prepared by serial dilution of the stock with 
PBS. Appropriate dilution of this working standard gave concentrations of 3.90 
to 125 µg/mL 
Calibration curves were obtained using these concentration ranges and linearity (quoted 
as R2) was evaluated by linear regression analysis, which was calculated by the least 
square regression method. The precision of the assay was determined by injecting two 
standard concentrations (7.61 and 60.93 μg/mL C1, 8 and 64.5 μg/mL C1-L, 7.8 and 
62.5 μg/mL CP) five times on the HPLC column. The intra-day repeatability was 
assessed by injecting the same standards six times at different times in a day. The inter-
day repeatability was determined by injecting the same standards six times on 3 different 
days. The intra- and inter-day repeatability was quoted as the coefficient of variance. 
5.2.3.2 Lower limit of detection (LOD) and quantitation (LOQ) 
The minimum detectable and quantifiable limits (LOD and LOQ) were measured by 
diluting the stock solutions of C1, C1-L and core peptide in PBS to give a concentration 
range from 1.90 to 121.86 μg/mL, 4 to 129 µg/mL and 3.90 to 125 µg/mL respectively 
and then injected on the HPLC. The LOD was calculated as greater than 3 times the 
baseline noise level: LOD = 3 × average peak height of noise/ slope. The LOQ was 
calculated as 10 times the baseline noise level: LOQ = 10 × average peak height of noise 
/ slope 
5.2.4 Skin stability study 
The influence of human skin on the stability of the cyclised and core peptide was 
determined by placing the skin in a vial containing peptide solutions to provide an 
estimate of their stability during the skin diffusion experiments. Vials containing 2 mL 
of 100 µg/mL C1, C1-L and CP solutions were stored at 37°C. Samples (150 μL) were 
withdrawn at 0, 2, 4, 6, 8, 24 and 48h. The samples were analysed by HPLC to quantify 
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the amount of peptide remaining at the end of each test period. The results were 
expressed as the percentage of active peptide at the end of the test period and were 
calculated as follows: 
Intact peptide =  Final amount of peptide ×100% 
     Initial amount of peptide 
5.2.5 Preparation of human skin 
Full thickness human skin samples excised from female patients undergoing 
abdominoplasty at Perth hospitals were refrigerated immediately after surgery (42 and 
50 year old female abdominal section was used in this study). Sampling was approved 
by the Human Research Ethics Committee of Curtin University (Approval numbers 
HR132/2001, HR 70/2007 and HR 129/2008) and was conducted in compliance with the 
guidelines of the National Health and Medical Research Council of Australia. Epidermal 
sheets were prepared and stored as previously described.  
5.2.6 Formulation optimization 
An appropriate amount of each of the three peptides was dissolved in 100% DMSO, 
100% propylene glycol (PG) and 75:25 DMSO:PBS to test solubility in these solvents. 
In the biological efficacy studies conducted by the Manolios group, peptides were 
initially dissolved in 100% DMSO and then diluted to working concentrations due to the 
good solubility of the peptides in DMSO. Based on the solubility of the peptides in the 
different solvents, it was decided to use 100% DMSO as the donor vehicle. Solutions of 
peptides in 100% PG or 75:25 DMSO:PBS were cloudy in appearance with undissolved 
compound still present in solution. It was decided to use 90:10 PBS: DMSO as the 
receptor medium to aid in the solubility of the peptides in the receptor compartment and 
prevent salting out. 
 145
5.2.7 In-vitro skin diffusion of C1, C1-L and CP 
Skin samples were allowed to thaw at room temperature. The heat separated epidermal 
membrane was mounted on a Franz-type diffusion cell (effective diffusion surface area 
approximately 1 cm2 and receptor volume approximately 3 ml) with the stratum 
corneum facing the donor compartment. The receptor compartment was filled with 
90:10 DMSO: PBS and allowed to equilibrate in a 35°C water bath with the receptor 
phase stirring continuously for approximately 24h before the addition of the peptide to 
the donor compartment. The conductivity across the epidermis was measured using a 
digital multimeter to determine membrane integrity. The donor compartment was loaded 
with 300 µL of 3 mg peptide (C1, C1-L and CP) and sealed. These amounts were 
completely soluble at these concentrations. The apparatus was maintained at 35°C 
throughout the duration (48h or 6 days) of the experiment. The duration of experiment 
was varied to assess the effect of time on skin permeation. Aliquots (200 µL) were taken 
from the receptor compartment at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 and 48 h or 6 days then 
replaced immediately with 200 µL of receptor medium pre-equilibrated at 35°C. At the 
termination of the experiment samples were also taken from the donor compartment and 
peptide content in all samples analysed. Samples collected were kept at 4°C in the 
injecting tray while awaiting analysis by reverse phase HPLC.  
5.2.8 Recovery of the peptides from the epidermis 
Human epidermal membranes were immersed in 2 mL of standard solution of peptides 
for 48h at 35°C. At the end of 48h, the skin samples were placed in 500 µL methanol in 
an Eppendorf tube and agitated for 2 mins. The sample was then transferred to a second 
Eppendorf containing 500 µL methanol and agitated for another 2 min. The skin sample 
was then extracted with 500 µL 75:25 DMSO: PBS for 2 hours with agitation. After 2 
hours the methanolic and DMSO: PBS extracts with skin were centrifuged at 10,000 
RPM for 10 mins. The supernatants were withdrawn, diluted appropriately and injected 
on HPLC to quantify the amount of peptides in the skin. This procedure was validated to 
determine the % recovery of peptide from the epidermal membrane. 
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For mass balance/recovery purposes, the donor solution was removed from the donor 
compartment and diluted appropriately to quantify the amount of peptide in the donor at 
the end of the experiment. The donor compartment with the skin was rinsed with 300 µL 
PBS and the wash was collected. The receptor compartment was emptied and washed 
with 500 µL PBS. Samples from both the washes were injected on HPLC to quantify the 
peptides present in the washes. 
5.2.9 Statistical analysis 
Differences between the permeation and stability of CP, C1 and C1-L were analysed for 
statistical significance (p < 0.05) using an Analysis of Variance (ANOVA) at each of the 
prescribed time points. The ANOVA model was implemented using the GENMOD 
procedure in the SAS software system, with the control group being the reference group 
in each model.  Because of the skewness in the concentrations, the regression model was 
applied to the log-transformed data (in order to obtain the p-values for comparison of 
treatments). The overall p-values were found to be significant for most of the 
comparisons. 
5.3  Results and discussion 
5.3.1 Chromatography 
HPLC chromatograms of C1, C1-L and CP are shown in Figure 5.1. Good resolution of 
the peptides on the column was achieved and they eluted without any interfering peaks 
at 19.18, 15.64 and 13.9 mins for C1, C1-L and CP respectively. 
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(a)  
 
(b) 
 
 
 
 148
(c) 
 
Figure 5.1 Chromatograms for (a) CP at 62.5 µg/mL, (b) C1-L at 64.5 µg/mL and (c) C1 at 60.93 
µg/mL 
5.3.1.1 Linearity 
A calibration curve was obtained by plotting the peak area versus concentration of 
standards injected. The best-fit straight lines were determined using the method of least 
squares. All plots passed through the origin. To obtain a satisfactory UV response for all 
peptides, the detection wavelength was selected at 220 nm. Table 5-2 reports the results 
for calibration curve linearity. Excellent linearity was obtained for all three peptides over 
the concentration range studied. 
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Table 5-2 Correlation coefficient of C1, C1-L and CP 
Peptide 
Correlation coefficient 
(r2) 
Linear range(µg/mL) 
C1 0.9991 1.90-121.86 
C1-L 1.000 4-129 
CP 0.9998 3.90-125 
5.3.1.2 Assay precision 
The coefficient of variation (CV) for precision was determined from the relative 
standard deviation (n = 5).  The intra-day and inter-day precisions of the assay are 
summarised in Table 5-3. Intra and inter day coefficients of variation (C.V.) of the assay 
for the three peptides were below 5% 
Table 5-3 Assay precision, Intra-day and Inter-day variations of C1, C1-L and 
CP 
Peptide Precision (n=5) 
Intra-day variation 
(n=5) 
Inter-day variation 
(n=9) 
 7.61 µg/mL 
60.93 
µg/mL 
7.61 µg/mL 
60.93 
µg/mL 
7.61 µg/mL 
60.93 
µg/mL 
C1 C.V.(%) 0.82 0.94 1.93 1.83 2.0 1.83 
 8 µg/mL 64.5 µg/mL 8 µg/mL 64.5 µg/mL 8 µg/mL 64.5 µg/mL
C1-L C.V. 
(%) 
2.91 1.30 2.91 1.12 4.80 1.26 
 7.8 µg/mL 62.5 µg/mL 7.8 µg/mL 62.5 µg/mL 7.8 µg/mL 62.5 µg/mL
CP C.V. 
(%) 
1.86 1.24 2.39 3.89 1.89 1.18 
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5.3.1.3 Low limit of detection and low limit of quantitation 
The LOD calculated as greater than 3 times the baseline noise in the assay was 240 ng 
C1, 270 ng for C1-L and 210 ng for CP. The LOQ calculated as greater than 10 times 
the baseline noise in the assay were 800 ng for C1, 930 ng for C1-L and 710 ng for CP. 
5.3.2 Stability of C1, C1-L and CP 
The degradation profile of C1, C1-L and CP is shown in Figure 5.2. The stability data 
was presented as the percentage of active peptide remaining over time when placed in 
contact with skin at 37ºC.  It was observed that when epidermal membrane was placed in 
a vial containing CP solution at 37ºC about 75% of the peptide was lost in 8h and 80% 
in 24 h compared to 23 and 58% loss of C1-L in 8 and 24h and 30 and 50% loss of C1 in 
8 and 24h (Figure 5.2). C1 and C1-L had significantly higher stability as compared to 
CP when incubated with skin at 37ºC (p< 0.001 at 8h and p<0.05 at 24h for C1 and 
C1L).  
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Figure 5.2 Degradation profiles of CP, C1 and C1-L 
The amount of peptide remaining intact at the end of 24h was higher in the skin 
diffusion studies as compared to the stability study. One of the reasons may be because 
the samples in the permeation studies were collected from the receptor compartment 
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which has a lower concentration of the peptide and is affected by the skin permeability 
of the peptide. 
Cyclisation of a peptide is a strategy often employed to enhance stability. For example, 
Kampi et al studied the solution stability of linear (Arg-Gly-Asp-Phe-OH; 1) verses 
cyclic (cyclo-(1,6)-Ac-Cys-Arg-Gly-Asp-Phe-Pen-NH2; 2) RGD (Arg-Gly-Asp) 
peptides and found that the cyclic peptide 2 was 30-fold more stable than the linear 
peptide 1 at pH 7. The increase in stability of the cyclic peptide 2 compared to linear 
peptide 1, especially at neutral pH, may be due to decreased structural flexibility 
imposed by the ring.226 In another study, the cellular permeation, chemical and 
enzymatic stability of phenylpropionic acid-based cyclic prodrugs of opioid peptides 
[Leu5]-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) and DADLE (H-Tyr-D-Ala-Gly-Phe-
D-Leu-OH) were investigated. When applied to the apical side of a Caco-2 cell 
monolayer both the cyclic prodrug and DADLE exhibited significantly greater stability 
against peptidase metabolism than [Leu5]-enkephalin.227 Cyclization can thus be used to 
synthesize more stable peptide analogues that mimic the biological activity of natural 
peptide structures, resulting in enhanced conformational stability when compared to 
their natural counterparts.228  
5.3.3 In-vitro permeation of C1, C1-L and CP across human epidermis 
The cumulative amount of C1, C1-L and CP penetrating the human epidermis to the 
receptor solution over 48h is demonstrated in Figure 5.3. The duration of the experiment 
was varied (48h and 6 days) to assess the effect of time on in-vitro diffusion of the 
peptides across the epidermis. The use of DMSO as donor vehicle is not ideal as it is 
capable of interacting with the skin to reduce the barrier properties. However with very 
limited compound and poor solubility of the peptides in aqueous vehicle, it was decided 
to use DMSO as the solvent. 
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Figure 5.3 Permeation profiles for individual C1, C1-L and CP across human epidermis from 0-
48h. Results are expressed as mean (±SEM: n=6 for C1, n=4 for C1-L and n=6 for CP) 
The results indicated an increase in the amount and rate of permeation of C1 over 48h 
(Table 5-4). C1 and C1-L permeation was significantly increased compared to 
permeation of CP over the time period of the experiment (p<0.0001 for C1 and p<0.05 
for C1-L) over 48h. The permeation of C1 was slow but a significant increase was 
observed at the 24 (p<0.05) and 48h (p<0.0001) time periods. On the other hand, the in-
vitro diffusion of C1-L was more rapid initially but there was no substantial increase in 
the permeation after 8h. The estimated transdermal flux was 2.15 µg/cm2/h for C1, 1.07 
µg/cm2/h for C1-L and 0.29 µg/cm2/h for CP. The estimated permeability coefficient for 
C1 was 7.1 x 10-4 cm/h, 3.5 x 10-4 cm/h for C1-L and 9.8 x 10-5 cm/h for CP. Based on 
the mean cumulative permeation graph the area under the curve (AUC, Sigma Plot 8.0) 
was calculated. AUC of the cumulative amount of C1, C1-L and CP in the receptor 
compartment verses time graph yielded values of 966.02, 779.41 and 212.90 μg/cm2/h 
for C1, C1-L and CP respectively. It was thus observed that there was an approximately 
7.2-fold enhancement in the delivery of cyclic peptide as compared to the core peptide 
and 3.6 fold enhancement in the linear peptide as compared to the core peptide based on 
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the mean cumulative permeation over 48h . The skin permeation was affected by the 
stability of the parent peptide and the type of the analogue. 
Table 5-4 Comparison of permeation parameters of C1, C1-L and CP over 48 h 
Peptide 
Cumulative 
amount (µg/cm2) 
AUC (µg/cm2/h) 
Transdermal 
flux (µg/cm2/h) 
Permeability 
coefficient (cm/h) 
C1 34.48 (± 13.05) 966.02 2.15 7.1 x 10-4 
C1-L 17.19 (± 7.21) 779.41 1.07 3.5 x 10-4 
CP 4.73 (± 4.22) 212.90 0.29 9.8 x 10-5 
The 48h data showed that the permeation of the peptides was relatively slow so a longer 
duration experiment was undertaken to further assess in vitro skin diffusion. In the 
longer duration study (6 days) it was similarly observed that the permeation of C1 was 
higher than C1-L and core peptide though the absolute values were different from the 
48h study due to the use of a skin sample from a different donor. C1 and C1-L 
permeation was significantly increased compared to permeation of CP over the time 
period of the experiment (p<0.0001 for C1 and C1-L). The cumulative amount of C1, 
C1-L and CP penetrating the human epidermis to the receptor solution over 6 days is 
demonstrated in Figure 5.4 and Table 5-5. The relative permeation follows the same 
trend as that observed in the 48h study. The estimated transdermal flux calculated over 
24h time period was 0.74 µg/cm2/h for C1, 0.46 µg/cm2/h for C1-L and 0.019 µg/cm2/h 
for CP. The estimated permeability coefficient for C1 was  2.4 ×10-4 cm/h, 1.5 ×10-4 
cm/h for C1-L and 6.4×10-6 cm/h for CP. The enhancement ratio of C1 and C1-L was 
greater for the longer duration experiment and there was an increase of approximately 4 
µg/cm2  in the cumulative amount of C1 at the end of the experiment. Based on the mean 
cumulative permeation graph the area under the curve (AUC, Sigma Plot 8.0) was 
calculated. AUC of the cumulative amount of C1, C1-L and CP in the receptor 
compartment verses time graph yielded values of 3235.35, 2308.62 and 224.01 μg/cm2/h 
for C1, C1-L and CP respectively. Based on the mean cumulative permeation over 6 
days, there was approximately a 38.2 fold enhancement in the delivery of the cyclic 
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peptide as compared to the core peptide and 23.9 fold enhancement in the linear peptide 
as compared to the core peptide.  
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Figure 5.4 Permeation profiles for C1, C1-L and CP across human epidermis from 0-154h. 
Results are expressed as mean (±SEM: n=3 for C1-L and C1, n=4 for CP)  
Table 5-5 Comparison of permeation parameters of C1, C1-L and CP over 6 
days 
Peptide 
Cumulative 
amount (µg/cm2) 
AUC (µg/cm2/h) 
Transdermal 
flux (µg/cm2/h) 
Permeability 
coefficient,(cm/h) 
C1 38.07 (± 8.16) 3235.35 0.74 2.4 ×10-4 
C1-L 23.86 (± 10.38) 2308.62 0.46 1.5 x 10-4 
CP 0.99 (± 0.62) 224.01 0.019 6.4 x 10-6 
A number of linear and cyclic peptides inhibit the immune response and inflammation in 
the skin; thereby have potential as novel therapeutic agents. Efficient delivery to the site 
of action following topical administration can offer opportunities for use of these 
peptides as novel and highly effective dermatologicals and cosmeceuticals. A number of 
cyclic peptides have activity in the skin. Cyclosporin A is a cyclic nonribosomal peptide 
of 11 amino acids produced by the fungus Beauveria nivea. It inhibits cytochrome C 
release and is of therapeutic value in conditions such as psoriasis, severe atopic 
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dermatitis and pyoderma gangrenosum.229. Melanin concentrating hormone (MCH) 
regulates skin colour by causing the aggregation of melanin granules and lightning the 
skin. Thus this cyclic peptide plays an important role in skin and hair pigmentation.230 
Cyclic histatin is a potent wound healing peptide from human saliva. Cyclization of this 
peptide potentiated its activity at least 10-fold when compared to uncyclized histatin.231.  
Cyclic peptides are of considerable interest as potential protein ligands. It has been 
postulated that cyclic molecules might be more cell permeable than their linear 
counterparts due to their reduced conformational flexibility.232 Cyclic peptides are of 
considerable interest for a couple of reasons: their inherent limited conformational 
flexibility and their resistance to proteolytic hydrolysis and degradation. Recently 
Borchardt et al introduced the concept of making cyclic prodrugs of peptides as a way to 
modify their physicochemical properties sufficiently to allow them to permeate 
biological barriers (i.e., intestinal mucosa). Specifically, acyloxyalkoxy-, 
phenylpropionic acid- and 5 coumarinic acid-based cyclic prodrugs of [Leu ]-enkephalin 
(H-Tyr-Gly-Gly-Phe-Leu-OH) and its metabolically stable analog DADLE (H-Tyr-D-
Ala-Gly-Phe-D-Leu-OH) were prepared and their metabolic and biopharmaceutical 
properties determined. The cyclic prodrugs of these opioid peptides were shown to have: 
(i) favorable physicochemical properties (e.g., increased lipophilicity) for membrane 
permeation; (ii) unique solution structures (e.g., b-turns) that reduce their hydrogen 
bonding potential; and (iii) metabolic stability to exo- and endopeptidases. The 
phenylpropionic acid- and coumarinic acid-based cyclic prodrugs of [Leu ]-enkephalin 
and DADLE were shown to have significantly better cell permeation characteristics 
through Caco-2 cell monolayers than the parent opioid peptides.228  
In the present study we found that, the permeation of the cyclic peptides was higher than 
its linear counterpart and the core peptide though the permeation of C1-L was higher 
than C1 till 8h and then decreased. This may be due to the rate of partitioning of C1 into 
the epidermis and its conformational flexibility.  We cannot directly compare the data in 
the present study with the apparent permeability coefficients observed by Borchardt et al 
because the experiments were conducted in Caco-2 cell layers. Cyclisation also 
improved the stability of the core peptide by 40%. The greater stability of the cyclic 
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peptide makes it possible to detect and quantify the intact peptide at the end of the skin 
diffusion experiments. Cyclization also led to increase in biological efficacy of the core 
peptide. The research group at Westmead Hospital has conducted biological activity 
studies in which the effect of these peptides on T cell function was examined in-vitro. 
They demonstrated improved and significant effectiveness by 80% of C1 compared to 
CP. To validate that the activity of C1 was not due to toxicity, antigen specific T-cell 
hybridoma cells (2B4) were incubated overnight with C1 at 50µM and examined by 
tryptan blue exclusion staining to assess cellular membrane integrity, and [3H] thymidine 
uptake for cellular proliferation. The results showed that C1 at 50µM caused a decrease 
in cellular proliferation (62.56% ± 14.25 SD), but only a marginal decrease in cell 
survival (viability = 86.63% ± 8.14 SD), hence C1 was not toxic to cells.  
The effectiveness of C1 in-vivo was compared to commercially available cyclosporine. 
C1 given subcutaneously to rats had a comparable effect to cyclosporine in reducing 
inflammation in the adjuvant induced arthritis model. Significance between C1 and 
placebo treated rats was p<0.0001 and no significance was observed between C1 and 
cyclosporine treated rats.  
One major drawback of the study was the use of DMSO as the donor vehicle. Using 
DMSO as a donor vehicle was a compromise as we needed to solubilise the peptide and 
had very little compound to use for vehicle choice in this preliminary screening of 
permeability. Alternatively, we could have looked at essential oils such as eucalyptus 
oil, menthol or cineole as donor vehicles. Permeation data are therefore most relevant in 
relative terms rather than absolute terms as they may be an over-estimate due to the 
effect of DMSO on the skin barrier properties. It has been suggested that the skin 
penetration enhancement produced by DMSO not only involves changes in protein 
structure but may also be related to alterations in stratum corneum lipid organizations.233 
Measurement of resistance of skin membranes was used as an integrity check and we 
found that there was a slight drop in resistance at the end of the test period. Also when 
using DMSO as a solvent it is important to consider the membrane used in the study. 
Actions of DMSO on animal tissue may be dramatically greater than the effects seen on 
a human skin membrane.  
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5.3.4 Recovery and mass balance 
Figure 5.5 indicates the amounts of C1, C1-L and CP in the skin after the 8 and 48 h 
permeation experiments. The % recovery of C1, C1-L and CP from the skin using the 
extraction procedure described in Section 5.2.8 was 95%, 92.9% and 91% respectively. 
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Figure 5.5 Amount of C1-L, CP and C1 in the skin after (a) 8 h (n=3) and (b) 48 h (n=4). Results 
are expressed as mean (± SEM) 
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The method for extraction of C1, C1-L and CP from the epidermis resulted in high 
recovery. The amount of the cyclic peptide (C1) and linear counterpart of the cyclic 
peptide (C1-L) in the skin was higher than the core peptide. The amount of peptide 
present in the skin was affected by the duration of the skin diffusion experiment with 
more present in the 48h study as compared to the 8h study. The amount in the epidermis 
did not vary much for all the three peptides in the 8h study because the duration of the 
experiment was short and peptide did not partition well into the epidermis at the earlier 
time points. As discussed in Section 5.3.3 the permeation and hence partitioning of C1 
and CP into the epidermis was low during the initial time period. In case of the 48h 
study the amount of C1-L (38.32 µg/cm2 ± 9.58) retained in the skin was higher than C1 
(25.32 µg/cm2 ± 5.49) and CP (16.92 µg/cm2 ± 2.42). This may be due to the higher 
molecular weight of C1-L or more importantly due to the structural and conformational 
differences between the linear counterpart and cyclic peptide of C1-L which might lead 
to stronger binding with the stratum corneum lipids. 
5.4 Conclusions 
In conclusion these results demonstrate that the epidermal penetration and stability of 
the core anti-inflammatory peptide improved after cyclisation.  The order of permeation 
of the analogues was C1>C1-L>CP after 48h and 6 days. The amount of peptide 
retained in the skin was higher after 48h as compared to 8h due to greater partitioning of 
these peptides in the skin. This improved delivery to the skin and the previously 
demonstrated improvement in biological activity and specificity demonstrate the 
potential of cyclic peptides for skin therapeutics.  
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Chapter 6.  
                      Summary and Conclusions 
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In recent years the revolutionary advances in biotechnology have increased interest in 
protein and peptide entities with therapeutic potential.234 However, unless these 
compounds can be administered efficiently, survive degradation by enzymes and be 
absorbed across cell membranes, they are unlikely to succeed as therapeutic moieties.106 
Proteins and peptides are generally delivered by the parenteral route because of their 
poor oral bioavailability, raising several issues such as poor patient compliance. 
Therefore, alternative non-invasive delivery techniques have been extensively 
studied.235 There has been an increasing recongnition of the importance of skin as a 
route of administration of drugs.236 The advantages of TDD have been well documented. 
They include: therapeutic benefits such as sustained delivery of drugs to provide a 
steady plasma profile, particularly for drugs with short half-lives, and hence reduced 
systemic side effects; reducing the typical dosing schedule to once daily or even once 
weekly, hence generating the potential for improved patient compliance; and avoidance 
of the first-pass metabolism effect for drugs with poor oral bioavailability.237   
Peptides and proteins are poor candidates for passive transdermal delivery as they are 
usually charged at physiological pH. Although transdermal delivery enables 
administration of these compounds, thus avoiding degradation in the gastrointestinal 
tract and first-pass metabolism associated with oral delivery, it requires special 
enhancement techniques. In this project we have assessed the potential of 
Dermaportation (Pulsed electromagnetic field technology), chemical conjugation of a 
therapeutic and cosmetic peptide with lipoamino acid and cyclisation of an anti-
inflammatory peptide to enhance delivery across the skin. Figure 6.1 outlines the 
techniques and peptides investigated to optimize transdermal delivery. 
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Figure 6.1 Optimization of peptide delivery 
Chapter 2 describes the enhancement in percutaneous penetration of a model dipeptide, 
Ala-Trp across human epidermis with Dermaportation. The stability of this dipeptide 
was also assessed in different conditions with or without contact with skin. It was 
observed that Dermaportation significantly enhanced the delivery of Ala-Trp through 
human epidermis in vitro over an 8 h period when compared to passive diffusion. The 
dipeptide was found to be unstable on exposure to human epidermis with the amount of 
degradation product increasing steadily in the receptor compartment over 6h. 
Dermaportation may thus provide an effective means of delivering molecules which are 
highly susceptible to degradation like dipeptides, in higher amounts and in a relatively 
short duration of time.  
In Chapter 3, enhanced delivery of the HNE inhibitor, Ala-Ala-Pro-Val was achieved by 
chemical modification by conjugation with lipoamino acids. C6, C8 and C10 LAAs 
were conjugated with AAPV and stability, in vitro epidermal permeability, skin 
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accumulation and biological activity of the resulting conjugated peptides was 
investigated and compared with the parent peptide. The stability of the lipoamino acid 
conjugates was significantly higher than the parent peptide with C8(D,L)-LAA-AAPV 
being the most stable conjugate. The addition of LAA generated two stereoisomers, D- 
and L-. It was observed that the skin permeability of the D- diastereomer was found to 
be higher as compared to the L- diastereomer. Permeation of C10(D,L)-LAA-AAPV 
was significantly greater at higher donor concentration and skin hydration. Overall the 
permeation of D-diastereomer of C6(D)-LAA-AAPV was found to be highest followed 
by C8(D)-LAA-AAPV. The racemic mixture of C6(D,L)-LAA-AAPV showed lower 
permeability as compared to C6(D)-LAA-AAPV and C8(D)-LAA-AAPV. Permeability 
of C10(D,L)-LAA-AAPV increased only after 8 h which may be due to the higher 
molecular weight of this conjugate which may have resulted in binding with the stratum 
corneum lipids resulting in slower release. The amount of the C10(D,L)-LAA-AAPV 
was found to be highest in the skin followed by C8(D,L)-LAA-AAPV and C6(D,L)-
LAA-AAPV after in vitro diffusion studies.  A preliminary study undertaken to 
investigate the surface activity of the peptides indicated that there was a decrease in the 
surface tension of the lipoamino acid conjugates as compared to control PBS. There was 
no significant difference in the biological activity of the lipoamino acid conjugates as 
compared to AAPV. We conclude that the degree of penetration enhancement of AAPV 
is associated with the lipophilicity, molecular weight and chain length of the LAA 
conjugates. Lower chain length conjugates (C6 and C8) of AAPV resulted in increase in 
delivery with lower lag time and donor concentration. Our studies suggest that LAA 
conjugation is a good technique to increase the permeation of AAPV across epidermis 
but further studies need to be undertaken to optimize the penetration and tissue 
distribution of the peptides to be able to effectively quantify them in the different layers 
of the skin. Studies should also be undertaken to ascertain the surface active properties 
of these peptides which will be an important step in understanding the mechanism of 
action of the native and conjugated peptides. This structural modification of the native 
peptide by conjugating it with LAA is a non-invasive technique for enhancing the 
delivery of peptides across the skin and does not have the disadvantages associated with 
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active technologies such as iontophoresis and electroporation that can cause skin 
irritation and may also decrease the stability of the peptide due to electrical pulses. 
The permeation of C12 (A) and (B)-LAA conjugate of acetyl hexapeptide-3 is described 
in chapter 4. There was no permeation of either of the conjugates across the human 
epidermis. This may be due its high molecular weight and lipophilicity which may result 
in binding with the lipid bilayer components. The permeation of acetyl hexapeptide-3 by 
itself was very low and variable. The skin accumulation data showed that C12 (B)-LAA 
was found in the highest quantity in the skin followed by C12 (A)-LAA and acetyl 
hexapeptide-3. This may be useful from a cosmetic standpoint since topical application 
of a cosmetic agent should result in appreciable accumulation of the molecule of interest 
in the upper layers of skin to exert its effect. The delivery potential of actyl hexapeptide-
3 could be increased with shorter chain length LAAs such as C6 and C8-LAA and also 
by increasing the concentration of the peptide in the donor. 
In chapter 5 we investigated cyclisation strategy to improve the transdermal permeability 
of an anti-inflammatory peptide, core peptide (CP). Two analogues of CP were 
synthesized, cyclic peptide (C1) and a linear counterpart (C1-L). Stability of the cyclic 
peptide and C1-L was found to be significantly higher as compared to CP. Skin 
permeability was assessed over 48h and 6 days and it was observed that there was a 
steady increase in the cumulative amount of C1 permeating the receptor at the end of the 
test period. The mass balance studies indicate that higher amount C1-L was found in the 
skin when compared to C1 and CP after 48h. This may be due to the conformational 
differences between the two compounds. Future work should be directed at studying the 
solubility of these peptides in different vehicles which will make it possible to use a 
more polar solvent for skin permeation studies. We thus conclude that the cyclization 
strategy increased the stability, skin permeability and biological efficacy of an anti-
inflammatory peptide.  
Overall, it can be concluded that all the three strategies investigated in this project can 
modify the permeation characteristics of peptides after topical application. Further work 
needs to be undertaken to optimize the formulation strategies used to deliver these 
peptides across the skin so that the peptide can be made available to the site of action 
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without causing any irreversible damage to the barrier properties of the skin. Also 
optimization in terms of the chain length of LAA used is an important consideration and 
lastly more research needs to be undertaken to understand the stereo-selective 
permeation of these lipoamino acid conjugates across the skin since the activity of these 
peptides remains considerably unaffected by the stereochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 165
 
 
 
 
 
 
 
 
 
 
Chapter 7.  
References 
 166
 
1. Goebel A, Neubert RHH. Dermal peptide delivery using colloidal carrier 
systems. Skin Pharmacology and Physiology. 2008; 21(1):3-9.  
2. Loffet A. Peptides as drugs: Is there a market? Journal of Peptide Science. 
2001; 8(1):1-7.  
3. Namjoshi S, Caccetta R, Benson HAE. Skin peptides: biological activity and 
therapeutic opportunities. Journal of Pharmaceutical Sciences. 2008; 97(7):2524-42.  
4. Moody RP, Wester RC, Melendres JL, Maibach HI. Dermal absorption of the 
phenoxy herbicide 2,4-D dimethylamine in humans: effect of DEET anatomic site. 
Journal of Toxicology and Environmental Health. 1992; 36(3):241-250.  
5. Guy RH, Maibach HI. Drug delivery to local subcutaneous structures 
following topical administration. Journal of Pharmaceutical Sciences. 1983; 
72(12):1375-80.  
6. Kikwai L, Babu J, Prado R, Kolot A, Armstrong CA, Ansel JC, et al. In Vitro 
and In Vivo Evaluation of Topical Formulations of Spantide II. AAPS 
PharmSciTech. 2005; 6(4):565-572.  
7. Whitehouse MW, Roberts MS. Drugs for pain and inflammation. New York: 
Marcel Dekker; 1998. 
8. Menon GK. New insights into skin structure: scratching the surface. 
Advanced Drug Delivery Reviews. 2002; 54(Supplement 1):S3-S17.  
9. Kumar R, Philip A. Modified transdermal technologies: Breaking the barriers 
of drug permeation via the skin. Tropical Journal of Pharmaceutical Research. 2007; 
6(1):633-644.  
10. Williams AC. Structure and function of human skin. 2003. 
11. Ong PY, Ohtake T, Brandt C, Strickland I, MLeung DY. Endogenous 
antimicrobial peptides and skin infections in atopic dermatitis. New England Journal 
of Medicine. 2002; 347(15):1151–1160.  
 167
12. Guy RH. Current status and future prospects of transdermal drug delivery. 
Pharmaceutical Research. 1996; 13(1765-1769).  
13. Ting WW, Vest CD, Sontheimer RD. Review of traditional and novel 
modalities that enhance the permeability of local therapeutics across the stratum 
corneum. International Journal of Dermatology. 2004; 43(7):538-547.  
14. Fearon DT, Locksley RM. The instructive role of innate immunity in the 
acquired immune response. Science. 1996; 272:50-53.  
15. Izadpanah A, Gallo RL. Antimicrobial peptides. Journal of the American 
Academy of Dermatology. 2005; 52:381–390.  
16. Niyonsaba F, Ogawa H. Protective roles of the skin against infection: 
Implication of naturally occurring human antimicrobial agents [beta]-defensins, 
cathelicidin LL-37 and lysozyme. Journal of Dermatological Science. 2005; 40:157-
168.  
17. Harder J, Schroder JM. Psoriatic scales: A promising source for the isolation 
of human skin derived antimicrobial proteins. Journal of Leukocyte Biology  2005; 
77:476–486.  
18. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from 
human skin. Nature. 1997; 387:861.  
19. Frohm M, Agerberth B, Ahangari G. The expression of the gene coding for 
the antibacterial peptide LL-37 is induced in human keratinocytes during 
inflammatory disorders. Journal of Biological Chemistry. 1997; 272:15258–15263.  
20. Nilsson MF, Sandstedt B, Sorensen O, Stahle-Backdahl M. The human 
cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in 
human squammous epithelia and colocalizes with interlukin 6. Infection and 
Immunity. 1999; 67:2561-66.  
21. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid Q. New 
insights into atopic dermatitis. Journal of Clinical Iinvestigation. 2004; 113(5):651-
657.  
 168
22. Christophers E, Henseler T. Contrasting disease patterns in psoriasis and 
atopic dermatitis. Archives of Dermatological Research. 1987; 279(1):S48–S51.  
23. Gallo RL, Ono M, Povsic T. Syndecans, cell surface heparan sulfate 
proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. 
Proceedings of the Natural Academy of Sciences of the United States of America 
1994; 91(23):11035– 9.  
24. Howell MD, Jones JF, Kisich KO, Streib JE, LGallo R, Leung DY. Selective 
killing of vaccinia virus by LL-37: Implications for eczema vaccinatum. The Journal 
of Immunology. 2004; 172:1763–67.  
25. Cooper KD. Atopic dermatitis: Recent trends in pathogenesis and therapy. 
Journal of Investigative Dermatology. 1994; 103(5):128-137.  
26. Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, et al. 
Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with 
atopic dermatitis correlates with an impaired innate defense of human skin in vivo. 
The Journal of Immunology. 2005; 174(12):8003– 10.  
27. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, et al. 
Molecular cloning, occurrence, and expression of a novel partially secreted protein 
"psoriasin" that is highly up-regulated in psoriatic skin. Journal of Investigative 
Dermatology. 1991; 97(4):701-712.  
28. Ruzicka T, Simmet T, Peskar B, Ring J. Skin levels of arachidonic acid—
Derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. 
Journal of Investigative Dermatology. 1986; 86(2):105–108.  
29. Watson PH, Leygue ER, Murphy LC. Psoriasin (S100A7). The International 
Journal of Biochemistry & Cell Biology. 1998; 30(5):567–571.  
30. Tonel G, Conrad C. Interplay between keratinocytes and immune cells--
Recent insights into psoriasis pathogenesis. The International Journal of 
Biochemistry & Cell Biology. 2009; 41(5):963-968.  
 169
31. Nonomura K, Yamanish K, Yasuno H. Upregulation of elafin/SKALP gene 
expression in psoriatic epidermis. Journal of Investigative Dermatology. 1994; 
103(1):88–91.  
32. Baumann H, Gauldie J. The accute phase response. Immunology Today. 
1994; 15(2):74–80.  
33. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S. Elafin is induced in 
epidermis in skin disorders with dermal neutrophilic infiltration: Interleukin-1beta 
and tumour necrosis factor alpha stimulate its secretion in vitro. British Journal of 
Dermatology. 2000; 143(4):728–732.  
34. Raychaudhri SK, Raychaudhri SP, Farber EM. Anti-Chemotactic activities of 
peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis. 
International Journal of Immunopharmacology. 1998; 20(111):661-667.  
35. Wiedow O, Young J, Davison M, Christophers E. Antileukoprotease in 
psoriatic scales. Journal of Investigative Dermatology. 1993; 101(3):305–309.  
36. Wiedow O, Harder J, Bartels J, Streit V, Christophers E. Antileukoprotease in 
Human Skin: An Antibiotic Peptide Constitutively Produced by Keratinocytes. 
Biochemical and Biophysical Research Communications. 1998; 248:904–909.  
37. Baker BS, Fry L. The immunology of psoriasis. British Journal of 
Dermatology. 1991; 126(2):1-9.  
38. Nanney LB, Stoscheck CM, Magid M, King LE. Altered epidermal growth 
factor binding and receptor distribution in psoriasis. Journal of Investigative 
Dermatology. 1986; 86(3):260–265.  
39. Sticherling M, Bornscheuer E, Schroder JM, Christophers E. Localization of 
neutrophil-activating peptide-1/interlukin-8-immunoreactivity in normal and 
psoriatic skin. Journal of Investigative Dermatology. 1991; 96(1):26–30.  
40. Horvath A, Olive C, Wong A, Clair T, Yarwood P, Good M, et al. A 
Lipophilic adjuvant carrier system for antigenic peptides. Letters in Peptide Science. 
2002; 8:285-288.  
 170
41. Schroder JM, Harder J. Human beta-defensin-2. The International Journal of 
Biochemistry and Cell Biology. 1999; 31(6):645–651.  
42. Raychaudhuri SP, Raychaudhuri SK. Relationship between kinetics of 
lesional cytokines and secondary infection in inflammatory skin disorders: A 
hypothesis. International Journal of Dermatology. 1993; 32(6):409–412.  
43. Harder J, Schröder J-M. RNase 7, a Novel Innate Immune Defense 
Antimicrobial Protein of Healthy Human Skin. Journal of Biological Chemistry. 
2002; 277(48):46779-46784.  
44. Schroder JM, Harder J. Antimicrobial peptides in skin disease. Drug 
Discovery Today: Therapeutic strategies. 2006; 3(1):93–100.  
45. Mckay IA, Leigh IM. Epidermal cytokines and their roles in cutaneous 
wound healing. British Journal of Dermatology. 1991; 124(6):513–518.  
46. Barrandon Y, Green H. Cell migration is essential for sustained growth of 
keratinocyte colonies: The roles of transforming growth factor and epidermal growth 
factor. Cell. 1987; 50(7):1131-1137.  
47. Meyer-Ingold W. Wound therapy: Growth factors as agents to promote 
healing. Trends in Biotechnology. 1993; 11(9):387–392.  
48. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing. 
Single and synergistic effects on partial thickness porcine skin wounds. The Journal 
of Clinical Iinvestigation. 1989; 84(2):640–646.  
49. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard 
N. Wound healing and expression of antimicrobial peptides/polypeptides in human 
keratinocytes, a consequence of common growth factors. Journal of Immunology. 
2003; 170(11):5583–89.  
50. Rennekampff H-O, Hansbrough JF, Kiessig V, Dore C, Sticherling M, 
Schroder J-M. Bioactive Interleukin-8 Is Expressed in Wounds and Enhances Wound 
Healing. Journal of Surgical Research. 2000; 93:41-54.  
 171
51. Vigor C, Rolfe KJ, Richardson J, Baker R, Grobbelaar A, Linge C. The 
involvement of the ECM and RGD peptides in apoptosis induction during wound 
healing. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2006; 59(9):S4-S4.  
52. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-
Toellner D, et al. RGD peptides induce apoptosis by direct caspase-3 activation. 
Nature. 1999; 397:534–539.  
53. Buffoni F, Pino R, Pozzo AD. Effect of tripeptide-copper complexes on the 
process of skin wound healing and on cultured fibroblasts. Arch Int Pharmacodyn 
Ther. 1995; 330(3):345–360.  
54. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. 
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper 
complex glycyl-L-histidyl-L-lysine- Cu2+. FEBS Letters. 1988; 238(2):343–346.  
55. Carraway JH. Using Aldara, copper peptide, and niacinamide for skin care 
Aesthetic Surgery Journal 2004; 24(1):83-84  
56. Martinez A, Elsasser TH, Cacho CM, Cuttitta F. Expression of 
adrenomedullin and its receptor in normal and malignant human skin: A potential 
pluripotent role in the integument. Endocrinology. 1997; 138(12):5597–04.  
57. Lundy FT, Orr DF, Gallagher JR, Maxwell P, Shaw C, Napier SS, et al. 
Identification and overexpression of human neutrophil [alpha]-defensins (human 
neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. 
Oral Oncology. 2004; 40(2):139-144.  
58. Zouki C, Ouellet S, Filep J. The anti-inflammatory peptides, antiflammins, 
regulate the expression of adhesion molecules on human leukocytes and prevent 
neutrophil adhesion to endothelial cells. FASEB Journal. 2000; 14:572–580.  
59. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al. 
Cathelicidin deficiency predisposes to eczema herpeticum. Journal of Allergy and 
Clinical Immunology. 2006; 117(4):836-841.  
 172
60. Lai Y-P, Peng Y-F, Zuo Y, Li J, Huang J. Functional and structural 
characterization of recombinant dermcidin-1L, a human antimicrobial peptide 
Biochemical and Biophysical Research Communications 2005; 328(1):243-50.  
61. Molhuizen HO, Alkemade HA, Zeeuwen PL, Jongh GJd, Wieringa B, 
Schalkwijk J. SKALP/elafin: An elastase inhibitor from cultured human 
keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase 
cross-linking. Journal of Biological Chemistry 1993; 268(12028–12032).  
62. Raychaudhuri SP, Jiang WY, Raychaudhuri SK, Krensky AM. Lesional T 
cells and dermal dendrocytes in psoriasis plaque express increased levels of 
granulysin. Journal of the American Academy of Dermatology. 2004; 51(6):1006-
1008.  
63. Slominski A, Malarkey WB, Wortsman J, Asa SL, Carlson A. Human skin 
expresses growth hormone but not the prolactin gene. Journal of Laboratory and 
Clinical Medicine. 2000; 136(6):476-481.  
64. Fulton C, Anderson GM, Zasloff M, Bull R, Quinn AG. Expression of natural 
peptide antibiotics in human skin. The Lancet. 1997; 350(9093):1750-1751  
65. Toth I, Christodoulou M, Bankowsky K, Flinn N, Hornebeck W. Design of 
potent lipophilic - peptide inhibitors of human neutrophil elastase : in vitro and in 
vivo studies. International Journal of Pharmaceutics. 1995; 125:117 - 122.  
66. Tsatmali M, Ancans J, Thody AJ. Melanocyte Function and Its Control by 
Melanocortin Peptides. The Journal of Histochemistry & Cytochemistry. 2002; 
50(2):125–133.  
67. Suzuki I, Cone RD, Sungbin IM, Nordlund JM, Abdel-Malek ZA. Binding of 
Melanotropic Hormones to the Melanocortin Receptor MClR on Human 
Melanocytes Stimulates Proliferation and Melanogenesis. Endocrinology. 1996; 
127(5):1627-1633.  
68. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM. 
Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli 
infection. Natural immunology. 2005; 6(1):57-64.  
 173
69. Lucca AJD, Walsh TJ. Antifungal peptides: Origin, activity, and therapeutic 
potential. Rev Iberoam Micol. 2000; 17:116-120.  
70. Mor A, Chartrel N, Vaudry H, Nicolas P. Skin peptide tyrosine-tyrosine, a 
member of the pancreatic polypeptide family: Isolation, structure, synthesis, and 
endocrine activity. Proc Natl Acad Sci. 1994; 91:10295-10299.  
71. Falanga V, Gerhardt CO, Dasch JR. Skin distribution and differential 
expression of transforming growth factor beta1 and beta2. Journal of Dermatological 
Science. 1992; 3(3):131–136.  
72. Choi CM, Berson DS. Cosmeceuticals. Seminars in Cutaneous Medicine and 
Surgery. 2006; 25:163-168.  
73. Katyama K, Armendariz-Borunda J, Rachow R. A pentapeptide from Type I 
procollgen promotes extracellular matrix production. Journal of Biological 
Chemistry. 1993; 268:9941-9944.  
74. Bascom CC, inventor; The Procter and Gamble Company, assignee. 
Compositions for treating wrinkles comprising a peptide. United States patent 
5492894. 1993 June 25. 
75. Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: Its properties, functions 
and potential therapeutic applications. Molecular aspects of Medicine. 1992; 13:379-
444.  
76. Hipkiss AR. Carnosine, a protective, anti-ageing peptide? The International 
Journal of Biochemistry and Cell Biology. 1998; 30:863-868.  
77. Conner K, Nern K, Rudisill J, O’Grady T, Gallo RL. The antimicrobial 
peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca 
vulgaris. Journal of the American Academy of Dermatology. 2002; 47(3):347–350.  
78. Martinez A, Elsasser TH, Cacho CM-, Cuttitta F. Expression of 
adrenomedullin and its receptor in normal and malignant human skin : A potential 
pluripotent role in the integument. Endocrinology. 1997; 138:5597-5604.  
 174
79. Dureja H, Kaushik D, Gupta M, Kumar V, Lather V. Cosmeceuticals: An 
emerging concept. Indian Journal of Pharmacology. 2005; 37(3):155-158.  
80. Lupo MP. Cosmeceutical peptides. Dermatologic Surgery. 2005; 31:832-836.  
81. Togashi S-i, Takahashi N, Iwama M, Fukui T. Antioxidative collagen-derived 
peptides in human-placenta extract. Placenta. 2002; 23:497-502.  
82. Yann M, inventor; Societe L' Oreal S.A., assignee. Modulating body/cranial 
hair growth with derivatives of the alpha type melanocyte stimulating hormone. 
France patent 5739111. 1996 April 29. 
83. Kansci G, Genot C, Meynier A, Gandemer G. The antioxidant activity of 
carnosine and its consequences on the volatile profiles of liposomes during 
iron/ascorbate induced phospholipid oxidation. Food Chemistry. 1997; 60(2):165-
175.  
84. Schwartz RA, Centurion SA. Cosmeceuticals. 2006 [updated 27/04/2007]. 
Available  
85. Fitzpatrick RE, Rostan EF. Reversal of photodamage with topical growth 
factors: a pilot study. Journal of Cosmetic and Laser Therapy. 2003; 5:25–34.  
86. Linter K, inventor; Sederma, assignee. Cosmetic or dermopharmaceutical use 
of peptides for healing, hydrating and improving skin appearance during natural or 
induced ageing (Heliodermia, Pollution). France. 2003. 
87. Martin DC, inventor; L'Oreal Paris, assignee. Cosmetic compositions 
containing a lipid ceramide compund and a peptide having a fatty chain and their 
uses. France. 1998. 
88. Amsden BG, Goosen MFA. Transdermal delivery of peptide and protein 
drugs: an overview. Bioengineering, Food and Natural products. 1995; 41(8):1972-
1997.  
89. Benson HAE. Transdermal drug delivery: Penetration enhancement 
techniques. Current Drug Delivery. 2005; 2:23-33.  
 175
90. Higuchi WI. Analysis of data on the medicament release from ointments. 
Journal of Pharmaceutical Sciences. 1962; 51(8):802-804.  
91. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through 
human skin: Theory and in vitro experimental measurement. American Institute of 
Chemical Engineers (AIChE) Journal. 1975; 21(5):985–996.  
92. Elias PM, Menon GK. Structural and lipid biochemical correlates of the 
epidermal permeability barrier. Advances in Lipid Research. 1991; 24:1-26.  
93. Ogiso T, Iwaki M, Tanino T, Yono A, Ito A. In vitro skin penetration and 
degradation of peptides and their analysis using a kinetic model. Biological and 
Pharmaceutical Bulletin. 2000; 23(11):1346–51.  
94. Shah PK, Borchardt RT. A comparison of peptidase activities and peptide 
metabolism in cultured mouse keratinocytes and neonatal mouse epidermis. 
Pharmaceutical Research. 1991; 8(1):70–75.  
95. Steinstrasser I, Merkle HP. Dermal metabolism of topically applied drugs: 
Pathways and models reconsidered. Pharmaceutica Acta Helvetiae. 1995; 70(1):3–
24.  
96. Cross SE, Roberts MS. Physical enhancement of transdermal drug 
application: Is delivery technology keeping up with pharmaceutical developments? 
Current Drug Delivery. 2004; 1:81-92.  
97. Magnusson BM, Runn P. Effect of penetration enhancers on the permeation 
of the thyrotropin releasing hormone analogue pGlu-3-methyl-His- Pro amide 
through human epidermis. International Journal of Pharmaceutics. 1999; 178(2):149-
159.  
98. Karande P, Jain A, Arora A, Ho MJ, Mitragotri S. Synergistic effects of 
chemical enhancers on skin permeability: A case study of sodium lauroylsarcosinate 
and sorbitan monolaurate. European Journal of Pharmaceutical Sciences. 2007; 
31(1):1-7.  
 176
99. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of 
chemical penetration enhancers for transdermal drug delivery. Proceedings of the 
Natural Academy of Sciences of the United States of America. 2005; 102(13):4688-
4693.  
100. Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M. Dermal 
and transdermal delivery of protein pharmaceuticals: Lipid-based delivery systems 
for interferon alpha. Biotechnology and Applied Biochemistry. 1999; 30(2):129-137.  
101. Dkeidek I, Touitou E. Transdermal absorption of polypeptides. AAPS 
PharmSci. 1999; 1(S202).  
102. Gupta PN. Non invasive vaccine delivery in transferosomes, niosomes and 
liposomes: a comparative study. International Journal of Pharmaceutics. 2005; 
293(1-2):73-82.  
103. Manconi M. Niosomes as carriers for tretinoin III. A study into the invitro 
cutaneous delivery of vesicle-incorporated tretinoin International Journal of 
Pharmaceutics. 2006; 311(1-2):11-19.  
104. Benson HAE. Transfersomes for transdermal drug delivery. Expert Opinion 
on drug Delivery. 2006; 3(6):727-737.  
105. Benson HAE, Namjoshi S. Proteins and peptides: Strategies for delivery to 
and across the skin. Journal of Pharmaceutical Sciences. 2008; 97(9):3591-10.  
106. Blanchfield JT, Toth I. Modification of peptides and other drugs using 
lipoamino acids and sugars. Methods in Molecular Biology. 2005; 298:45-61.  
107. Ali M, Manolios N. Peptide delivery systems. Letters in Peptide Science. 
2002; 8:289–294.  
108. Toth I. A novel chemical approach to drug delivery: Lipidic amino acid 
conjugates Journal of Drug Targeting 1994; 2(3):217-239.  
109. Barry BW. Mode of action of penetration enhancers in human skin. Journal 
of Controlled Release. 1987; 6(1):85-97.  
 177
110. Roberts M, Walker M. The most natural penetration enhancer. In. New York: 
Marcel Dekker Inc; 1993. 
111. Potts RD. Physical characterization of the stratum corneum: the relationship 
of mechanical and barrier properties to lipid and protein structure. New York: Marcel 
Dekker; 1989. 
112. Barry BW. Novel mechanisms and devices to enable successful transdermal 
drug delivery. European Journal of Pharmaceutical Aciences. 2001; 14(2):101–114.  
113. Delgado-Charro MB, Guy RH. Characterization of convective solvent flow 
during iontophoresis. Pharmaceutical Research. 1994; 11(7):929–935.  
114. Schuetz YB, Naik A, Guy RH, Kalia YN. Effect of amino acid sequence on 
transdermal iontophoretic peptide delivery. European Journal of Pharmaceutical 
Aciences. 2005; 26(5)::429–437.  
115. Lau DT, Sharkey JW, Petryk L, Mancuso FA, Yu Z, Tse FL. Effect of current 
magnitude and drug concentration on iontophoretic delivery of octreotide acetate 
(Sandostatin) in the rabbit. Pharmaceutical Research. 1994; 11(12):1742–46.  
116. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. 
Iontophoresis of lecithin vesicles of cyclosporin A. International Journal of 
Pharmaceutics. 2004; 274(1-2):185-190.  
117. Pillai O, Kumar N, Dey CS, Borkute S, Nagalingam S, RPanchagnula. 
Transdermal iontophoresis of insulin. Part 1: A study on the issues associated with 
the use of platinum electrodes on rat skin. Journal of Pharmacy and Pharmacology. 
2003; 55(11):1505-13.  
118. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of 
mammalian skin: A mechanism to enhance transdermal drug delivery. Proceedings 
of the Natural Academy of Sciences of the United States of America. 1993; 
70(22):10504–08.  
119. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. Transdermal 
delivery of heparin by skin electroporation. Biotechnology (NY). 1995; 13:1205-09.  
 178
120. Sen A, Daly ME, Hui SW. Transdermal insulin delivery using lipid enhanced 
electroporation. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2002; 
1564(1):5-8.  
121. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized 
controlled study of electrochemotherapy in the local treatment of skin metastases of 
melanoma 
115–121. Journal of Cutaneous Medicine and Surgery. 2006; 10:115-121.  
122. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery—A general 
review. Expert Opinion on Drug Delivery. 2004; 1(1):37-56.  
123. Alvarez-Roman R, Merino G, Kalia YN, Naik A, Guy RH. Skin permeability 
enhancement by low frequency sonophoresis: Lipid extraction and transport 
pathways. Journal of Pharmaceutical Sciences. 2003; 92(6):1138-46.  
124. Park EJ, Werner J, Smith NB. Ultrasound mediated transdermal insulin 
delivery in pigs using a lightweight transducer. Pharmaceutical Research. 2007; 
24(7):1396-01.  
125. Katz NP, Shapiro DE, Herrmann TE, Kost J, Custer LM. Rapid onset of 
cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-
emitting device. Anaesthesia and Analgesia. 2004; 98(2):371-376.  
126. Lee S, McAuliffe DJ, Kollias N, Flotte TJ, Doukas AG. Photomechanical 
delivery of 100-nm microspheres through the stratum corneum: Implications for 
transdermal drug delivery. Lasers in Surgery and Medicine. 2002; 31(3):207-210.  
127. Lee S, McAuliffe DJ, Mulholland SE, Doukas AG. Photomechanical 
transdermal delivery of insulin in vivo. Lasers in Surgery and Medicine. 2001; 
28(3):282-285.  
128. Murthy SN. Magnetophoresis: an approach to enhance transdermal drug 
diffusion. Pharmazie. 1999; 54(5):377-409.  
129. Santini JT, Cima MJ, Langer R. Acontrolled-release microchip. Nature. 1999; 
397(28):335-338.  
 179
130. Mooney V. A randomized double-blind prospective study of the efficacy of 
pulsed electromagnetic fields for interbody lumbar fusions. Spine. 1990; 15(7):708-
712.  
131. Simko M, Mattsson MO. Extremely low frequency electromagnetic fields as 
effectors of cellular responses in vitro: possible immune cell activation. Journal of 
Cellular Biochemistry. 2004; 93(1):83-92.  
132. Namjoshi S, Caccetta R, Edwards J, Benson HAE. Liquid chromatography 
assay for 5-aminolevulinic acid: Application to in vitro assessment of skin 
penetration via Dermaportation. Journal of Chromatography B. 2007; 852(1-2):49-
55.  
133. Benson HAE, Caccetta R, Eijkenboom M. 8th World Congress on 
Inflammation [2007. Copenhagen, Denmark: 
134. Benson HAE, Caccetta R, Namjoshi S, Edwards J, Eijkenboom M. World 
Congress on Pain [2005. Sydney: 
135. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug 
Delivery Reviews. 2004; 56(5):581-587.  
136. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated 
microneedles: A novel approach to transdermal drug delivery. Journal of 
Pharmaceutical Sciences. 1998; 88(9):922-925.  
137. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. 
Transdermal delivery of insulin using microneedles in vivo. Pharmaceutical 
Research. 2004; 21(6):947-952.  
138. Nelson JS, McCullough JL, Glenn TC, Wright WH, Liaw LH, Jacques SL. 
Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous 
transport of drugs. Journal of Investigative Dermatology. 1991; 97(5):874-879.  
139. Svedman P, Lundin S, Hoglund P, Hammarlund C, Malmros C, Pantzar N. 
Passive drug diffusion via standardized skin mini-erosion; methodological aspects 
 180
and clinical findings with new device. Pharmaceutical Research. 1996; 13(9):1354-
59.  
140. Badkar AV, Smith AM, Eppstein JA, Banga AK. Transdermal delivery of 
interferon alpha-2B using microporation and iontophoresis in hairless rats. 
Pharmaceutical Research. 2007; 24(7):1389–95.  
141. Barry BW. Breaching the skin’s barrier to drugs. Nature Biotechnology. 
2004; 22:165-167.  
142. Srinivasan V, Su MH, Higuchi WI, Behl CR. Iontophoresis of polypeptides: 
Effect of ethanol pretreatment of human skin. Journal of Pharmaceutical Sciences. 
1990; 79(7):588-591.  
143. Choi EH, Lee SH, Ahn SK, Hwang SM. The pretreatment effect of chemical 
skin penetration enhancers in transdermal drug delivery using iontophoresis. Skin 
Pharmacology and Applied Skin Physiology. 1999; 12(6):326-335.  
144. Blanchfield J, Toth I. Lipid, sugar and liposaccharide based drug delivery 
systems 2. Current Medicinal Chemistry. 2004; 11:2375-82.  
145. Toth I, Christodoulou M, Bankowsky K, Flinn N, Gibbons WA, Godeau G, et 
al. Design of potent lipophilic-peptide inhibitors of human neutrophil elastase: In 
vitro and in vivo studies. International Journal of Pharmaceutics. 1995; 125(1):117-
122.  
146. Kellam B, Drouillat B, Dekany G, Starr MS, Toth I. Synthesis and in vitro 
evaluation of lipoamino acid and carbohydrate modified enkephalins as potential 
antinociceptive agents. International Journal of Pharmaceutics. 1998; 161(1):55-64.  
147. Hughes RA, Toth I, Ward P, McColmn AM, Cox DM, Anderson GJ, et al. 
Lipidic peptides. V: Penicillin and cephalosporin acid conjugates with increased 
lipophilic character. Journal of Pharmaceutical Sciences. 1992; 81(8):845-848.  
148. Toth I, Flinn N, Hillery A, Gibbons WA, Artursson P. Lipidic conjugates of 
luteinizing hormone releasing hormone (LHRH)+ and thyrotropin releasing hormone 
(TRH)+ that release and protect the native hormones in homogenates of human 
 181
intestinal epithelial (Caco-2) cells. International Journal of Pharmaceutics. 1994; 
105(3):241-247.  
149. Toth I, Malkinson JP, Flinn NS, Keri G. Novel lipoamino acid- and 
liposaccharide-based system for peptide delivery: application for oral administration 
of tumor-selective somatostatin analogues. Journal of Medicinal Chemistry. 1999; 
42:4010-13.  
150. Toth I, Danton M, Flinn N, Gibbons WA. A combined adjuvant and carrier 
system for enhancing synthetic peptides immunogenicity utilising lipidic amino 
acids. Tetrahedron Letters. 1993; 34(24):3925-3928.  
151. Pignatello R, Puleo A, Puglisi G, Vicari L, Messina A. Effect of liposomal 
delivery on in vitro antitumor activity of lipophilic conjugates of methotrexate with 
lipoamino acids. Drug Delivery. 2003; 10(95-100).  
152. Bergeon JA, Toth I. Enhancement of oral drug absorption--Effect of lipid 
conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-
NH2. Bioorganic & Medicinal Chemistry. 2007; 15(22):7048-7057.  
153. Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, et al. 
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. 
Bioorganic & Medicinal Chemistry. 2008; 16(11):6286-6296.  
154. Staffan T, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P. A 
new principal for tight junction modulation based on occludin peptides. Molecular 
Pharmacology. 2003; 64(6):1530-40.  
155. Yamamoto A, Setoh K, Murakami M, Shironoshita M, Kobayashi T, 
Fujimoto K, et al. Enhanced transdermal delivery of phenylalanyl-glycine by 
chemical modification with various fatty acids. International Journal of 
Pharmaceutics. 2003; 250(1):119-128.  
156. Uchiyama T, Kotani A, Tatsumi H, Kishida T, Okamoto A, Okada N, et al. 
Development of novel lipophilic derivatives of DADLE (leucine enkephalin 
analogue): intestinal permeability characteristics of DADLE derivatives in rats. 
Pharmaceutical Research. 2000; 17(12).  
 182
157. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et 
al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery 
and inhibition of inflammation. Nat Med. 2000; 6(11):1253-1257.  
158. Liang MT, Hennessy T, Toth I, Davies NM, Hook S. Synthetic lipopeptides 
formulated in liposomes: effect on their immune stimulatory capacity in vitro. 
Nanoscience and Nanotechnology. 2006:286-289.  
159. Koda Y, Liang MT, Blanchfield JT, Toth I. In vitro stability and permeability 
studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. 
International Journal of Pharmaceutics. 2008; 356(1-2):37-43.  
160. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. 
International Journal of Pharmaceutics. 2001; 224(1-2):19-38.  
161. Liu Z, Wu XY, Ballinger JR, Bendayan R. Synthesis and characterization of 
surface-hydrophobic ion-exchange microspheres and the effect of coating on drug 
release rate. Journal of Pharmaceutical Sciences. 2000; 89(6):807 - 817.  
162. Hashizume M, Douen T, Murakami M, Yamamoto A, Takada K, Muranishi 
S. Improvement of large intestinal absorption of insulin by chemical modification 
with palmitic acid in rats. Journal of Pharmacy and Pharmacology. 1992; 44:555-
559.  
163. Whittaker RG, Hayes PJ, Bender VJ. A gentle method of linking Tris to 
amino acids and peptides. Peptide Research. 1993; 6:125-128.  
164. Setoh K, Murukami M, Araki N, Fujita T, Yamamoto A, Muranishi S. 
Improvement of transdermal delivery of tetragastrin by lipophilic modification with 
fatty acids Journal of Pharmacy and Pharmacology. 1995; 47(10):808-811.  
165. Fujita T, Fujita T, Morikawa K, Tanaka H, Iemura O, Yamamoto A, et al. 
Improvement of intestinal absorption of human calcitonin by chemical modification 
with fatty acids: Synergistic effects of acylation and absorption enhancers. 
International Journal of Pharmaceutics. 1996; 134(1-2):47-57.  
 183
166. Linter K, Peschard O. Biologically active peptides: from a laboratory bench 
curiosity to a functional skin care product International Journal of Cosmetic Science. 
2000; 22:207-218.  
167. Osborne R, inventor; Personal care compositions. US patent 20070020220. 
2006. 
168. Lintner K, inventor; Lys-thr dipeptides and their use. France patent 
WO/2006/114657. 2006. 
169. Marie-christine S, inventor; Exsymol S.A.M. (Monaco, MC), assignee. 
Citrullinylarginine dipeptide analogs and their dermatological uses as care and 
treatment agents US patent 7270824. 2007. 
170. Acetyl-dipetiide-1 cetyl ester. 01/08/09 ]. Available from: 
http://www.cosmeticsdatabase.com. 
171. Dipeptide-2. 05/08/09]. Available from: 
http://www.truthinaging.com/ingredients/dipeptide-2/. 
172. Namjoshi S, Chen Y, Edwards J, Benson HAE. Enhanced transdermal 
delivery of a dipeptide by dermaportation. Biopolymers Peptide Science. 2008; 
90(5):655-662.  
173. Rose Ii WA, Tuthill C, Pyles RB. An immunomodulating dipeptide, SCV-07, 
is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). 
International Journal of Antimicrobial Agents. 2008; 32(3):262-266.  
174. Sidwell RW, Smee DF, Huffman JH, Bailey KW, Warren RP, Burger RA, et 
al. Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide 
analog. Antiviral Research. 1995; 26(2):145-159.  
175. Krivorutchenko YL, Andronovskaja IB, Hinkula J, Krivoshein YS, 
Ljungdahl-Ståhle E, Pertel SS, et al. Study of the adjuvant activity of new MDP 
derivatives and purified saponins and their influence on HIV-1 replication in vitro. 
Vaccine. 15(12-13):1479-1486.  
 184
176. Neu J, Grant MB, inventors; University of Florida Research Foundation, Inc., 
assignee. Arginyl-glutamine dipeptide for treatment of pathological vascular 
proliferation. US patent 7148199. 2006. 
177. Kohler H, Klowik M, Brand O, Gobel U, Schroten H. Influence of glutamine 
and glycyl-glutamine on in vitro lymphocyte proliferation in children with solid 
tumors Supportive Care in Cancer. 2001; 9(4):261-266.  
178. Yagasaki M, Hashimoto S-i. Synthesis and application of dipeptides; current 
status and perspectives Applied Microbiology and Biotechnology. 2008; 81(1):13-
22.  
179. Lin R-Y, Hsu C-W, Chen W-Y. A method to predict the transdermal 
permeability of amino acids and dipeptides through porcine skin. Journal of 
Controlled Release. 1996; 38(2-3):229-234.  
180. Abla N, Naik A, Guy RH, Kalia YN. Effect of charge and molecular weight 
on transdermal peptide delivery by Iontophoresis. Pharmaceutical Research. 2005; 
22(11):2069-78.  
181. Babizhayev MA. Biological activities of the natural imidazole-containing 
peptidomimetics n-acetylcarnosine, carcinine and l-carnosine in ophthalmic and skin 
care products. Life Sciences. 2006; 78(20):2343-2357.  
182. Alasbahi R, Melzig M. The In vitro Inhibition of human neutrophil elastase 
activity by some yemeni medicinal plants. Scientia Pharmaceutica. 2008; 76:471–
483.  
183. Steinbrecher T, Hrenn A, Dormann KL, Merfort I, Labahn A. Bornyl (3,4,5-
trihydroxy)-cinnamate - An optimized human neutrophil elastase inhibitor designed 
by free energy calculations. Bioorganic & Medicinal Chemistry. 2008; 16(5):2385-
2390.  
184. Yasutake A, Powers JC. Reactivity of human leukocyte elastase and porcine 
pancreatic elastase toward peptide-4-nitroanilides containing model desmosine 
residues. Evidence that human leukocyte elastase is selective for crosslinked regions 
of elastin. Biochemistry. 2002; 20(13):3675-3679.  
 185
185. Hassal H, Johnson WH, Kennedy AJ, Roberts NA. A new class of inhibitors 
of human leucocyte elastase. FEBS Letters. 1985; 183:201-205.  
186. Hornebeck W, Moczar E, Szecsi J, Robert L. Fatty acid peptide derivatives as 
model compounds to protect elastin against degradation by elastases. Biochemical 
Pharmacology. 1985; 34(18):3315-3321.  
187. Rasoamanantena P, Moczar E, Robert L, Wei SM, Godeau G, Hornebeck W. 
Protective effect of oleoyl peptide conjugates against elastolysis by neutrophil 
elastase and kappa elastin-induced monocyte chemotaxis. American Journal of 
Respiratory Cell and Molecular Biology. 1993; 8(1).  
188. Hrenn A, Steinbrecher T, Labahn A, Schwager J, Schempp CM, Merfort I. 
Plant phenolics inhibit neutrophil elastase. Planta Medica. 2006; 72(12):1127-31.  
189. Wieczorek M, Gyorkos A, Spruce LW, Ettinger A, Ross SE, Kroona HS, et 
al. Biochemical Characterization of [alpha]-Ketooxadiazole Inhibitors of Elastases. 
Archives of Biochemistry and Biophysics. 1999; 367(2):193-201.  
190. Caccetta R, Blanchfield JT, Harrison J, Toth I, Benson HAE. Epidermal 
penetration of a therapeutic peptide by lipid conjugation; stereo-selective peptide 
availability of a topical diastereoisomeric lipopeptide. International Journal of 
Peptide Research and Therapeutics. 2006; 12(3):327-333.  
191. Babu RJ, Kikwai L, Jaiani LT, Kanikkannan N, Armstrong CA, Ansel JC, et 
al. Percutaneous absorption and anti-Inflammatory effect of a substance P receptor 
antagonist: Spantide II. Pharmaceutical Research. 2004; 21(1):108-113.  
192. Christophers E, Sterry W. Psoriasis. In: Dermatology in General Medicine. 
New York: McGraw Hill; 1993. p. 489-514. 
193. Manolios N, Collier S, Taylor J, Pollard J, Harrison LC, Bender V. T-cell 
antigen receptor transmembrane peptides modulate T-cell function and T-cell 
mediated disease. Nature Medicine. 1997; 3(1):84-88.  
194. Manolios N, Ali M, Kurosaka N. 4th Australian Peptide Conference [2001. 
Lindeman Island, Queensland, Australia: 
 186
195. Luger TA, Brzoska T. Alpha MSH related peptides: a new class of anti-
inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. 
2007; 66(3):52-5.  
196. Kim J.  In: Broad spectrum antimicrobial peptide for the treatment of acne 
and skin cancer. 2003 UCLA technology. 
197. Mize NK, Buttery M, Ruis N, Leung I, Cormier M, Daddona P. Antiflammin 
1 peptide delivered noninvasively by iontophoresis reduces irritantinduced 
inflanimation in vivo. Experimental Dermatology. 1997; 6:181-185.  
198. Christophers E, Kligman AM. Visualization of the cell layers of the stratum 
corneum. Journal of Investigative Dermatology. 1964; 42:407-409.  
199. Egelrud T. Purification and preliminary characterization of stratum corneum 
chymotryptic enzyme: a proteinase that may be involved in desquamation. Journal of 
Investigative Dermatology. 1993; 101(2):200-204.  
200. Horie N, Fukuyama K, Ito Y, Epstien WL. Detection and characterization of 
epidermal proteinases by polyacrylamide gel electrophoresis. Comparative 
Biochemistry and Physiology. 1984; 77B:349-353.  
201. Choi H, Flynn GL, Amidon GL. Transdermal delivery of bioactive peptides: 
the effect of n-decylmethylsulfoxide, pH and inhibitors on enkephalin metabolism 
and transport. Pharmaceutical Research. 1990; 7 1099-05.  
202. Niven GW. The characterization of two aminopeptidase activities from the 
cyanobacterium Anabaena flos-aquae. Biochimica et Biophysica Acta 1995; 
1253(2):193-198.  
203. Simat TJ, Steinhart H. Oxidation of Free Tryptophan and Tryptophan 
Residues in Peptides and Proteins. Journal of Agricultural and Food Chemistry. 
1998; 46(2):490-498.  
204. Altenbach M, Schnyder N, Zimmermann C, Imanidis G. Cutaneous 
metabolism of a dipeptide influences the iontophoretic flux of a concomitant 
uncharged permeant. International Journal of Pharmaceutics. 2006; 307(2):308-317.  
 187
205. Benson HAE, Caccetta R, Chen Y, Kearns P, Toth I. Transdermal delivery of 
a tetrapeptide: Evaluation of passive diffusion Letters in Peptide Science. 2003; 
10(5-6):615-620.  
206. Afouna MI, Fincher TK, Khan MA, Reddy IK. Percutaneous permeation of 
enantiomers and racemates of chiral drugs and prediction of their flux ratios using 
thermal data: A pharmaceutical perspective. Chirality. 2003; 15:456-465.  
207. Brittain HG. Crystallographic consequences of molecular dissymmetry. 
Pharmaceutical Research. 1990; 7(7):683–690.  
208. Heard CM, Brain KR. Does solute stereochemistry influence percutaneous 
penetration? Chirality. 1995; 7:305-309.  
209. Benezra C, Stampf JL, Barbier P, Ducombs G. Enantiospecificity in allergic 
contact dermatitis. Contact Dermatitis. 1985; 13:110-114.  
210. Suedee R, Brain KR, Heard CM. Differential permeation of propranolol 
enantiomers across human skin in vitro from formulations containing an 
enantioselective excipient. Chirality. 1999; 11:680-683.  
211. Miyazaki K, Kaiho F, Inagaki A, Dohi M, Hazemoto N, Haga M, et al. 
Enantiomeric difference in percutaneous penetration of propanolol through rat 
excised skin. Chemical and Pharmaceutical Bulletin. 1992; 40:1075.  
212. Ahmed S, Imai T, Otagiri M. Evaluation of stereoselective transdermal 
transport and concurrent cutaneous hydrolysis of several ester prodrugs of 
propranolol: mechanism of stereoselective permeation. Pharmaceutical Research. 
1996; 13(10):1524–1529.  
213. Asada H, Douen T, Waki M, Adachi S, Fujita T, Yamamoto A, et al. 
Absorption characteristics of chemically modified-insulin derivatives with various 
fatty acids in the small and large intestine. Journal of Pharmaceutical Sciences. 1995; 
84:682-687.  
214. E Touitou, Chow DD, Lawter JR. Chiral beta blockers for transdermal 
delivery. International Journal of Pharmaceutics. 1994; 104:19-28.  
 188
215. Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN. Transdermal 
iontophoretic delivery of vapreotide acetate across porcine skin in vitro. 
Pharmaceutical Research. 2005; 22(8):1305-12.  
216. Walter K, Kurz H. Binding of drugs to human skin: influencing factors and 
the role of tissue lipids. Journal of Pharmacy and Pharmacology. 1988; 40(10):689-
693.  
217. Infante MR, Pérez L, Pinazo A, Clapés P, Morán MC, Angelet M, et al. 
Amino acid-based surfactants. Comptes Rendus Chimie. 7(6-7):583-592.  
218. Surfactin. Wikipedia24/10/09]. Available from: 
http://en.wikipedia.org/wiki/Surfactin. 
219. Ashton P, Walters KA, Brain KR, Hadgraft J. Surfactant effects in 
percutaneous absorption I. Effects on the transdermal flux of methyl nicotinate. 
International Journal of Pharmaceutics. 1992; 87(1-3):261-264.  
220. Baby AR, Lacerda ACL, Velasco MVR, Lopes PS, Kawano Y, Kaneko TM. 
Evaluation of the interaction of surfactants with stratum corneum model membrane 
from Bothrops jararaca by DSC. International Journal of Pharmaceutics. 2006; 
317(1):7-9.  
221. Rona C, Vailati F, Berardesca E. The cosmetic treatment of wrinkles. journal 
of Cosmetic Dermatology. 2004; 3:26-34.  
222. Bissett DL. Common cosmeceuticals. Clinics in Dermatology. 2009; 27:435–
445.  
223. Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. 
Journal of Cosmetic Dermatology. 2009; 8:8-13.  
224. Foldvari M, Attah-Poku S. Palmitoyl derivatives of interferon alpha: potent 
for cutaneous delivery. Journal of Pharmaceutical Sciences. 1998; 87:1203-8.  
225. Blanes-Mira C, Clemente J, Jodas G. Australian Society of Cosmetic 
Chemists Annual Conference [In: A synthetic hexapeptide (Argireline) with 
antiwrinkle activity., 2003 
 189
226. Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, Dillman RK, Siahaan 
TJ. Solution stability of linear vs. cyclic RGD peptides. Journal of Peptide Research. 
1999; 53(5):530-541.  
227. Gudmundsson OS, Nimkar K, Gangwar S, SIAHAAN T, Borchardt RT. 
Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic 
stability to peptidases and excellent cellular permeation. Pharmaceutical Research. 
1999; 16(1):16-22.  
228. Borchardt RT. Optimizing oral absorption of peptides using prodrug 
strategies. Journal of Controlled Release. 1999; 62:231-238.  
229. Borel JF. History of the discovery of cyclosporin and of its early 
pharmacological development. Wien Klin Wochenschr. 2002; 114(12):433-507.  
230. Shi Y. Beyond skin color: emerging roles of melanin-concentrating hormone 
in energy homeostasis and other physiological functions. Peptides. 2004; 25:1605-
11.  
231. Oudhoff MJ, Kroeze KL, Nazmi K, Veerman ECI. Structure-activity analysis 
of histatin, a potent wound healing peptide from human saliva: cyclization of histatin 
potentiates molar activity 1000-fold. The FASEB Journal. 2009.  
232. Kwon Y-U, Kodadek T. Quantitative comparison of the relative cell 
permeability of cyclic and linear peptides. Chemistry & Biology. 2007; 14:671-677.  
233. Anigbogu ANC, Williams AC, Barry BW, Edwards HGM. Fourier transform 
raman spectroscopy of interactions between the penetration enhancer dimethyl 
sulfoxide and human stratum corneum. International Journal of Pharmaceutics. 1995; 
125(2):265-282.  
234. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the 
transdermal delivery of peptide and protein drugs. Expert Opinion on Drug Delivery. 
2005; 2(3):533-548.  
 190
235. Henchoz Y, Abla N, Veuthey J-L, Carrupt P-A. A fast screening strategy for 
characterizing peptide delivery by transdermal iontophoresis. Journal of Controlled 
Release. 2009; 137(2):123-129.  
236. Wilkinson SC, Maas WJM, Nielson JB, Greaves LC, Sandt JJMVD, 
Williams FM. Interactions of skin thickness and physicochemical properties of test 
compounds in percutaneous penetration studies. International Archives of 
Occupational and Environmental Health 2006; 79(5):405-413.  
237. Guy RH, Hadgraft J. Transdermal drug delivery: developmental issues and 
research initiatives. Marcel Dekker; 1989. 
"Every reasonable effort has been made to acknowledge the owners of copyright 
material. I would be pleased to hear from any copyright owner who has been omitted 
or incorrectly acknowledged." 
 
 
 
 
 
 
 
 
 
 
 
 
 191
 
 
 
 
 
 
 
 
 
Chapter 8.  
Appendix 
 
 
 
 
 
 
 
 
 
 
 192
Poster presentations 
1. Sarika Namjoshi, Yan Chen, Joanne Blanchfield, Istvan Toth and Heather 
Benson, Skin permeability and biological activity of a therapeutic peptide and its 
lipoamino acid conjugates. Poster presentation at 36thannual meeting and exposition 
of the controlled Release Society, Bella Center, Copenhagen, Denmark, July 2009 
2. Heather Benson, Sarika Namjoshi, Marina Ali and Nicholas Manolios, Cyclic 
peptides as potential therapeutic agents for skin disorders. Poster presentation at 1st 
International Conference On Circular Proteins, Herron island resort, Queensland, 
Australia, October 2009 
3. Heather Benson, Sarika Namjoshi, Marina Ali and Nicholas Manolios, Skin 
permeation of an antiinflammatory peptide and analogues exhibiting improved 
biological efficacy and specificity. Poster presentation at 8th Australian Peptide 
Conference, Couran Cove, South Stradbroke Island, Queensland, Australia, October 
2009 
4. Sarika Namjoshi, Yan Chen, Jeffery Edwards and Heather Benson, 
Electromagnetophoresis: potential for enhanced skin permeation of peptides. Poster 
presentation at Skin and Formulation, 3rd Symposium and 10th Skin Forum, 
Versailles, France, March 2009 
5. Heather Benson, Jeffery Edwards, Gayathri Krishnan and Sarika Namjoshi, 
Electromagnetophoresis: potential for enhanced skin permeation of drugs and 
cosmetics. Poster presentation at Skin and Formulation, 3rd Symposium and 10th 
Skin Forum, Versailles, France, March 2009 
6. Sarika Namjoshi, Yan Chen, Jeffery Edwards and Heather Benson, Enhanced 
transdermal delivery of a dipeptide by Dermaportation. Poster presentation at 7th 
Australian Peptide Conference, Cairns, Queensland, Australia, October 2007. 
 
 
